WO2012110777A2 - Feed additive composition - Google Patents

Feed additive composition Download PDF

Info

Publication number
WO2012110777A2
WO2012110777A2 PCT/GB2012/050123 GB2012050123W WO2012110777A2 WO 2012110777 A2 WO2012110777 A2 WO 2012110777A2 GB 2012050123 W GB2012050123 W GB 2012050123W WO 2012110777 A2 WO2012110777 A2 WO 2012110777A2
Authority
WO
WIPO (PCT)
Prior art keywords
phytase
feed
additive composition
feed additive
protease
Prior art date
Application number
PCT/GB2012/050123
Other languages
French (fr)
Other versions
WO2012110777A3 (en
Inventor
Luis Fernando Romero MILLÁN
Original Assignee
Dupont Nutrition Biosciences Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2013553998A priority Critical patent/JP2014508519A/en
Priority to PL12701263T priority patent/PL2675285T3/en
Priority to EP12701263.1A priority patent/EP2675285B1/en
Priority to BR112013020855-4A priority patent/BR112013020855B1/en
Priority to AU2012216897A priority patent/AU2012216897A1/en
Priority to CA2825489A priority patent/CA2825489A1/en
Priority to ES12701263.1T priority patent/ES2657543T3/en
Priority to DK12701263.1T priority patent/DK2675285T3/en
Application filed by Dupont Nutrition Biosciences Aps filed Critical Dupont Nutrition Biosciences Aps
Priority to US13/985,847 priority patent/US20130330307A1/en
Priority to CN2012800093151A priority patent/CN103442587A/en
Publication of WO2012110777A2 publication Critical patent/WO2012110777A2/en
Publication of WO2012110777A3 publication Critical patent/WO2012110777A3/en
Priority to ZA2013/05267A priority patent/ZA201305267B/en
Priority to US16/257,556 priority patent/US11172693B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/10—Shaping or working-up of animal feeding-stuffs by agglomeration; by granulation, e.g. making powders
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/189—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03026—4-Phytase (3.1.3.26), i.e. 6-phytase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus

Definitions

  • the present invention relates to methods for improving feed compositions using a direct fed microbial in combination with a specific combination of enzymes, and to a feed additive composition comprising a direct fed microbial in combination with a specific combination of enzymes.
  • the present invention further relates to uses and kits.
  • Supplemental enzymes are used as additives to animal feed, particularly poultry and swine feeds, as a means to improve nutrient utilization and production performance characteristics.
  • Enzyme blends are available to improve the nutritional value of diets containing soybean meal, animal protein meals, or high fibre food by-products.
  • DFM direct fed microbials
  • a seminal finding of the present invention is that a DFM in combination with a protease and a phytase has significant beneficial effects on the performance of an animal.
  • a seminal finding of the present invention is that a DFM in combination with a protease and phytase has significant beneficial effects on the performance of an animal, including improving one or more of the following: feed conversion ratio (FCR), ability to digest a raw material (e.g. nutrient digestibility, such as amino acid digestibility), nitrogen retention, survival, carcass yield, growth rate, weight gain, feed efficiency animals resistance to necrotic enteritis, immune response of the subject, the growth of beneficial bacteria in the gastrointestinal tract of a subject.
  • FCR feed conversion ratio
  • Another surprising effect of the present invention is that it can reduce nutrient excretion in manure (e.g. reduce nitrogen and phosphorus) content of a subject's manure.
  • the present invention provides a feed additive composition comprising (or consisting essentially of or consisting of) a direct fed microbial in combination with a protease and a phytase.
  • the present invention provides a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for avoiding the negative effects of necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g.
  • a feed e.g. nutrient digestibility, such as amino acid digestibility
  • FCR feed conversion ratio
  • a yet further aspect of the present invention is use of a direct fed microbial in combination with a protease and a phytase for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility) or for improving nitrogen retention) or for avoiding the negative effects of necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject, or for reducing nutrient excretion in manure.
  • a direct fed microbial in combination with a protease and a phytase for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as
  • kits comprising a direct fed microbial, a protease, a phytase (and optionally at least one vitamin and/or optionally at least one mineral) and instructions for administration.
  • the present invention provides a method of preparing a feed additive composition, comprising admixing a direct fed microbial with a protease and a phytase and (optionally) packaging.
  • feed or feedstuff comprising a feed additive composition comprising (or consisting essentially of or consisting of) a direct fed microbial in combination with a protease and a phytase.
  • a premix comprising a feed additive composition comprising (or consisting essentially of or consisting of) a direct fed microbial in combination with a protease and a phytase, and at least one mineral and/or at least one vitamin.
  • the present invention provides a method of preparing a feedstuff comprising admixing a feed component with a feed additive composition comprising (or consisting essentially of or consisting of) a direct fed microbial in combination with a protease and a phytase.
  • the present invention relates to a feed additive composition for preventing and/or treating coccidiosis and/or necrotic enteritis in a subject.
  • the present invention yet further provides a method of preventing and/or treating necrotic enteritis and/or coccidiosis wherein an effective amount of a feed additive composition according to the present invention is administered to a subject.
  • Figure 1 shows that a combination of DFM (Enviva Pro® available from Danisco A/S) with a combination of a protease (e.g. Bacillus subtilis protease) and a phytase (e.g. 500FTU/kg of Phyzyme XP (an E. coli phytase) available from Danisco A/S) significantly improved (reduced) necrotic enteritis lesion scores in the gut of the animals compared with the challenged control.
  • a protease e.g. Bacillus subtilis protease
  • a phytase e.g. 500FTU/kg of Phyzyme XP (an E. coli phytase) available from Danisco A/S
  • Figure 2 shows percentage of morality related to necrotic enteritis (NE) lesions from 20 to 42 d of age.
  • DFM Endviva Pro® available from Danisco A/S
  • protease e.g. Bacillus subtilis protease
  • phytase e.g. 500FTU/kg of Phyzyme XP (an E. coli phytase) available from Danisco A S
  • Figure 3 shows the body weight gain of broiler chickens from 0 to 23 d in a necrotic enteritis challenge model.
  • Figure 4 shows the body weight gain of broiler chickens from 0- 12 days in necrotic enteritis challenge model. Pooled SBM-4.86.
  • Figure 7 shows a heat map of expression profiles of genes of interest for all treatments for jejunum at 23 days of age.
  • Unchallenged control Unchallenged Control + phytase
  • CC+ EP Challenged Control + phytase + Enviva Pro
  • Figure 8 shows a heat map of expression profile of chicken alpha amylase for all treatments in pancreas at 23 days of age.
  • Unchallenged control Unchallenged Control + phytase
  • CC+ EP Challenged Control + phytase + Enviva Pro
  • each of the enzymes used in the present invention are exogenous to the DFM.
  • the enzymes are preferably added to or admixed with the DFM.
  • Amino acids are referred to herein using the name of the amino acid, the three letter abbreviation or the single letter abbreviation.
  • protein includes proteins, polypeptides, and peptides.
  • amino acid sequence is synonymous with the term “polypeptide” and/or the term “protein”. In some instances, the term “amino acid sequence” is synonymous with the term “peptide”. In some instances, the term “amino acid sequence” is synonymous with the term “enzyme”.
  • the enzymes for use in the present invention can be produced either by solid or submerged culture, including batch, fed-batch and continuous-flow processes. Culturing is accomplished in a growth medium comprising an aqueous mineral salts medium, organic growth factors, the carbon and energy source material, molecular oxygen, and, of course, a starting inoculum of one or more particular microorganism species to be employed.
  • the DFM comprises a viable microorganism.
  • the DFM comprises a viable bacterium or a viable yeast or a viable fungi.
  • the DFM comprises a viable bacteria.
  • viable microorganism means a microorganism which is metabolically active or able to differentiate.
  • the DFM may be a spore fomiing bacterium and hence the term DFM may be comprised of or contain spores, e.g. bacterial spores. Therefore in one embodiment the term "viable microorganism" as used herein may include microbial spores, such as endospores or conidia.
  • the DFM in the feed additive composition according to the present invention is not comprised of or does not contain microbial spores, e.g. endospores or conidia.
  • the microorganism may be a naturally occurring microorganism or it may be a transformed microorganism.
  • the microorganism may also be a combination of suitable microorganisms.
  • the DFM according to the present invention may be one or more of the following: a bacterium, a yeast, a fungi.
  • the DFM according to the present invention is a probiotic microorganism.
  • DFM direct fed microbial encompasses direct fed bacteria, direct fed yeast, direct fed fungi and combinations thereof.
  • the DFM is a direct fed bacterium.
  • the DFM is a combination comprising two or more bacteria, e.g. three or more or four or more; or the DFM is a combination comprising two or more bacterial strains, e.g. three or more or four or more.
  • the bacterium or bacteria is or are isolated.
  • the DFM may comprise a bacterium from one or more of the following genera: Lactobacillus, Lactococcus, Streptococcus, Bacillus, Pediococcus, Enterococcus, Leuconostoc, Carnobacterium, Propionibacterium, Bifidobacterium, Clostridium and Megasphaera and combinations thereof.
  • the DFM may be selected from the following Bacillus spp: Bacillus subtilis, Bacillus cereus, Bacillus licheniformis and Bacillus amyloliquefaciens.
  • the DFM may be a combination comprising two or more Bacillus strains.
  • the DFM may be a combination of two or more the Bacillus subtilis strains 3A-P4 (PTA-6506); 15A-P4 (PTA-6507); 22C-P1 (PTA-6508); 2084 (NRRL B- 500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B-50105); BS 18 (NRRL B-50633); and BS 278 (NRRL B-50634).
  • Strains 3A-P4 (PTA-6506), 15A-P4 (PTA-6507) and 22C-P1 (PTA-6508) are publically available from American Type Culture Collection (ATCC).
  • Strains 2084 (NRRL B-500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B-50105) are publically available from the Agricultural Research Service Culture Collection (NRRL).
  • Strain Bacillus subtilis LSSA01 is sometimes referred to as B. subtilis 8. These strains are taught in US 7, 754, 469 B2.
  • Bacillus subtilis BS 18 and Bacillus subtilis BS 278 were deposited by Andy Madisen of W227 N752 Westmound Dr. Waukesha, WI 53186, USA for Danisco USA Inc. of W227 N752 Westmound Dr. Waukesha, WI 53186, USA under the Budapest Treaty at the Agricultural Research Service Culture Collection (NRRL) at 1815 North University Street, Peoria, Illinois 61604, United States of America, under deposit numbers NRRL B-50633 and NRRL B-50634, respectively on 9 January 2012. Andy Madison of W227 N752 Westmound Dr. Waukesha, WI 531 86, USA and Danisco USA Inc. of W227 N752 Westmound Dr.
  • NRRL Agricultural Research Service Culture Collection
  • the DFM may be selected from the following Lactococcus spp: Lactococcus cremoris and Lactococcus lactis and combinations thereof.
  • the DFM may be selected from the following Lactobacillus spp: Lactobacillus buchneri, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus kefiri, Lactobacillus bifidus, Lactobacillus brevis, Lactobacillus helveticus, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus curvatus, Lactobacillus bulgaricus, Lactobacillus sakei, Lactobacillus reuteri, Lactobacillus fermentum, Lactobacillus farciminis, Lactobacillus lactis, Lactobacillus delbreuckii, Lactobacillus plantarum, Lactobacillus paraplantarum, Lactobacillus farciminis, Lactobacillus rhamnosus, Lactobacillus crispatus, Lactobacillus gasseri
  • the DFM may be selected from the following Bifidobacteria spp: Bifidobacterium lactis, Bifidobacterium bifidium, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium catenulatum, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, and Bifidobacterium angulatum, and combinations of any thereof.
  • Bifidobacteria spp Bifidobacterium lactis, Bifidobacterium bifidium, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium catenulatum, Bifidobacterium pseudocatenulatum, Bif
  • the DFM may comprise a bacterium from one or more of the following species: Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Enterococcus faecium, Enterococcus spp, and Pediococcus spp, Lactobacillus spp, Bifidobacterium spp, Lactobacillus acidophilus, Pediococsus acidilactici, Lactococcus lactis, Bifidobacterium bifidum, Bacillus subtilis, Propionibacterium thoenii, Lactobacillus farciminis, Lactobacillus rhamnosus, Megasphaera elsdenii, Clostridium butyricum, Bifidobacterium animalis ssp. animalis, Lactobacillus reuteri, Bacillus cereus, Lactobacillus salivarius ssp. Salivarius, Propion
  • the direct fed bacterium used in the present invention may be of the same type (genus, species and strain) or may comprise a mixture of genera, species and/or strains.
  • the DFM according to the present invention may be one or more of the products or the microorganisms contained in those products as in the Table below:
  • the DFM may be Enviva Pro®.
  • Enviva Pro® is commercially available from Danisco A/S and is a combination of Bacillus strain 2084 Accession No. NRRl B-50013, Bacillus strain LSSAOl Accession No. NRRL B-50104 and Bacillus strain 15A-P4 ATCC Accession No. PTA-6507 (as taught in US 7,754,469 B - incorporated herein by reference).
  • the DFM may comprise a yeast from the genera: Saccharomyces spp.
  • the DFM to be used in accordance with the present invention is a microorganism which is generally recognised as safe and, which is preferably GRAS approved.
  • the DFM used in accordance with the present invention is one which is suitable for animal consumption.
  • the viable DFM should remain effective through the normal "sell-by" or “expiration” date of the product during which the feed or feed additive composition is offered for sale by the retailer.
  • the desired lengths of time and normal shelf life will vary from feedstuff to feedstuff and those of ordinary skill in the art will recognise that shelf-life times will vary upon the type of feedstuff, the size of the feedstuff, storage temperatures, processing conditions, packaging material and packaging equipment.
  • the DFM may be a thermotolerant microorganism, such as a thermotolerant bacteria, including for example Bacillus spp.
  • a thermotolerant bacteria including for example Bacillus spp.
  • Bacilli e.g. Bacillus spp. Bacilli are able to from stable endospores when conditions for growth are unfavorable and are very resistant to heat, pi 1, moisture and disinfectants.
  • the DFM may decrease or prevent intestinal establishment of pathogenic microorganism (such as Clostridium perfringens and/or E. coli and/or Salmonella spp and/or Campylobacter spp.).
  • the DFM according to the present invention may be any suitable DFM.
  • the following assay "DFM ASSAY” may be used to determine the suitability of a microorganism to be a DFM.
  • a DFM selected as an inhibitory strain (or an antipathogen DFM) in accordance with the "DFM ASSAY" taught herein is a suitable DFM for use in accordance with the present invention, i.e. in the feed additive composition according to the present invention.
  • Tubes were seeded each with a representative pathogen from a representative cluster. Supernatant from a potential DFM grown aerobically or anaerobically was added to the seeded tubes and incubated.
  • Colonies of (potential DFM) strains that produced a lowered OD compared with the control were classified as an inhibitory strain (or an antipathogen DFM).
  • the representative pathogen used in assay is one (or more) of the following: Clostridium, such as Clostridium perfringens and/or Clostridium difficile, and/or E. coli and/or Salmonella spp and/or Campylobacter spp.
  • the assay is conducted with one or more of Clostridium perfringens and/or Clostridium difficile and/or E. coli, preferably Clostridium perfringens and/or Clostridium difficile, more preferably Clostridium perfringens.
  • the DFM of the present invention is preferably an antipathogen.
  • antipathogen means that the DFM counters an effect (e.g. a negative effect) of a pathogen.
  • a DFM is an antipathogen in accordance with the present invention the above mentioned DFM assay may be used.
  • a DFM is considered to be an antipathogen or an antipathogen DFM if it is classed as an inhibitory strain in the above mentioned DFM assay, particularly when the pathogen is Clostridium perfringens.
  • the antipathogen DFM may be one or more of the following bacteria: Bacillus subtilis strain 2084 Accession No. NR L B-50013,
  • Bacillus subtilis strain BS27 ATCC Accession No. NRRL B-50105 Bacillus subtilis strain BS27 ATCC Accession No. NRRL B-50105. For the avoidance of doubt these strains are available and are referred to in US 7,754,459 B.
  • the DFM used in accordance with the present invention is not Lactobacillus gasseri BNR 17 Strain Acc No. KCTC 10902BP as taught in WO2008/016214.
  • the DFM is not an inactivated microorganism.
  • the DFM as used here is a composition comprising one or more DFM microorganisms as described herein.
  • the composition may additionally comprise the enzymes of the present invention.
  • the composition can be fed to an animal as a direct-fed microbial (DFM).
  • DFM direct-fed microbial
  • One or more carrier(s) or other ingredients can be added to the DFM.
  • the DFM may be presented in various physical forms, for example, as a top dress, as a water soluble concentrate for use as a liquid drench or to be added to a milk replacer, gelatin capsule, or gels.
  • freeze-dried fermentation product is added to a carrier, such as whey, maltodextrin, sucrose, dextrose, limestone (calcium carbonate), rice hulls, yeast culture, dried starch, and/or sodium silico aluminate.
  • a carrier such as whey, maltodextrin, sucrose, dextrose, limestone (calcium carbonate), rice hulls, yeast culture, dried starch, and/or sodium silico aluminate.
  • a water soluble carrier such as whey, maltodextrin, sucrose, dextrose, dried starch, sodium silico aluminate
  • a liquid is added to form the drench or the supplement is added to milk or a milk replacer.
  • freeze-dried fermentation product is added to a carrier, such as whey, maltodextrin, sugar, limestone (calcium carbonate), rice hulls, yeast culture dried starch, and/or sodium silico aluminate.
  • a carrier such as whey, maltodextrin, sugar, limestone (calcium carbonate), rice hulls, yeast culture dried starch, and/or sodium silico aluminate.
  • the bacteria and carrier are enclosed in a degradable gelatin capsule.
  • freeze-dried fermentation product is added to a carrier, such as vegetable oil, sucrose, silicon dioxide, polysorbate 80, propylene glycol, butylated hydroxyanisole, citric acid, ethoxyquin, and/or artificial coloring to form the gel.
  • the DFM(s) may optionally be admixed with a dry formulation of additives including but not limited to growth substrates, enzymes, sugars, carbohydrates, extracts and growth promoting micro-ingredients.
  • the sugars could include the following: lactose; maltose; dextrose; maltodextrin; glucose; fructose; mannose; tagatose; sorbose; raffinose; and galactose.
  • the sugars range from 50-95%, either individually or in combination.
  • the extracts could include yeast or dried yeast fermentation solubles ranging from 5-50%.
  • the growth substrates could include: trypticase, ranging from 5-25%; sodium lactate, ranging from 5-30%; and, Tween 80, ranging from 1-5%.
  • the carbohydrates could include mannitol, sorbitol, adonitol and arabitol. The carbohydrates range from 5-50% individually or in combination.
  • the micro-ingredients could include the following: calcium carbonate, ranging from 0.5-5.0%; calcium chloride, ranging from 0.5-5.0%; dipotassium phosphate, ranging from 0.5-5.0%; calcium phosphate, ranging from 0.5-5.0%; manganese proteinate, ranging from 0.25- 1 .00%; and, manganese, ranging from 0.25-1.0%.
  • the culture(s) and carrier(s) (where used) can be added to a ribbon or paddle mixer and mixed for about 15 minutes, although the timing can be increased or decreased.
  • the components are blended such that a uniform mixture of the cultures and carriers result.
  • the final product is preferably a dry, flowable powder.
  • the DFM(s) or composition comprising same can then be added to animal feed or a feed premix, added to an animal's water, or administered in other ways known in the art (preferably simultaneously with the enzymes of the present invention).
  • a feed for an animal can be supplemented with one or more DFM(s) described herein or with a composition described herein.
  • a mixture of at least two strains is meant a mixture of two, three, four, five, six or even more strains.
  • the proportions can vary from 1% to 99%.
  • Other embodiments of a mixture of strains are from 25% to 75%.
  • Additional embodiments of a mixture of strains are approximately 50% for each strain.
  • the strains can be present in substantially equal proportions or in different proportions in the mixture.
  • the DFM may be dosed appropriately.
  • dosages of DFM in the feed may be between about lxlO 3 CFU/g feed to about lxl 0 9 CFU/g feed, suitably between about lxlO 4 CFU/g feed to about lxlO 8 CFU/g feed, suitably between about 7.5x10 4 CFU/g feed to about lxlO 7 CFU/g feed.
  • the DFM is dosed in the feedstuff at more than about 1x10 CFU/g feed, suitably more than about lxl 0 4 CFU/g feed, suitably more than about 7.5x10 4 CFU/g feed.
  • dosages of DFM in the feed additive composition may be between about lxl 0 5 CFU/g composition to about l xl O 13 CFU/g composition, suitably between about lxlO 6 CFU/g composition to about lxlO 12 CFU/g composition, suitably between about 3.75x 10 7 CFU/g composition to about lxl O 1 1 CFU/g composition.
  • the DFM is dosed in the feed additive composition at more than about lxlO 5 CFU/g composition, suitably more than about lxlO 6 CFU/g composition, suitably more than about 3.75x10 7 CFU/g composition. In one embodiment the DFM is dosed in the feed additive composition at more than about 2x 10 3 CFU/g composition, suitably more than about 2xl0 6 CFU/g composition, suitably more than about 3.75 10 7 CFU/g composition.
  • CFU means colony forming units and is a measure of viable cells in which a colony represents an aggregate of cells derived from a single progenitor cell.
  • protease as used herein is synonymous with peptidase or proteinase.
  • the protease for use in the present invention may be a subtilisin (E.C. 3.4.21.62) or a bacillolysin (E.C. 3.4.24.28) or an alkaline serine protease (E.C. 3.4.21.x) or a keratinase (E.C. 3.4.X.X).
  • the protease in accordance with the present invention is a subtilisin.
  • Suitable proteases include those of animal, vegetable or microbial origin. Chemically modified or protein engineered mutants are also suitable.
  • the protease may be a serine protease or a metalloprotease, e.g., an alkaline microbial protease or a trypsin-like protease.
  • alkaline proteases are subtilisins, especially those derived from Bacillus sp., e.g., subtilisin Novo, subtilisin Caiisberg, subtilisin 309 ⁇ see, e.g., U.S. Patent No. 6,287,841), subtilisin 147, and subtilisin 168 ⁇ see, e.g. , WO 89/06279).
  • trypsin-like proteases are trypsin (e.g., of porcine or bovine origin), and Fusarium proteases ⁇ see, e.g. , WO 89/06270 and WO 94/25583).
  • useful proteases also include but are not limited to the variants described in WO 92/19729 and WO 98/201 15.
  • the protease may be a protease from B. subtilis.
  • the protease may be a Nocardiopsis protease available from Novozymes A/S.
  • the protease is present in the feedstuff in range of about lOOOU/kg to about 20,000PU/kg feed, more preferably about 1500PU/kg feed to about lOOOOPU/kg feed, more preferably about 2000PU/kg feed to about 6000PU/kg feed.
  • the protease is present in the feedstuff at more than about lOOOPU/kg feed, suitably more than about 1500PU/kg feed, suitably more than about 2000PU/kg feed.
  • the protease is present in the feedstuff at less than about 20,000PU/kg feed, suitably less than about lOOOOPU/kg feed, suitably less than about 7000PU/kg feed, suitably less than about 6000PU/kg feed.
  • the protease is present in the feed additive composition in range of about 200PU/g to about 400,000PU/g composition, more preferably about 300PU/g composition to about 200,000PU/g composition, and even more preferably about 5000PU/g composition to about 100,000 PU/g composition, and even more preferably about 700PU/g composition to about 70,000 PU/g composition, and even more preferably about l OOOPU/g composition to about 60,000 PU/g composition.
  • the protease is present in the feed additive composition at more than about 200PU/g composition, suitably more than about 300PU/g composition, suitably more than about 400PU/g composition, suitably more than about 500PU/g composition, suitably more than about 750PU/g composition, suitably more than about 1 OOOPU/g composition.
  • the protease is present in the feed additive composition at less than about 400, OOOPU/g composition, suitably less than about 200,000PU/g composition, suitably less than about 100,000PU/g composition, suitably less than about 80, OOOPU/g composition, suitably less than about 70000PU/g composition, suitably less than about 60000PU/g composition.
  • one protease unit is the amount of enzyme that liberates from the substrate (0.6% casein solution) one microgram of phenolic compound (expressed as tyrosine equivalents) in one minute at pH 7.5 (40mM Na 2 P0 4 / lactic acid buffer) and 40°C. This may be referred to as the assay for determining 1PU.
  • the enzyme is classified using the E.G. classification above, and the E.G. classification designates an enzyme having that activity when tested in the assay taught herein for determining 1 PU.
  • the phytase for use in the present invention may be classified a 6-phytase (classified as E.G. 3.1.3.26) or a 3 -phytase (classified as E.G. 3.1.3.8).
  • the phytase may be a 6-phytase (E.G. 3.1.3.26).
  • Quantum 2500D Pichia pastoris or 5000L ABVista 6-phytase Trichoderma
  • consensus gene means that the DNA vector used to transform the organism contains a synthetic phytase gene based on a consensus sequence, a URA gene from the non-pathogenic yeast Saccharomyces cerevisiae and the origin of replication of the Escherichia coli plasmid pBR322.
  • the phytase is a Citrobacter phytase derived from e.g. Citrobacter freundii, preferably C. freundii NCIMB 41247 and variants thereof e.g. as disclosed in WO2006/038062 (incorporated herein by reference) and WO2006/038128 (incorporated herein by reference), Citrobacter braakii YH-15 as disclosed in WO 2004/085638, Citrobacter braakii ATCC 51113 as disclosed in WO2006/037328 (incorporated herein by reference), as well as variants thereof e.g.
  • Citrobacter amalonaticus preferably Citrobacter amalonaticus ATCC 25405 or Citrobacter amalonaticus ATCC 25407 as disclosed in WO2006037327 (incorporated herein by reference)
  • Citrobacter gillenii preferably Citrobacter gillenii DSM 13694 as disclosed in WO2006037327 (incorporated herein by reference)
  • Citrobacter intermedius Citrobacter koseri, Citrobacter murliniae, Citrobacter rodentium, Cilrobacter sedl kii, Citrobacter washnanii, Citrobacter youngae, Citrobacter species polypeptides or variants thereof.
  • the phytase may be a phytase from Citrobacter, e.g. from Citrobacter freundii, such as the phytase enzyme(s) taught in WO2006/038128, which reference is incorporated herein by reference.
  • the phytase is preferably E. coli phytase marketed under the name Phy/.yme XPTM by Danisco A/S.
  • the phytase may be a Buttiauxella phytase, e.g. a Buttiauxella agrestis phytase, for example, the phytase enzymes taught in WO 2006/043178, WO 2008/097619, WO2009/129489, WO2008/092901, PCT/US2009/4101 1 or PCT/IB2010/051804, all of which are incorporated herein by reference.
  • the phytase may be a phytase from Hafnia, e.g. from Hafnia alvei, such as the phytase enzyme(s) taught in US2008263688, which reference is incorporated herein by reference.
  • the phytase may be a phytase from Aspergillus, e.g. from Apergillus orzyae.
  • the phytase may be a phytase from Penicillium, e.g. from Penicillium funiculosum.
  • the phytase is present in the feedstuff in range of about 200FTU/kg to about l OOOFTU/kg feed, more preferably about 300FTU/kg feed to about 750FTU/kg feed, more preferably about 400FTU/kg feed to about 500FTU/kg feed.
  • the phytase is present in the feedstuff at more than about 200FTU/kg feed, suitably more than about 300FTU/kg feed, suitably more than about 400FTU/kg feed.
  • the phytase is present in the feedstuff at less than about l OOOFTU/kg feed, suitably less than about 750 FTU/kg feed.
  • the phytase is present in the feed additive composition in range of about 40FTU/g to about 40,000FTU/g composition, more preferably about 80FTU/g composition to about 20,000FTU/g composition, and even more preferably about l OOFTU/g composition to about 10,000FTU/g composition, and even more preferably about 200FTU/g composition to about 10,000FTU/g composition.
  • the phytase is present in the feed additive composition at more than about 40FTU/g composition, suitably more than about 60FTU/g composition, suitably more than about l OOFTU/g composition, suitably more than about 150FTU/g composition, suitably more than about 200FTU/g composition.
  • the phytase is present in the feed additive composition at less than about 40,000FTU/g composition, suitably less than about 20,000FTU/g composition, suitably less than about 15,000FTU/g composition, suitably less than about 10,000FTU/g composition.
  • 1 FTU (phytase unit) is defined as the amount of enzyme required to release 1 ⁇ of inorganic orthophosphate from a substrate in one minute under the reaction conditions defined in the ISO 2009 phytase assay -
  • a standard assay for determining phytase activity and 1 FTU can be found at International Standard ISO/DIS 30024: 1-17, 2009.
  • the enzyme is classified using the E.G. classification above, and the E.G. classification designates an enzyme having that activity when tested in the assay taught herein for determining 1 FTU.
  • One advantage of the present invention is that the feed additive composition according to the present invention can avoid the negative effects of necrotic enteritis or can be used for improving the subject's resistance to necrotic enteritis.
  • phytase catalyzes the sequential hydrolysis of phytate, a principal storage form of phosphorus in cereals and legumes, to less phosphorylated myo-inositol derivatives with concomitant release of inorganic phosphate.
  • Hydrolysis of phytate causes a reduction of endogenous losses of amino acids to the intestinal lumen.
  • a reduction of endogenous amino acid losses in the intestine reduces the availability of nitrogen for bacterial growth, which helps the activity of DFMs on inhibition of C. perfringens and other pathogenic bacteria.
  • proteases cause non-specific hydrolysis of dietary protein yielding a variety of polypeptides in the intestinal lumen. Animals finalise protein hydrolysis and absorb such amino acids.
  • pathogenic bacteria may take advantage of higher peptide availability in the lumen of jejunum and ileum.
  • DFMs inhibit the growth of entero-pathogens by for example competing for N sources, as well as by direct inhibition.
  • the DFM and the enzymes may be formulated in any suitable way to ensure that the formulation comprises viable DFMs and active enzymes.
  • the DFM and enzymes may be formulated as a liquid, a dry powder or a granule.
  • the dry powder or granules may be prepared by means known to those skilled in the art, such as, in top-spray fluid bed coater, in a buttom spray Wurster or by drum granulation (e.g. High sheer granulation), extrusion, pan coating or in a microingredients mixer.
  • the DFM and/or the enzyme(s) may be coated, for example encapsulated.
  • the DFM and enzymes may be formulated within the same coating or encapsulated within the same capsule.
  • one or both of the enzymes may be formulated within the same coating or encapsulated within the same capsule and the DFM could be formulated in a coating separate to the one or both of the enzymes.
  • the DFM may be provided without any coating.
  • the DFM endospores may be simply admixed with one or both enzymes.
  • the enzymes may be coated, e.g.
  • one or both of the enzymes may be coated, e.g. encapsulated.
  • the enzymes may be encapsulated as mixtures (i.e. comprising one or both) of the enzymes or they may be encapsulated separately, e.g. as single enzymes. In one preferred embodiment both enzymes may be coated, e.g. encapsulated, together.
  • the coating protects the enzymes from heat and may be considered a fhennoprotectant.
  • the feed additive composition is formulated to a dry powder or granules as described in WO2007/044968 (referred to as TPT granules) or WO 1997/016076 or WO 1992/012645 (each of which is incorporated herein by reference).
  • the feed additive composition may be formulated to a granule for feed compositions comprising: a core; an active agent; and at least one coating, the active agent of the granule retaining at least 50% activity, at least 60% activity, at least 70% activity, at least 80% activity after conditions selected from one or more of a) a feed pelleting process, b) a steam-heated feed pretreatment process, c) storage, d) storage as an ingredient in an unpelleted mixture, and e) storage as an ingredient in a feed base mix or a feed premix comprising at least one compound selected from trace minerals, organic acids, reducing sugars, vitamins, choline chloride, and compounds which result in an acidic or a basic feed base mix or feed premix.
  • At least one coating may comprise a moisture hydrating material that constitutes at least 55% w/w of the granule; and/or at least one coating may comprise two coatings.
  • the two coatings may be a moisture hydrating coating and a moisture barrier coating.
  • the moisture hydrating coating may be between 25% and 60% w/w of the granule and the moisture barrier coating may be between 2% and 15% w/w of the granule.
  • the moisture hydrating coating may be selected from inorganic salts, sucrose, starch, and maltodextrin and the moisture bamer coating may be selected from polymers, gums, whey and starch.
  • the granule may be produced using a feed pelleting process and the feed pretreatment process may be conducted between 70°C and 95°C for up to several minutes, such as between 85°C and 95°C.
  • the feed additive composition may be formulated to a granule for animal feed comprising: a core; an active agent, the active agent of the granule retaining at least 80% activity after storage and after a steam-heated pelleting process where the granule is an ingredient; a moisture barrier coating; and a moisture hydrating coating that is at least 25% w/w of the granule, the granule having a water activity of less than 0.5 prior to the steam- heated pelleting process.
  • the granule may have a moisture barrier coating selected from polymers and gums and the moisture hydrating material may be an inorganic salt.
  • the moisture hydrating coating may be between 25% and 45% w/w of the granule and the moisture barrier coating may be between 2% and 10% w/w of the granule.
  • the granule may be produced using a steam-heated pelleting process which may be conducted between 85°C and 95°C for up to several minutes.
  • the DFM (e.g. DFM endospores for example) may be diluted using a diluent, such as starch powder, lime stone or the like.
  • a diluent such as starch powder, lime stone or the like.
  • the composition is in a liquid formulation suitable for consumption preferably such liquid consumption contains one or more of the following: a buffer, salt, sorbitol and/or glycerol.
  • the feed additive composition may be formulated by applying, e.g. spraying, the enzyme(s) onto a carrier substrate, such as ground wheat for example.
  • the feed additive composition according to the present invention may be fomiulated as a premix.
  • the premix may comprise one or more feed components, such as one or more minerals and/or one or more vitamins.
  • the DFM and/or enzymes for use in the present invention are fomiulated with at least one physiologically acceptable carrier selected from at least one of maltodextrin, limestone (calcium carbonate), cyclodextrin, wheat or a wheat component, sucrose, starch, Na 2 S0 4 , Talc, PVA, sorbitol, benzoate, sorbiate, glycerol, sucrose, propylene glycol, 1 ,3- propane diol, glucose, parabens, sodium chloride, citrate, acetate, phosphate, calcium, metabisulfite, formate and mixtures thereof.
  • at least one physiologically acceptable carrier selected from at least one of maltodextrin, limestone (calcium carbonate), cyclodextrin, wheat or a wheat component, sucrose, starch, Na 2 S0 4 , Talc, PVA, sorbitol, benzoate, sorbiate, glycerol, sucrose, propylene glycol, 1
  • the feed additive composition and/or premix and/or feed or feedstuff according to the present invention is packaged.
  • the feed additive composition and/or premix and/or feed or feedstuff is packaged in a bag, such as a paper bag.
  • the feed additive composition and/or premix and/or feed or feedstuff may be sealed in a container. Any suitable container may be used.
  • the feed additive composition of the present invention may be used as or in the preparation of - a feed.
  • feedstuff is used synonymously herein with "feedstuff.
  • the feed may be in the form of a solution or as a solid - depending on the use and/or the mode of application and/or the mode of administration.
  • composition of the present invention may be used in conjunction with one or more of: a nutritionally acceptable carrier, a nutritionally acceptable diluent, a nutritionally acceptable excipient, a nutritionally acceptable adjuvant, a nutritionally active ingredient.
  • the feed additive composition of the present invention is admixed with a feed component to form a feedstuff.
  • feed component means all or part of the feedstuff. Part of the feedstuff may mean one constituent of the feedstuff or more than one constituent of the feedstuff, e.g. 2 or 3 or 4.
  • the term "feed component” encompasses a premix or premix constituents.
  • the feed may be a fodder, or a premix thereof, a compound feed, or a premix thereof.
  • the feed additive composition according to the present invention may be admixed with a compound feed, a compound feed component or to a premix of a compound feed or to a fodder, a fodder component, or a premix of a fodder.
  • fodder as used herein means any food which is provided to an animal (rather than the animal having to forage for it themselves). Fodder encompasses plants that have been cut.
  • fodder includes hay, straw, silage, compressed and pelleted feeds, oils and mixed rations, and also sprouted grains and legumes.
  • Fodder may be obtained from one or more of the plants selected from: alfalfa (lucerne), barley, birdsfoot trefoil, brassicas, Chau moellier, kale, rapeseed (canola), rutabaga (swede), turnip, clover, alsike clover, red clover, subterranean clover, white clover, grass, false oat grass, fescue, Bermuda grass, brome, heath grass, meadow grasses (from naturally mixed grassland swards, orchard grass, rye grass, Timothy-grass, corn (maize), millet, oats, sorghum, soybeans, trees (pollard tree shoots for tree-hay), wheat, and legumes.
  • alfalfa lucerne
  • barley birdsfoot trefoil
  • brassicas Chau moellier
  • kale kale
  • rapeseed canola
  • rutabaga rutabaga
  • compound feed means a commercial feed in the form of a meal, a pellet, nuts, cake or a crumble.
  • Compound feeds may be blended from various raw materials and additives. These blends are formulated according to the specific requirements of the target animal.
  • Compound feeds can be complete feeds that provide all the daily required nutrients, concentrates that provide a part of the ration (protein, energy) or supplements that only provide additional micronutrients, such as minerals and vitamins.
  • the main ingredients used in compound feed are the feed grains, which include corn, soybeans, sorghum, oats, and barley.
  • a premix as referred to herein may be a composition composed of microingredients such as vitamins, minerals, chemical preservatives, antibiotics, fermentation products, and other essential ingredients. Premixes are usually compositions suitable for blending into commercial rations.
  • Any feedstuff of the present invention may comprise one or more feed materials selected from the group comprising a) cereals, such as small grains (e.g., wheat, barley, rye, oats and combinations thereof) and/or large grains such as maize or sorghum; b) by products from cereals, such as corn gluten meal, Distillers Dried Grain Solubles (DDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm kernel, and citrus pulp; c) protein obtained from sources such as soya, sunflower, peanut, lupin, peas, fava beans, cotton, canola, fish meal, dried plasma protein, meat and bone meal, potato protein, whey, copra, sesame; d) oils and fats obtained from vegetable and animal sources; e) minerals and vitamins.
  • cereals such as small grains (e.g., wheat, barley, rye, oats and combinations thereof) and/or large
  • a feedstuff of the present invention may contain at least 30%, at least 40%, at least 50% or at least 60% by weight corn and soybean meal or com and full fat soy, or wheat meal or sunflower meal.
  • a feedstuff of the present invention may comprise at least one high fibre feed material and/or at least one by-product of the at least one high fibre feed material to provide a high fibre feedstuff.
  • high fibre feed materials include: wheat, barley, rye, oats, by products from cereals, such as com gluten meal, Distillers Dried Grain Solubles (DDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm kernel, and citrus pulp.
  • Some protein sources may also be regarded as high fibre: protein obtained from sources such as sunflower, lupin, fava beans and cotton.
  • the feed may be one or more of the following: a compound feed and premix, including pellets, nuts or (cattle) cake; a crop or crop residue: com, soybeans, sorghum, oats, barley, com stover, copra, straw, chaff, sugar beet waste; fish meal; freshly cut grass and other forage plants; meat and bone meal; molasses; oil cake and press cake; oligosaccharides; conserved forage plants: hay and silage; seaweed; seeds and grains, either whole or prepared by crushing, milling etc.; sprouted grains and legumes; yeast extract.
  • the term feed in the present invention also encompasses in some embodiments pet food.
  • a pet food is plant or animal material intended for consumption by pets, such as dog food or cat food.
  • Pet food such as dog and cat food, may be either in a diy form, such as kibble for dogs, or wet canned form.
  • Cat food may contain the amino acid taurine.
  • the term feed in the present invention also encompasses in some embodiments fish food.
  • a fish food normally contains macro nutrients, trace elements and vitamins necessary to keep captive fish in good health.
  • Fish food may be in the form of a flake, pellet or tablet. Pelleted forms, some of which sink rapidly, are often used for larger fish or bottom feeding species.
  • Some fish foods also contain additives, such as beta carotene or sex hormones, to artificially enhance the color of ornamental fish.
  • feed in the present invention also encompasses in some embodiment bird food.
  • Bird food includes food that is used both in birdfecders and to feed pet birds. Typically bird food comprises of a variety of seeds, but may also encompass suet (beef or mutton fat).
  • the term "contacted" refers to the indirect or direct application of the composition of the present invention to the product (e.g. the feed). Examples of the application methods which may be used, include, but are not limited to, treating the product in a material comprising the feed additive composition, direct application by mixing the feed additive composition with the product, spraying the feed additive composition onto the product surface or dipping the product into a preparation of the feed additive composition.
  • the feed additive composition of the present invention is preferably admixed with the product (e.g. feedstuff).
  • the feed additive composition may be included in the emulsion or raw ingredients of a feedstuff.
  • compositions of the present invention may be applied to intersperse, coat and/or impregnate a product (e.g. feedstuff or raw ingredients of a feedstuff) with a controlled amount of DFM and enzymes.
  • a product e.g. feedstuff or raw ingredients of a feedstuff
  • the DFM and enzymes may be used simultaneously (e.g. when they are in admixture together or even when they are delivered by different routes) or sequentially (e.g. they may be delivered by different routes). In one embodiment preferably the DFM and enzymes are applied simultaneously. Preferably the DFM and enzymes are admixed prior to being delivered to a feedstuff or to a raw ingredient of a feedstuff.
  • the DFM in feed additive compositions according to the present invention - can be added in suitable concentrations - such as for example in concentrations in the final feed product which offer a daily dose of between about 2x1 ⁇ 3 CFU to about 2x10 11 CFU, suitably between about 2xl 0 6 to about lxl O 10 , suitably between about 3.75xl0 7 CFU to about IxlO 10 CFU.
  • the feed additive composition of the present invention will be thermally stable to heat treatment up to about 70 °C; up to about 85°C; or up to about 95°C.
  • the heat treatment may be performed for up to about 1 minute: up to about 5 minutes; up to about 10 minutes; up to about 30 minutes; up to about 60 minutes.
  • thermally stable means that at least about 75% of the enzyme components and/or DFM that were present/active in the additive before heating to the specified temperature are still present/active after it cools to room temperature. Preferably, at least about 80% of the enzyme components and/or DFM that were present and active in the additive before heating to the specified temperature are still present and active after it cools to room temperature.
  • the feed additive composition is homogenized to produce a powder.
  • the feed additive composition is formulated to granules as described in WO2007/044968 (referred to as TPT granules) incorporated herein by reference.
  • the granules comprise a hydrated barrier salt coated over the protein core.
  • the advantage of such salt coating is improved thermo-tolerance, improved storage stability and protection against other feed additives otherwise having adverse effect on the enzyme and/or DFM.
  • the salt used for the salt coating has a water activity greater than 0.25 or constant humidity greater than 60 % at 20 °C.
  • the salt coating comprises a Na 2 S0 4 .
  • the method of preparing a feed additive composition may also comprise the further step of pelleting the powder.
  • the powder may be mixed with other components known in the art.
  • the powder, or mixture comprising the powder may be forced through a die and the resulting strands are cut into suitable pellets of variable length.
  • the pelleting step may include a steam treatment, or conditioning stage, prior to formation of the pellets.
  • the mixture comprising the powder may be placed in a conditioner, e.g. a mixer with steam injection.
  • the mixture is heated in the conditioner up to a specified temperature, such as from 60-100°C, typical temperatures would be 70°C, 80°C, 85°C, 90°C or 95°C.
  • the residence time can be variable from seconds to minutes and even hours. Such as 5 seconds, 10 seconds, 15 seconds, 30 seconds, 1 minutes, 2 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes and 1 hour. It will be understood that the feed additive composition of the present invention is suitable for addition to any appropriate feed material.
  • feed material refers to the basic feed material to be consumed by an animal. It will be further understood that this may comprise, for example, at least one or more unprocessed grains, and/or processed plant and/or animal material such as soybean meal or bone meal.
  • feedstuff refers to a feed material to which one or more feed additive compositions have been added.
  • the feedstuff may comprise feed materials comprising maize or com, wheat, barley, triticale, rye, rice, tapioca, sorghum, and/ or any of the by-products, as well as protein rich components like soybean mean, rape seed meal, canola meal, cotton seed meal, sunflower seed mean, animal -by-product meals and mixtures thereof. More preferably, the feedstuff may comprise animal fats and / or vegetable oils.
  • the feedstuff may also contain additional minerals such as, for example, calcium and/or additional vitamins.
  • additional minerals such as, for example, calcium and/or additional vitamins.
  • the feedstuff is a corn soybean meal mix.
  • feedstuff is typically produced in feed mills in which raw materials are first ground to a suitable particle si/.e and then mixed with appropriate additives.
  • the feedstuff may then be produced as a mash or pellets; the later typically involves a method by which the temperature is raised to a target level and then the feed is passed through a die to produce pellets of a particular size. The pellets are allowed to cool. Subsequently liquid additives such as fat and enzyme may be added.
  • Production of feedstuff may also involve an additional step that includes extrusion or expansion prior to pelleting - in particular by suitable techniques that may include at least the use of steam.
  • the feedstuff may be a feedstuff for a nionogastric animal, such as poultry (for example, broiler, layer, broiler breeders, turkey, duck, geese, water fowl), swine (all age categories), a pet (for example dogs, cats) or fish, preferably the feedstuff is for poultry.
  • poultry for example, broiler, layer, broiler breeders, turkey, duck, geese, water fowl
  • swine all age categories
  • a pet for example dogs, cats
  • fish preferably the feedstuff is for poultry.
  • the feedstuff is not for a layer.
  • a feedstuff for chickens e.g. broiler chickens may be comprises of one or more of the ingredients listed in the table below, for example in the %ages given in the table below:
  • a feedstuff laying hens may be comprises of one or more ingredients listed in the table below, for example in the %ages given in the table below:
  • a feedstuff for turkeys may be comprises of one or more of the ingredients listed in the table below, for example in the %ages given in the table below:
  • a feedstuff for piglets may be comprises of one or more ingredients listed in the table below, for example in the %ages given in the table below:
  • a feedstuff for grower/fmisher pigs may be comprises of one or more of the ingredients listed in the table below, for example in the %ages given in the table below:
  • Vegetable oil 0.5 By way of example only the diet specification for grower/finisher pigs may be as set out in the Table below:
  • the feed additive composition of the present invention and other components and/or the feedstuff comprising same may be used in any suitable form.
  • the feed additive composition of the present invention may be used in the form of solid or liquid preparations or alternatives thereof.
  • solid preparations include powders, pastes, boluses, capsules, pellets, tablets, dusts, and granules which may be wettable, spray- dried or freeze-dried.
  • liquid preparations include, but are not limited to, aqueous, organic or aqueous-organic solutions, suspensions and emulsions.
  • DFM or feed additive compositions of the present invention may be mixed with feed or administered in the drinking water.
  • the dosage range for inclusion into water is about lxl 0 3 CFU/animal/day to about l x lO 10 CFU/animal/day, and more preferably about lx l O 7 CFU/animal/day.
  • Suitable examples of forms include one or more of: powders, pastes, boluses, pellets, tablets, pills, capsules, ovules, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.
  • composition of the present invention may also contain one or more of: excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine; disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycoUate, croscamiellose sodium and certain complex silicates; granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia; lubricating agents such as magnesium stcaratc, stearic acid, glyceryl behenate and talc may be included.
  • excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine
  • disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycoUate, croscamiellos
  • Examples of nutritionally acceptable carriers for use in preparing the forms include, for example, water, salt solutions, alcohol, silicone, waxes, petroleum jelly, vegetable oils, polyethylene glycols, propylene glycol, liposomes, sugars, gelatin, lactose, amylose, magnesium stearate, talc, surfactants, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, and the like.
  • Preferred excipients for the forms include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols.
  • composition of the present invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, propylene glycol and glycerin, and combinations thereof.
  • Non-hydroscopic whey is often used as a carrier for DFMs (particularly bacterial DFMs) and is a good medium to initiate growth.
  • Bacterial DFM containing pastes may be formulated with vegetable oil and inert gelling ingredients.
  • Fungal products may be formulated with grain by-products as carriers.
  • the feed additive composition according to the present invention is not in the form of a microparticle system, such as the microparticle system taught in WO2005/123034.
  • Dosing The DFM and/or feed additive composition according to the present invention may be designed for one-time dosing or may be designed for feeding on a daily basis.
  • composition and each component therein
  • the optimum amount of the composition (and each component therein) to be used in the combination of the present invention will depend on the product to be treated and/or the method of contacting the product with the composition and/or the intended use for the same.
  • the amount of DFM and enzymes used in the compositions should be a sufficient amount to be effective and to remain sufficiently effective in improving the performance of the animal fed feed products containing said composition. This length of time for effectiveness should extend up to at least the time of utilisation of the product (e.g. feed additive composition or feed containing same).
  • the ratio of DFM to each enzyme in the feed can be in the ranges given below:
  • DFM phyta.se (CFU/FTU): In range from 5.0xl0 2 CFU DFM: 1 FTU enzyme to 5.0xl0 9 CFU
  • 1FTU enzyme preferably in the range from 7.5xl0 FU DFM: 1FTU enzyme to 2.5x10' CFU : 1 FTU enzyme.
  • DFM protease (CFU/PU): In range from S.Ox l O'CFU DFM: 1PU enzyme to l .Ox lO 9 CFU : 1 PU enzyme; preferably in the range from 1.25xl0 4 CFU DFM: 1PU enzyme to 5.0xl0 6 CFU : 1PU enzyme.
  • the feedstuff comprises the following:
  • a phytase at at least 500FTU/kg of feed
  • Envivo Pro at at least 75,000 CFU/g to 150,000 CFU/g of feed.
  • the feedstuff comprises the following:
  • the feedstuff comprises the following:
  • Envivo Pro (DFM) at 75,000 CFU/g to 1 50,000 CFU/g of feed.
  • Envivo Pro (DFM) at 37,500 CFU/g to 75,000 CFU/g of feed.
  • Envivo Pro (DFM) at 75,000 CFU/g to 150,000 CFU/g of feed.
  • Envivo Pro (DFM) at 37,500 CFU/g to 75,000 CFU/g of feed.
  • the DFM and enzyme(s) for use in the present invention may be used in combination with other components.
  • the present invention also relates to combinations.
  • the DFM in combination with a protease and phytase may be referred to herein as "the feed additive composition of the present invention".
  • the combination of the present invention comprises the feed additive composition of the present invention (or one or more of the constituents thereof) and another component which is suitable for animal consumption and is capable of providing a medical or physiological benefit to the consumer.
  • the "another component” is not a further enzyme or a further DFM.
  • the components may be prebiotics.
  • Prebiotics are typically non-digestible carbohydrate (oligo- or polysaccharides) or a sugar alcohol which is not degraded or absorbed in the upper digestive tract.
  • oligo- or polysaccharides typically non-digestible carbohydrate (oligo- or polysaccharides) or a sugar alcohol which is not degraded or absorbed in the upper digestive tract.
  • Known prebiotics used in commercial products and useful in accordance with the present invention include inulin (fructo-oligosaccharide, or FOS) and transgalacto- oligosaccharides (GOS or TOS).
  • Suitable prebiotics include pal ati noseo 1 i gosacchari dc, soybean oligosaccharide, alginate, xanthan, pectin, locust bean gum (LBG), inulin, guar gum, galacto-oligosaccharide (GOS), fructo-oligosaccharide (FOS), non-degradable starch, lactosaccharose, lactulose, lactitol, maltitol, maltodextrin, polydextrose (i.e.
  • Dietary fibres may include non-starch polysaccharides, such as arabinoxylans, cellulose and many other plant components, such as resistant dextrins, inulin, lignin, waxes, chitins, pectins, beta-glucans and oligosaccharides.
  • non-starch polysaccharides such as arabinoxylans, cellulose and many other plant components, such as resistant dextrins, inulin, lignin, waxes, chitins, pectins, beta-glucans and oligosaccharides.
  • the present invention relates to the combination of the feed additive composition according to the present invention (or one or more of the constituents thereof) with a prebiotic.
  • the present invention relates to a feed additive composition comprising (or consisting essentially of or consisting of) a DFM in combination with a phytase, a protease and a prebiotic.
  • the prebiotic may be administered simultaneously with (e.g. in admixture together with or delivered simultaneously by the same or different routes) or sequentially to (e.g. by the same or different routes) the feed additive composition (or constituents thereof) according to the present invention.
  • components of the combinations of the present invention include polydextrose, such as Litesse®, and/or a maltodextrin and/or lactitol. These other components may be optionally added to the feed additive composition to assist the drying process and help the survival of
  • suitable components include one or more of: thickeners, gelling agents, emulsifiers, binders, crystal modifiers, sweeteners (including artificial sweeteners), rheology modifiers, stabilisers, anti-ox id ants, dyes, enzymes, earners, vehicles, excipients, diluents, lubricating agents, flavouring agents, colouring matter, suspending agents, disintegrants, granulation binders etc. These other components may be natural. These other components may be prepared by use of chemical and/or enzymatic techniques.
  • the DFM and/or enzymes may be encapsulated.
  • the feed additive composition and/or DFM and/or enzymes is/are formulated as a dry powder or granule as described in WO2007/044968 (referred to as TPT granules) - reference incorporated herein by reference.
  • the DFM and/or enzymes for use in the present invention may be used in combination with one or more lipids.
  • the DFM and/or enzymes for use in the present invention may be used in combination with one or more lipid micelles.
  • the lipid micelle may be a simple lipid micelle or a complex lipid micelle.
  • the lipid micelle may be an aggregate of orientated molecules of amphipathic substances, such as a lipid and/or an oil.
  • thickener or gelling agent refers to a product that prevents separation by slowing or preventing the movement of particles, either droplets of immiscible liquids, air or insoluble solids. Thickening occurs when individual hydrated molecules cause an increase in viscosity, slowing the separation. Gelation occurs when the hydrated molecules link to form a three-dimensional network that traps the particles, thereby immobilising them.
  • stabiliser as used here is defined as an ingredient or combination of ingredients that keeps a product (e.g. a feed product) from changing over time.
  • emulsifier as used herein refers to an ingredient (e.g. a feed ingredient) that prevents the separation of emulsions.
  • Emulsions are two immiscible substances, one present in droplet form, contained within the other. Emulsions can consist of oil-in-water. where the droplet or dispersed phase is oil and the continuous phase is water; or water-in-oil, where the water becomes the dispersed phase and the continuous phase is oil.
  • Binder refers to an ingredient (e.g. a feed ingredient) that binds the product together through a physical or chemical reaction. During “gelation” for instance, water is absorbed, providing a binding effect. However, binders can absorb other liquids, such as oils, holding them within the product. In the context of the present invention binders would typically be used in solid or low-moisture products for instance baking products: pastries, doughnuts, bread and others.
  • Carriers or “vehicles” mean materials suitable for administration of the DFM and/or enzymes and include any such material known in the art such as, for example, any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is non-toxic and which does not interact with any components of the composition in a deleterious manner.
  • the present invention provides a method for preparing a feed additive composition
  • a method for preparing a feed additive composition comprising admixing a DFM, a phytase and a protease with at least one physiologically acceptable carrier selected from at least one of maltodextrin, limestone (calcium carbonate), cyclodextrin, wheat or a wheat component, sucrose, starch. Na 2 SC>4, Talc, PVA, sorbitol, benzoate, sorbiate, glycerol, sucrose, propylene glycol, 1 ,3-propane diol, glucose, parabens, sodium chloride, citrate, acetate, phosphate, calcium, metabisulfite, formate and mixtures thereof.
  • excipients include one or more of: microcrystalline cellulose and other celluloses, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine, starch, milk sugar and high molecular weight polyethylene glycols.
  • disintcgrants include one or more of: starch (preferably com, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates.
  • granulation binders include one or more of: polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, maltose, gelatin and acacia.
  • lubricating agents include one or more of: magnesium stearate, stearic acid, glyceryl behenate and talc.
  • diluents include one or more of: water, ethanol, propylene glycol and glycerin, and combinations thereof.
  • the other components may be used simultaneously (e.g. when they are in admixture together or even when they are delivered by different routes) or sequentially (e.g. they may be delivered by different routes).
  • the DFM remains viable.
  • the feed additive according to the present invention does not contain glucanase.
  • the feed additive according to the present invention does not contain sorbic acid.
  • the DFMs for use in the present invention may be in the form of concentrates. Typically these concentrates comprise a substantially high concentration of a DFM.
  • Feed additive compositions according to the present invention may have a content of viable cells (colony forming units, CFUs) which is in the range of at least 10 4 CFU/g (suitably including at least 10 5 CFU/g, such as at least 10 6 CFU/g, e.g. at least 10 7 CFU/g, at least 10 s CFU/g) to about l O 10 CFU/g (or even about 10 u CFU/g or about 10 12 CFU/g).
  • viable cells colony forming units, CFUs
  • the feed additive compositions according to the present invention may have a content of viable cells in the range of at least 10 9 CFU/g to about 10 12 CFU/g, preferably at least 10 10 CFU/g to about 10 12 CFU/g.
  • Powders, granules and liquid compositions in the form of concentrates may be diluted with water or resuspended in water or other suitable diluents, for example, an appropriate growth medium such as milk or mineral or vegetable oils, to give compositions ready for use.
  • the DFM or feed additive composition of the present invention or the combinations of the present invention in the form of concentrates may be prepared according to methods known in the art.
  • Tn one aspect of the present invention the enzymes or feed is contacted by a composition in a concentrated form.
  • compositions of the present invention may be spray-dried or freeze-dried by methods known in the art.
  • Typical processes for making particles using a spray drying process involve a solid material which is dissolved in an appropriate solvent (e.g. a culture of a DFM in a fermentation medium).
  • an appropriate solvent e.g. a culture of a DFM in a fermentation medium.
  • the material can be suspended or emulsified in a non-solvent to form a suspension or emulsion.
  • Other ingredients (as discussed above) or components such as antimicrobial agents, stabilising agents, dyes and agents assisting with the drying process may optionally be added at this stage.
  • the solution then is atomised to form a fine mist of droplets.
  • the droplets immediately enter a drying chamber where they contact a drying gas.
  • the solvent is evaporated from the droplets into the drying gas to solidify the droplets, thereby forming particles.
  • the particles are then separated from the drying gas and collected.
  • subject means an animal that is to be or has been administered with a feed additive composition according to the present invention or a feedstuff comprising said feed additive composition according to the present invention.
  • subject means an animal.
  • the subject is a mammal, bird, fish or crustacean including for example livestock or a domesticated animal (e.g. a pet).
  • the "subject” is livestock.
  • livestock refers to any farmed animal.
  • livestock is one or more of cows or bulls (including calves), poultry, pigs (including piglets), poultry (including broilers, chickens and turkeys), birds, fish (including freshwater fish, such as salmon, cod, trout and carp, e.g. koi caip, and marine fish, such as sea bass), crustaceans (such as shrimps, mussels and scallops), horses (including race horses), sheep (including lambs).
  • livestock and/or poultry and/or chickens does not include egg layers.
  • the "subject” is a domesticated animal or pet or an animal maintained in a zoological environment.
  • domesticated animal or pet or animal maintained in a zoological environment refers to any relevant animal including canines (e.g. dogs), felines (e.g. cats), rodents (e.g. guinea pigs, rats, mice), birds, fish (including freshwater fish and marine fish), and horses.
  • canines e.g. dogs
  • felines e.g. cats
  • rodents e.g. guinea pigs, rats, mice
  • birds including freshwater fish and marine fish
  • horses including freshwater fish and marine fish
  • the subject may be challenged by an enteric pathogen.
  • a subject may have one or more enteric pathogens present in its gut or digestive tract.
  • a subject may have one or more enteric pathogens in its gut or digestive tract at a level which:
  • ii) is at clinically relevant levels
  • iii) is at sub-clinical levels.
  • the enteric pathogen may be Clostridium perfringens for example. Performance
  • animal performance may be determined by the feed efficiency and/or weight gain of the animal and/or by the feed conversion ratio and/or by the digestibility of a nutrient in a feed (e.g. amino acid digestibility) and/or digestible energy or metabolizable energy in a feed and/or by nitrogen retention and/or by animals ability to avoid the negative effects of necrotic enteritis and/or by the immune response of the subject.
  • a nutrient in a feed e.g. amino acid digestibility
  • digestible energy or metabolizable energy in a feed e.g. amino acid digestibility
  • animal performance is determined by feed efficiency and/or weight gain of the animal and/or by the feed conversion ratio.
  • improved animal performance it is meant that there is increased feed efficiency, and/or increased weight gain and/or reduced feed conversion ratio and/or improved digestibility of nutrients or energy in a feed and/or by improved nitrogen retention and/or by improved ability to avoid the negative effects of necrotic enteritis and/or by an improved immune response in the subject resulting from the use of feed additive composition of the present invention in feed in comparison to feed which does not comprise said feed additive composition.
  • feed efficiency refers to the amount of weight gain in an animal that occurs when the animal is fed ad-libitum or a specified amount of food during a period of time.
  • increase feed efficiency it is meant that the use of a feed additive composition according the present invention in feed results in an increased weight gain per unit of feed intake compared with an animal fed without said feed additive composition being present.
  • Feed Conversion Ratio FCR
  • feed conversion ratio refers to the amount of feed fed to an animal to increase the weight of the animal by a specified amount.
  • An improved feed conversion ratio means a lower feed conversion ratio.
  • lower feed conversion ratio or “improved feed conversion ratio” it is meant that the use of a feed additive composition in feed results in a lower amount of feed being required to be fed to an animal to increase the weight of the animal by a specified amount compared to the amount of feed required to increase the weight of the animal by the same amount when the feed does not comprise said feed additive composition.
  • Nutrient digestibility as used herein means the fraction of a nutrient that disappears from the gastro-intestinal tract or a specified segment of the gastro-intestinal tract, e.g. the small intestine. Nutrient digestibility may be measured as the difference between what is administered to the subject and what comes out in the faeces of the subject, or between what is administered to the subject and what remains in the digesta on a specified segment of the gastro intestinal tract, e.g. the ileum.
  • Nutrient digestibility as used herein may be measured by the difference between the intake of a nutrient and the excreted nutrient by means of the total collection of excreta during a period of time; or with the use of an inert marker that is not absorbed by the animal, and allows the researcher calculating the amount of nutrient that disappeared in the entire gastro-intestinal tract or a segment of the gastro-intestinal tract.
  • an inert marker may be titanium dioxide, chromic oxide or acid insoluble ash.
  • Digestibility may be expressed as a percentage of the nutrient in the feed, or as mass units of digestible nutrient per mass units of nutrient in the feed.
  • Nutrient digestibility as used herein encompasses starch digestibility, fat digestibility, protein digestibility, and amino acid digestibility.
  • Energy digestibility means the gross energy of the feed consumed minus the gross energy of the faeces or the gross energy of the feed consumed minus the gross energy of the remaining digesta on a specified segment of the gastro-intestinal tract of the animal, e.g. the ileum.
  • Metabolizable energy refers to apparent metabolizable energy and means the gross energy of the feed consumed minus the gross energy contained in the faeces, urine, and gaseous products of digestion.
  • Energy digestibility and metabolizable energy may be measured as the difference between the intake of gross energy and the gross energy excreted in the faeces or the digesta present in specified segment of the gastro-intestinal tract using the same methods to measure the digestibility of nutrients, with appropriate corrections for nitrogen excretion to calculate metabolizable energy of feed.
  • Nitrogen retention means as subject's ability to retain nitrogen from the diet as body mass. A negative nitrogen balance occurs when the excretion of nitrogen exceeds the daily intake and is often seen when the muscle is being lost. A positive nitrogen balance is often associated with muscle growth, particularly in growing animals.
  • Nitrogen retention may be measured as the difference between the intake of nitrogen and the excreted nitrogen by means of the total collection of excreta and urine during a period of time. It is understood that excreted nitrogen includes undigested protein from the feed, endogenous proteinaceous secretions, microbial protein, and urinary nitrogen.
  • survival means the number of subject remaining alive.
  • improved survival may be another way of saying “reduced mortality”.
  • carcass yield means the amount of carcass as a proportion of the live body weight, after a commercial or experimental process of slaughter.
  • carcass means the body of an animal that has been slaughtered for food, with the head, entrails, part of the limbs, and feathers or skin removed.
  • meat yield as used herein means the amount of edible meat as a proportion of the live body weight, or the amount of a specified meat cut as a proportion of the live body weight.
  • the present invention further provides a method of increasing weight gain in a subject, e.g. poultry or swine, comprising feeding said subject a feedstuff comprising a feed additive composition according to the present invention.
  • An ''increased weight gain refers to an animal having increased body weight on being fed feed comprising a feed additive composition compared with an animal being fed a feed without said feed additive composition being present.
  • Necrotic enteritis is an acute or chronic enterotoxemia seen in chickens, turkeys and ducks worldwide, caused by Clostridium perfringens. Necrotic enteritis is often characterised by a fibrino-necrotic enteritis, usually of the mid- small intestine. Mortality may be 5-50%, usually around 10%. Infection occurs by faecal-oral transmission. Spores of the causative organism are highly resistant. Predisposing factors include coccidiosis/coccidiasis, diet (high protein), in ducks possibly heavy strains, high viscosity diets (often associated with high rye and wheat inclusions in the diet), contaminated feed and/or water, other debilitating diseases.
  • the present invention relates to increasing the subject's resistance to necrotic enteritis.
  • the present invention relates to avoiding or reducing the negative effect of necrotic enteritis.
  • the term "resistance to” as used herein may encompasses the term "tolerance of. Therefore in one embodiment the subject may not be resistant to necrotic enteritis but the subject may be able to tolerate the necrotic enteritis, i.e. without negative effects on performance of the subject.
  • the present invention relates to a feed additive composition according to the present invention for treating or preventing necrotic enteritis in a subject.
  • the subject will be one which has been or will be challenged with Clostridium perfringens and/or Eimeria species. Such challenge may come from the environment or the application of live microorganisms in the feed or drinking water, e.g. when live coccidia vaccines are used.
  • the present invention in another embodiment relates to a feed additive composition for preventing and/or treating coccidiosis in a subject.
  • the present invention yet further provides a method of preventing and/or treating necrotic enteritis and/or coccidiosis wherein an effective amount of a feed additive composition according to the present invention is administered to a subject.
  • Immune response means one of the multiple ways in which DFMs modulate the immune system of animals, including increased antibody production, up-regulation of cell mediated immunity, up-regulation of pro-inflammatory cytokines, and augmented toll-like receptor signalling. It is understood that immuno-stimulation of the gastro intestinal tract by DFMs may be advantageous to protect the host against disease, and that immuno- suppress! on of the gastro intestinal tract may be advantageous to the host because less nutrients and energy are used to support the immune function.
  • the immune response is a cellular immune response.
  • immune response is measure by looking at immune markers.
  • pathogenic bacteria means for example toxigenic Clostridia species, e.g. Clostridium perfi'ingens and/or E. coli and/or Salmonella spp and/or Campylobacter spp. In one embodiment the pathogenic bacteria may be Avian pathogenic E. coli species.
  • the present invention may reduce populations of pathogenic bacteria in the gastrointestinal tract of a subject.
  • the present invention relates to reducing nutrient excretion in manure. This has positive effects on reducing environmental hazards.
  • the present invention relates to reducing nitrogen and/or phosphorus content in the subject's manure. This, therefore, reduces the amount of nitrogen and/or phosphorus in the environment, which can be beneficial.
  • the DFM in the composition of the present invention can exert a probiotic culture effect. It is also within the scope of the present invention to add to the composition of the present invention further probiotic and/or prebiotics.
  • a prebiotic is: "a non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth and/or the activity of one or a limited number of beneficial bacterid”.
  • probiotic culture defines live microorganisms (including bacteria or yeasts for example) which, when for example ingested or locally applied in sufficient numbers, beneficially affects the host organism, i.e. by conferring one or more demonstrable health benefits on the host organism.
  • Probiotics may improve the microbial balance in one or more mucosal surfaces.
  • the mucosal surface may be the intestine, the urinary tract, the respiratory tract or the skin.
  • probiotic as used herein also encompasses live microorganisms that can stimulate the beneficial branches of the immune system and at the same time decrease the inflammatory reactions in a mucosal surface, for example the gut.
  • At least 10 6 -10 12 Whilst there are no lower or upper limits for probiotic intake, it has been suggested that at least 10 6 -10 12 , preferably at least 10 6 -10 10 , preferably 10 8 - 10 9 , cfu as a daily dose will be effective to achieve the beneficial health effects in a subject.
  • the enzyme or DFM used in the present invention may be in an isolated form.
  • isolated means that the enzyme or DFM is at least substantially free from at least one other component with which the enzyme or DFM is naturally associated in nature and as found in nature.
  • the enzyme or DFM of the present invention may be provided in a form that is substantially free of one or more contaminants with which the substance might otherwise be associated. Thus, for example it may be substantially free of one or more potentially contaminating polypeptides and/or nucleic acid molecules.
  • the enzyme and/or DFM according to the present invention is in a purified form.
  • the term "purified” means that the enzyme and/or DFM is present at a high level.
  • the enzyme and/or DFM is desirably the predominant component present in a composition. Preferably, it is present at a level of at least about 90%, or at least about 95% or at least about 98%, said level being determined on a dry weight/dry weight basis with respect to the total composition under consideration. It is envisaged within the scope of the present invention that the embodiments of the invention can be combined such that combinations of any of the features described herein are included within the scope of the present invention. In particular, it is envisaged within the scope of the present invention that any of the therapeutic effects of the bacteria may be exhibited concomitantly.
  • Enviva Pro ® is combination of Bacillus subtilis strains Bs2084, LSSAO l and 15AP4, provided by Danisco AJS.
  • Bird weights by pen were recorded at study initiation, 23 d, 35 d, and termination (42d). The pen was the unit of measure. Broiler diets were fed as crumbles (starter) or pellets (grower and finisher). Diets met or exceeded NRC standards (Table 2). The mixer was flushed to prevent cross contamination of diets. All treatment feeds were mixed using a Davis S-20 mixer and pelleted using a California Pellet Mill (cold pellet temperature 65-70 C). Samples were collected from each treatment diet from the beginning, middle, and end of each batch and blended together to confirm enzyme activities and Enviva Pro presence in feed.
  • Birds receive feed ad-libitum appropriate to the treatment from Day 0 to 42. Enzymes and Enviva Pro are provided by Danisco in the appropriate mixtures and levels for all experimental treatments. All diets contained 500 FTU of E. coli phytase in the background. The pens are arranged within the facility to prevent direct contact in order to avoid contamination. A change from starter to grower occurred on Day 21. Grower diet is replaced with the finisher diet on Day 35. At each feed change, feeders are removed from pens by block, weighed back, emptied, and refilled with the appropriate treatment diet. On the final day of the study feed is weighed. Pens are checked daily for mortality. When a bird is culled or found dead, the date and removal weight (kg) are recorded. A gross necropsy is performed on all dead or culled birds to determine the sex and probable cause of death. Signs of Necrotic Enteritis are noted.
  • the challenged control treatment increased lesion scores compared to the unchallenged control treatment.
  • Addition of DFMs in a combination of a protease and phytase surprisingly reduce lesion scores compared to all other treatments.
  • Figure 2 shows percentage of morality related to necrotic enteritis (NE) lesions from 20 to 42 d of age.
  • FIG 3 shows that a combination of the DFM (Enviva Pro®) with a combination of a protease and a phytase significantly improves body weight gain (BW gain) in broiler chickens challenged with Clostridium perfringens compared with the challenged control.
  • the data shows that the DFM in combination with the protease and phytase surprisingly improved total BW gain to the level of the unchallenged control + phytase.
  • Enviva Pro DMF
  • protease and phytase significantly improved (reduced) FCR (g BW gain / g feed intake) of broilers from 0 to 12 d compared to the challenged control, and enzymes by themselves and the other treatments.
  • Enviva Pro DMF
  • protease and phytase significantly improved (reduced) FCR (g BW gain / g feed intake) of broilers 0 to 23 days compared to the challenged control, and enzymes by themselves and the other treatments.
  • Enviva Pro ® is combination of Bacillus subtilis strains Bs2084, LSSAOl and 15AP4, provided by Danisco A/S.
  • a total of 512 birds are individually weighed and assigned on the basis of body weight to 64 cages (8 birds/ cage).
  • the 8 dietary treatments are then randomly assigned to 8 cages each.
  • Birds receive starter feed ad-libitum appropriate to the treatment from 0 to 21 days.
  • Enzymes and Enviva Pro are provided by Danisco in the appropriate mixtures and levels for all experimental treatments.
  • All diets contain 500 FTU of E. coli phytase in the background. The pens are arranged within the facility to prevent direct contact in order to avoid contamination. Birds are fed starter diets (Table 4) in mash form throughout the experiment. Table 4.
  • Digesta from birds within a cage are pooled, resulting in 8 samples per dietary treatment. The digesta samples are frozen immediately after collection, lyophilised and processed. Digesta samples and diets are analysed for Ti, DM, GE, starch, fat, N, amino acids, excluding tryptophan, and soluble and insoluble non-starch polysaccharides (NSPs) as per standard procedures. Calculation of ileal digestibility coefficients is performed as reported by Ravindran et al. (2005), based on the concentration of indigestible Ti.
  • Representative samples of excreta per cage are collected over four consecutive days (from day 1 7 to 20) for the determination of nitrogen-corrected apparent metabolizable energy (AMEn) and Nitrogen retention, based on the concentration of Ti in feed and excreta samples.
  • Daily excreta collections are pooled within a cage, mixed in a blender and sub-sampled. Each sub sample was lyophilized, ground to pass through a 0.5 mm sieve and stored in airtight plastic containers at - 4 C pending analysis. Processed samples are analysed for Ti, DM, GE, N, and soluble and insoluble NSPs as per standard procedures.
  • Enviva Pro ® is combination of Bacillus subtilis strains Bs2084, LSSAOl and 15AP4, provided by Danisco A/S.
  • Calsporin is a DFM product containing Bacillus subtilis Strain C3102.
  • Gallipro Tect is a DFM product containing Bacillus licheniformis DSM17236.
  • a total of 384 birds are individually weighed and assigned on the basis of body weight to 64 cages (6 birds/ cage).
  • the 8 dietary treatments are then randomly assigned to 8 cages each.
  • Birds receive starter feed ad-libitum appropriate to the treatment from 0 to 21 days.
  • Enzymes and Enviva Pro are provided by Danisco in the appropriate mixtures and levels for all experimental treatments.
  • the pens are arranged within the facility to prevent direct contact in order to avoid contamination. Birds were fed starter diets (Table 6) in mash form throughout the experiment.
  • Digesta from birds within a cage are pooled, resulting in 8 samples per dietary treatment. The digesta samples are frozen immediately after collection, lyophilised and processed. Digesta samples and diets are analysed for Ti, DM, GE, starch, fat, N, and soluble and insoluble NSPs as per standard procedures. Calculation of ileal digestibility coefficients is performed as reported by Ravindran et al. (2005), based on the concentration of indigestible Ti.
  • Feed intake and total excreta output are measured quantitatively per cage over four consecutive days (from day 17 to 20) for the determination of nitrogen-corrected apparent metabolizable energy (AMEn) and Nitrogen retention.
  • Daily excreta collections are pooled within a cage, mixed in a blender and sub-sampled. Each sub sample is lyophilized, ground to pass through a 0.5 mm sieve and stored in airtight plastic containers at - 4 C pending analysis. Processed samples are analysed for DM, GE, N, and soluble and insoluble NSPs as per standard procedures.
  • Tissue samples were taken from broiler chicks from the trial presented in Example 1 at 23 days of age. Treatment specifications are presented in Table 1. The jejunum, pancreas and liver were removed from 2 birds from every pen and the mucosa pooled resulting in eight samples per treatment. The samples were rinsed in buffer solution (PBS) immersed in a tissue storage reagent (RNAlater) according to manufacturer's protocol and stored at -80°C. Total RNA was isolated from each tissue sample using a single step phenol-chloroform extraction method as described by Chomczynski and Saachi (1987; Anal. Biochem. 162: 156-9).
  • RNA Concentration of the RNA was determined by measuring the absorbance at 260nm (Nanodrop) and monitored for integrity by gel electrophoresis on 1.2% agarose gels. Only RNA of sufficient purity and having a ratio of absorption at 260nm vs. 280nm greater than 1.87 were considered for use.
  • Microarrays were manufactured using 70 base pair oligo-nucleotides (Opereon Biotechnologies Inc) according to the protocol described by Druyan et al. (2008; Poult. Sci. 87:2418-29). The experimental design of the array was a complete interwoven loop design as described by Garosi et al. (2005; Br. J. Nutr.
  • RNA from individual samples was reversed transcribed to produce cDNA which was then used as a template for the qPCR amplifications as described by Druyan et al. (2008; Poult. Sci. 87:2418-29).
  • Thermocycling parameters were optimised for each gene and each gene was amplified independently in duplicate within a single instrument run.
  • Data files were generated from the scanned images of the microarrays but extracting the intensity raw data for each slide and dye combination using ScanAlyze Softare. Intensity data files were then analysed using JMP Genomics including and initial log2 transfomiation. Data normalisation was performed using locally- weighted regression and smoothing first within array and across all arrays. The resulting normalised log2 intensities were analysed using a mixed model ANOVA.
  • Expression data was collected using the microarray platform and a "heat map" produced to visualise the data for jejunum ( Figure 7) and pancreas ( Figure 8) at 23 days of age. Relative expression levels of six genes of interest were converted to visual cues based on the scale seen in Figure 7. Lowly expressed genes are marked with a minus sign ("-"), and highly expressed genes are marked with a plus sign ("+"); whereas a greater gray intensity depicts a greater difference from the mean expression level of the treatments. The genes that were measured and their purported functions are seen in Table 7. Real-time PGR was used to validate the gene expression shown in the heat map for sucrase isomaltase (SI) and fatty acid synthase (FASN) and were highly correlated to the array data.
  • SI sucrase isomaltase
  • FASN fatty acid synthase
  • Figure 7 shows a heat map of expression profiles of genes of interest for all treatments for jejunum at 23 days of age.
  • Figure 8 shows a heat map of expression profile of genes of interest for all treatments in liver at 23 days of age.
  • Unchallenged control Unchallenged Control + phytase
  • acetyl CoA carboxylase A (ACACA) was down-regulated in the challenged control but the combination of protease + phytase and Enviva Pro increased this to a level comparable with the unchallenged control treatment. Enviva Pro with only phytase or a protease + phytase without Enviva Pro did not have as noticeable an effect as the combination. ACACA is involved in the production of fatty acids from acetyl CoA and is used as a marker of lipogenesis.
  • Glucokinase (GC ) was down-regulated in the challenged control but the combination of protease + phytase with Enviva Pro produced an up-regulation similar to the unchallenged control. The extent of the up-regulation was greater than when protease + phytase were used without a DFM. A similar pattern was also seen with sucrase iso-maltase (SI) where the combination of Enviva Pro with protease + phytase increased expression compared to both the challenged and unchallenged control.
  • SI sucrase iso-maltase
  • GCK is a key enzyme in glucose metabolism and SI is responsible for hydrolysis of sucrose and iso-maltose, and so has an important role in the digestion and absorption of carbohydrates in animals.
  • PEPT1 oligo-peptide transport 1
  • ZO l Tight Junction protein 1
  • ZOl Tight Junction protein 1
  • ZOl is a protein that is on the cytoplasmic face of tight junctions, there are various roles for this protein ranging from signal transduction for tight junction assembly to stability of the tight junctions themselves.
  • the T-cell antigen CD3 (CD3D) was highly expressed in the challenged control.
  • the protease + phytase treatment had some effect in reducing the expression of this gene, but a greater effect was seen when protease + phytase were used in combination with Enviva Pro.
  • the same results were seen in the jejunum and the liver for CD3D which strengthen the results.
  • CD3D is a surface molecule found on T cells and plays an important role in signal transduction during T-cell receptor engagement and is part of the T-cell receptor/CD3 complex.
  • FASN Fatty acid synthase
  • the decreased glucokinase expression for the challenged control suggests that the Clostridium perfringens challenge caused damage to the mucosa and that addition of Enviva Pro and protease + phytase may have acted to remedy this.
  • the increase in expression of the peptide transporter oligopeptide transporter 1 (PEPT1 ) when protease + phytase alone and in combination with Enviva Pro suggests increased availability of peptides and thus an increased requirement for transport, which indicates an effect of enzymes and DFMs to increase the availability of peptides for the animal which allows for greater growth.
  • the increased fatty acid synthase (FASN) expression in the liver and the increased acetyl CoA carboxylase A in the jejunum suggest increased fatty acid synthesis due to increased carbohydrate availability.
  • Enzymes and Enviva Pro acted together to produce more available energy for the animal which resulted in more growth.
  • the effect of Enviva Pro on reducing the expression of Tight junction protein 1 indicates lower requirement for protein turn over, which may be related to a high intestinal integrity.
  • the increased expression in the challenged control suggests that turnover/requirement of the protein was high due to failing intestinal integrity possibly due to the coccidia and Clostridium perfringens infection.
  • T cell antigen CD3 d in the challenged control indicates increased cell-mediated immune response due to the challenge.
  • birds will be undergoing sub-optimal performance because the immune response will demand energy that could be used for growth, and because some birds will experience a systemic disease response.
  • the increased expression of this immunological marker is markedly reversed when Enviva Pro is used with phytase alone or in combination with protease + phytase.
  • Down regulation of immune response in the intestine may be one of the mechanisms by which the effectiveness of exogenous enzymes in nutrient absorption and performance is increased when a DFM is present, particularly in situations of enteric disease challenge.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Fodder In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A feed additive composition comprising a direct fed microbial in combination with a protease, and a phytase, and a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for improving the subject's resistance to necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject, which method comprising administering to a subject a direct fed microbial in combination with a protease and a phytase.

Description

FEED ADDITIVE COMPOSITION
FIELD OF INVENTION
The present invention relates to methods for improving feed compositions using a direct fed microbial in combination with a specific combination of enzymes, and to a feed additive composition comprising a direct fed microbial in combination with a specific combination of enzymes. The present invention further relates to uses and kits. BACKGROUND OF THE INVENTION
Supplemental enzymes are used as additives to animal feed, particularly poultry and swine feeds, as a means to improve nutrient utilization and production performance characteristics. Enzyme blends are available to improve the nutritional value of diets containing soybean meal, animal protein meals, or high fibre food by-products.
The concept of direct fed microbials (DFM) involves the feeding of beneficial microbes to animals, such as dairy cattle when they are under periods of stress (disease, ration changes, environmental or production challenges). Probiotics is another term for this category of feed additives. Probiotics or DFM have been shown to improve animal performance in controlled studies. DFM including direct fed bacteria and or yeast-based products.
Although combinations of DFMs with some enzymes have been contemplated, the interaction between DFMs and enzymes has never been fully understood. The present invention relates to novel specific combinations which surprisingly significantly improve production performance characteristics in animals. SUMMARY OF INVENTION
A seminal finding of the present invention is that a DFM in combination with a protease and a phytase has significant beneficial effects on the performance of an animal.
In particular, a seminal finding of the present invention is that a DFM in combination with a protease and phytase has significant beneficial effects on the performance of an animal, including improving one or more of the following: feed conversion ratio (FCR), ability to digest a raw material (e.g. nutrient digestibility, such as amino acid digestibility), nitrogen retention, survival, carcass yield, growth rate, weight gain, feed efficiency animals resistance to necrotic enteritis, immune response of the subject, the growth of beneficial bacteria in the gastrointestinal tract of a subject.
Another surprising effect of the present invention is that it can reduce nutrient excretion in manure (e.g. reduce nitrogen and phosphorus) content of a subject's manure.
In one aspect, the present invention provides a feed additive composition comprising (or consisting essentially of or consisting of) a direct fed microbial in combination with a protease and a phytase.
In another aspect, the present invention provides a method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for avoiding the negative effects of necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject, or for reducing nutrient excretion in manure, which method comprising administering to a subject a direct fed microbial in combination with a protease and a phytase.
A yet further aspect of the present invention is use of a direct fed microbial in combination with a protease and a phytase for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility) or for improving nitrogen retention) or for avoiding the negative effects of necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject, or for reducing nutrient excretion in manure.
In a further aspect of the present invention there is provided a kit comprising a direct fed microbial, a protease, a phytase (and optionally at least one vitamin and/or optionally at least one mineral) and instructions for administration.
In another aspect the present invention provides a method of preparing a feed additive composition, comprising admixing a direct fed microbial with a protease and a phytase and (optionally) packaging. In a yet further aspect the present invention provides feed or feedstuff comprising a feed additive composition comprising (or consisting essentially of or consisting of) a direct fed microbial in combination with a protease and a phytase.
A premix comprising a feed additive composition comprising (or consisting essentially of or consisting of) a direct fed microbial in combination with a protease and a phytase, and at least one mineral and/or at least one vitamin.
In another aspect, the present invention provides a method of preparing a feedstuff comprising admixing a feed component with a feed additive composition comprising (or consisting essentially of or consisting of) a direct fed microbial in combination with a protease and a phytase.
In a further aspect, the present invention relates to a feed additive composition for preventing and/or treating coccidiosis and/or necrotic enteritis in a subject.
The present invention yet further provides a method of preventing and/or treating necrotic enteritis and/or coccidiosis wherein an effective amount of a feed additive composition according to the present invention is administered to a subject.
BRIEF DESCRIPTION OF TPIE DRAWINGS
Figure 1 shows that a combination of DFM (Enviva Pro® available from Danisco A/S) with a combination of a protease (e.g. Bacillus subtilis protease) and a phytase (e.g. 500FTU/kg of Phyzyme XP (an E. coli phytase) available from Danisco A/S) significantly improved (reduced) necrotic enteritis lesion scores in the gut of the animals compared with the challenged control.
Figure 2 shows percentage of morality related to necrotic enteritis (NE) lesions from 20 to 42 d of age. A combination of DFM (Enviva Pro® available from Danisco A/S) with a combination of a protease (e.g. Bacillus subtilis protease) and a phytase (e.g. 500FTU/kg of Phyzyme XP (an E. coli phytase) available from Danisco A S) significantly improved (reduced) NE mortality.
Figure 3 shows the body weight gain of broiler chickens from 0 to 23 d in a necrotic enteritis challenge model. A combination of (Enviva Pro® available from Danisco A/S) with a combination of a protease (e.g. Bacillus subtilis protease) and a phytase (e.g. 500FTU/kg of Phyzyme XP (an E. coli phytase) available from Danisco A/S) significantly improved Body weight gain (BW gain) in broiler chickens challenged with Clostridium perfringens compared with the challenged control. Figure 4 shows the body weight gain of broiler chickens from 0- 12 days in necrotic enteritis challenge model. Pooled SBM-4.86.
Figure 5 shows the feed conversion ratio of broiler chickens in a necrotic enteritis challenge model. Pooled SEM=0.026.
Figure 6 shows the feed conversion ratio 0-23 d of broiler chickens in a necrotic enteritis challenge model. Pooled SEM=0.022.
Figure 7 shows a heat map of expression profiles of genes of interest for all treatments for jejunum at 23 days of age.
Unchallenged control = Unchallenged Control + phytase
CC = Challenged Control + phytase
CC+ Protease = Challenged Control + phytase + protease
CC+ EP = Challenged Control + phytase + Enviva Pro
CC+ EP + Protease = Challenged Control + phytase + protease + Enviva Pro.
Figure 8 shows a heat map of expression profile of chicken alpha amylase for all treatments in pancreas at 23 days of age.
Unchallenged control = Unchallenged Control + phytase
CC = Challenged Control + phytase
CC+ Protease - Challenged Control + phytase + protease
CC+ EP = Challenged Control + phytase + Enviva Pro
CC+ EP + Protease - Challenged Control + phytase + protease + Enviva Pro.
DETAILED DESCRIPTION OF THE INVENTION
Preferably each of the enzymes used in the present invention are exogenous to the DFM. In other words the enzymes are preferably added to or admixed with the DFM.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Singleton, et al, DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 20 ED., John Wiley and Sons, New York (1994), and Hale & Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide one of skill with a general dictionary of many of the terms used in this disclosure. This disclosure is not limited by the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of this disclosure. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, any nucleic acid sequences are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.
The headings provided herein are not limitations of the various aspects or embodiments of this disclosure which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.
Amino acids are referred to herein using the name of the amino acid, the three letter abbreviation or the single letter abbreviation.
The term "protein", as used herein, includes proteins, polypeptides, and peptides.
As used herein, the term "amino acid sequence" is synonymous with the term "polypeptide" and/or the term "protein". In some instances, the term "amino acid sequence" is synonymous with the term "peptide". In some instances, the term "amino acid sequence" is synonymous with the term "enzyme".
The terms "protein" and "polypeptide" are used interchangeably herein. In the present disclosure and claims, the conventional one-letter and three-letter codes for amino acid residues may be used. The 3-letter code for amino acids as defined in conformity with the IUPACIUB Joint Commission on Biochemical Nomenclature (JCBN). It is also understood that a polypeptide may be coded for by more than one nucleotide sequence due to the degeneracy of the genetic code. Other definitions of terms may appear throughout the specification. Before the exemplary embodiments are described in more detail, it is to understand that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within this disclosure. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within this disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in this disclosure. It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an enzyme" includes a plurality of such candidate agents and reference to "the feed" includes reference to one or more feeds and equivalents thereof known to those skilled in the ait, and so forth.
The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that such publications constitute prior art to the claims appended hereto. The enzymes for use in the present invention can be produced either by solid or submerged culture, including batch, fed-batch and continuous-flow processes. Culturing is accomplished in a growth medium comprising an aqueous mineral salts medium, organic growth factors, the carbon and energy source material, molecular oxygen, and, of course, a starting inoculum of one or more particular microorganism species to be employed.
Direct Fed Microbial (DFM)
The term "microbial" herein is used interchangeably with "microorganism". Preferably the DFM comprises a viable microorganism. Preferably the DFM comprises a viable bacterium or a viable yeast or a viable fungi.
Preferably the DFM comprises a viable bacteria.
The term "viable microorganism" means a microorganism which is metabolically active or able to differentiate.
In one embodiment the DFM may be a spore fomiing bacterium and hence the term DFM may be comprised of or contain spores, e.g. bacterial spores. Therefore in one embodiment the term "viable microorganism" as used herein may include microbial spores, such as endospores or conidia.
In another embodiment the DFM in the feed additive composition according to the present invention is not comprised of or does not contain microbial spores, e.g. endospores or conidia.
The microorganism may be a naturally occurring microorganism or it may be a transformed microorganism. The microorganism may also be a combination of suitable microorganisms. In some aspects, the DFM according to the present invention may be one or more of the following: a bacterium, a yeast, a fungi.
Preferably the DFM according to the present invention is a probiotic microorganism. In the present invention, the term direct fed microbial (DFM) encompasses direct fed bacteria, direct fed yeast, direct fed fungi and combinations thereof.
Preferably the DFM is a direct fed bacterium. Preferably the DFM is a combination comprising two or more bacteria, e.g. three or more or four or more; or the DFM is a combination comprising two or more bacterial strains, e.g. three or more or four or more. Preferably the bacterium or bacteria is or are isolated.
Suitably the DFM may comprise a bacterium from one or more of the following genera: Lactobacillus, Lactococcus, Streptococcus, Bacillus, Pediococcus, Enterococcus, Leuconostoc, Carnobacterium, Propionibacterium, Bifidobacterium, Clostridium and Megasphaera and combinations thereof.
In one embodiment the DFM may be selected from the following Bacillus spp: Bacillus subtilis, Bacillus cereus, Bacillus licheniformis and Bacillus amyloliquefaciens.
In one embodiment the DFM may be a combination comprising two or more Bacillus strains.
In one embodiment the DFM may be a combination of two or more the Bacillus subtilis strains 3A-P4 (PTA-6506); 15A-P4 (PTA-6507); 22C-P1 (PTA-6508); 2084 (NRRL B- 500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B-50105); BS 18 (NRRL B-50633); and BS 278 (NRRL B-50634).
Strains 3A-P4 (PTA-6506), 15A-P4 (PTA-6507) and 22C-P1 (PTA-6508) are publically available from American Type Culture Collection (ATCC).
Strains 2084 (NRRL B-500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B-50105) are publically available from the Agricultural Research Service Culture Collection (NRRL). Strain Bacillus subtilis LSSA01 is sometimes referred to as B. subtilis 8. These strains are taught in US 7, 754, 469 B2.
Bacillus subtilis BS 18 and Bacillus subtilis BS 278 were deposited by Andy Madisen of W227 N752 Westmound Dr. Waukesha, WI 53186, USA for Danisco USA Inc. of W227 N752 Westmound Dr. Waukesha, WI 53186, USA under the Budapest Treaty at the Agricultural Research Service Culture Collection (NRRL) at 1815 North University Street, Peoria, Illinois 61604, United States of America, under deposit numbers NRRL B-50633 and NRRL B-50634, respectively on 9 January 2012. Andy Madison of W227 N752 Westmound Dr. Waukesha, WI 531 86, USA and Danisco USA Inc. of W227 N752 Westmound Dr. Waukesha, WI 53186, USA authorise Danisco AJS of Langebrogade 1 , PO Box 17, DK-1001 , Copenhagen K, Denmark to refer to these deposited biological materials in this patent application and have given unreserved and irrevocable consent to the deposited material being made available to the public.
In some embodiments the DFM may be a combination comprising the Bacillus suhtilis strains as detailed in the table below:
Figure imgf000010_0001
In one embodiment the DFM may be selected from the following Lactococcus spp: Lactococcus cremoris and Lactococcus lactis and combinations thereof.
In one embodiment the DFM may be selected from the following Lactobacillus spp: Lactobacillus buchneri, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus kefiri, Lactobacillus bifidus, Lactobacillus brevis, Lactobacillus helveticus, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus curvatus, Lactobacillus bulgaricus, Lactobacillus sakei, Lactobacillus reuteri, Lactobacillus fermentum, Lactobacillus farciminis, Lactobacillus lactis, Lactobacillus delbreuckii, Lactobacillus plantarum, Lactobacillus paraplantarum, Lactobacillus farciminis, Lactobacillus rhamnosus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus johnsonii and Lactobacillus jensenii, and combinations of any thereof.
In one embodiment the DFM may be selected from the following Bifidobacteria spp: Bifidobacterium lactis, Bifidobacterium bifidium, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium catenulatum, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, and Bifidobacterium angulatum, and combinations of any thereof. Suitably the DFM may comprise a bacterium from one or more of the following species: Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Enterococcus faecium, Enterococcus spp, and Pediococcus spp, Lactobacillus spp, Bifidobacterium spp, Lactobacillus acidophilus, Pediococsus acidilactici, Lactococcus lactis, Bifidobacterium bifidum, Bacillus subtilis, Propionibacterium thoenii, Lactobacillus farciminis, Lactobacillus rhamnosus, Megasphaera elsdenii, Clostridium butyricum, Bifidobacterium animalis ssp. animalis, Lactobacillus reuteri, Bacillus cereus, Lactobacillus salivarius ssp. Salivarius, Propionibacteria sp and combinations thereof.
The direct fed bacterium used in the present invention may be of the same type (genus, species and strain) or may comprise a mixture of genera, species and/or strains.
Suitably the DFM according to the present invention may be one or more of the products or the microorganisms contained in those products as in the Table below:
Product Name Company Microorganism(s) Symbiotic
ingredients
Enviva Pro®, Danisco A/S Bacillus subtilis strain 2084 Accession
(formerly No. NRRl B-50013,
known as Bacillus subtilis strain LSSAOl
Avicorr®) Accession No. NRRL B-50104 and
Bacillus subtilis strain 15A-P4 ATCC
Accession No. PTA-6507
Calsporin® Calpis - Japan Bacillus subtilis Strain C3102
Clostat® Kemin Bacillus subtilis Strain PB6
Industries Inc.
Cylactin® DSM Enterococcus faecium NCIMB 10415
(SF68)
Gallipro® Chr. Hansen Bacillus subtilis Strain C3102
& A/S GalliproMax®
Gallipro®Tect® Chr. Hansen Bacillus licheniformis
A/S
Poultry star® Biomin, Inc Enterococcus and Pediococcus Fructo- oligosaccha rides
Protexin® Protexin Int Lactobacillus, Bifidobacterium and
another
Proflora® Alpharma Inc. Bacillus subtilis strain QST 713 β-Mos
p-mannan oligosaccha rides and β- glucans
Ecobiol® & Norel S.A. Bacillus amyloliquefaciens CECT-5940
Ecobiol® Plus
Fortiflora® Enterococcus faecium SF68
BioPlus2B® DSM Bacillus subtilis and Bacillus
licheniformis
Lactiferm® Chr. Hansen Lactic acid bacteria 7
Enterococcus faecium
CSI® Danisco A/S Bacillus strain
Yea-Sacc® Alltech Saccharomyces cerevisiae
Biomin Biomin Enterococcus faecium
IMB52®
Biomin C5® Biomin Pediococcus acidilactici,
Enterococcus faecium,
Bifidobacterium animalis ssp.
animalis,
Lactobacillus reuteri
Lactobacillus salivarius ssp. salivarius
Biacton® ChemVet Lactobacill us farciminis
Oralin E1707® Chevita GmBH Enterococcus faecium
Probios-pioneer Chr Hansen Enterococcus faecium (2 strains) PDFM® Lactococcus lactis DSM 1 1037
Sorbiflore® Dan i sco Animal Lactobacillus rhamnosus and
Nutrition Lactobacillus farcimims
Animavit® KRKA Bacillus subtilis
Bonvital® Lactosan GmbH Enterococcus faecium
Levueell SB Lallemand Saccharomyces cerevisiae
20®
Lcvuccll SC 0 & Lallemand Saccharomyces cerevisiae
SC10® ME
Bactocell Lallemand Pediococcus acidilacti
ActiSaf® Le S afire Saccharomyces cerevisiae
(formerly
BioSaf®)
Actisaf® SC47 Le Saffre Saccharomyces cerevisiae NCYC Sc47
Miya-Gold® Miyarisan Clostridium butyricum
Pharma
Fecinor and Norel S.A
Fecinor Plus® Enterococcus faecium
InteSwine® ntegro Gida ve
Ticaret AS
represented by
RM Associates Saccharomyces cerevisiae NCYC R- Ltd 625
BioSprint® ProSol SpA Saccharomyces cerevisia
Provita® Provita Enterococcus faecium and
Lactobacillus rhamnosus
PepSoyGen-C® Regal BV Bacillus subtilis and
(Nutraferma) Aspergillus oiyzae
Toyocerin® Rubinum Bacillus cereus
TOYOCERIN® Rubinum Bacillus cereus var. toyoi NCIMB
40112/CNCM 1-1012 In one embodiment suitably the DFM may be Enviva Pro®. Enviva Pro® is commercially available from Danisco A/S and is a combination of Bacillus strain 2084 Accession No. NRRl B-50013, Bacillus strain LSSAOl Accession No. NRRL B-50104 and Bacillus strain 15A-P4 ATCC Accession No. PTA-6507 (as taught in US 7,754,469 B - incorporated herein by reference).
Suitably, the DFM may comprise a yeast from the genera: Saccharomyces spp.
Preferably the DFM to be used in accordance with the present invention is a microorganism which is generally recognised as safe and, which is preferably GRAS approved.
A skilled person will readily be aware of specific species and or strains of microorganisms from within the genera described herein which are used in the food and/or agricultural industries and which are generally considered suitable for animal consumption.
Preferably, the DFM used in accordance with the present invention is one which is suitable for animal consumption.
Advantageously, where the product is a feed or feed additive composition, the viable DFM should remain effective through the normal "sell-by" or "expiration" date of the product during which the feed or feed additive composition is offered for sale by the retailer. The desired lengths of time and normal shelf life will vary from feedstuff to feedstuff and those of ordinary skill in the art will recognise that shelf-life times will vary upon the type of feedstuff, the size of the feedstuff, storage temperatures, processing conditions, packaging material and packaging equipment.
In some embodiments it is important that the DFM is tolerant to heat, i.e. is thermotolerant. This is particularly the case where the feed is pelleted. Therefore in one embodiment the DFM may be a thermotolerant microorganism, such as a thermotolerant bacteria, including for example Bacillus spp. In some embodiments it may be preterable that the DFM is a spore producing bacteria, such as Bacilli, e.g. Bacillus spp. Bacilli are able to from stable endospores when conditions for growth are unfavorable and are very resistant to heat, pi 1, moisture and disinfectants. In one embodiment suitably the DFM may decrease or prevent intestinal establishment of pathogenic microorganism (such as Clostridium perfringens and/or E. coli and/or Salmonella spp and/or Campylobacter spp.).
The DFM according to the present invention may be any suitable DFM. In one embodiment the following assay "DFM ASSAY" may used to determine the suitability of a microorganism to be a DFM. For the avoidance of doubt in one embodiment a DFM selected as an inhibitory strain (or an antipathogen DFM) in accordance with the "DFM ASSAY" taught herein is a suitable DFM for use in accordance with the present invention, i.e. in the feed additive composition according to the present invention.
DFM ASSAY:
Tubes were seeded each with a representative pathogen from a representative cluster. Supernatant from a potential DFM grown aerobically or anaerobically was added to the seeded tubes and incubated.
After incubation, the optical density (OD) of the control and supernatant treated tubes was measured for each pathogen.
Colonies of (potential DFM) strains that produced a lowered OD compared with the control were classified as an inhibitory strain (or an antipathogen DFM).
The DFM assay as used herein is explained in more detail in US2009/0280090 - incorporated herein by reference.
Preferably the representative pathogen used in assay is one (or more) of the following: Clostridium, such as Clostridium perfringens and/or Clostridium difficile, and/or E. coli and/or Salmonella spp and/or Campylobacter spp. In one preferred embodiment the assay is conducted with one or more of Clostridium perfringens and/or Clostridium difficile and/or E. coli, preferably Clostridium perfringens and/or Clostridium difficile, more preferably Clostridium perfringens.
In one embodiment the DFM of the present invention is preferably an antipathogen.
The term "antipathogen" as used herein means that the DFM counters an effect (e.g. a negative effect) of a pathogen.
In one embodiment to determine if a DFM is an antipathogen in accordance with the present invention the above mentioned DFM assay may be used. A DFM is considered to be an antipathogen or an antipathogen DFM if it is classed as an inhibitory strain in the above mentioned DFM assay, particularly when the pathogen is Clostridium perfringens.
In one embodiment the antipathogen DFM may be one or more of the following bacteria: Bacillus subtilis strain 2084 Accession No. NR L B-50013,
Bacillus subtilis strain LSSAO l Accession No. NRRL B-50104,
Bacillus subtilis strain 15A-P4 ATCC Accession No. PTA-6507,
Bacillus subtilis strain 3A-P4 ATCC Accession No. PTA-6506, and
Bacillus subtilis strain BS27 ATCC Accession No. NRRL B-50105. For the avoidance of doubt these strains are available and are referred to in US 7,754,459 B.
In one embodiment the DFM used in accordance with the present invention is not Lactobacillus gasseri BNR 17 Strain Acc No. KCTC 10902BP as taught in WO2008/016214.
Preferably the DFM is not an inactivated microorganism.
In one embodiment the DFM as used here is a composition comprising one or more DFM microorganisms as described herein. The composition may additionally comprise the enzymes of the present invention. The composition can be fed to an animal as a direct-fed microbial (DFM). One or more carrier(s) or other ingredients can be added to the DFM. The DFM may be presented in various physical forms, for example, as a top dress, as a water soluble concentrate for use as a liquid drench or to be added to a milk replacer, gelatin capsule, or gels. In one embodiment of the top dress form, freeze-dried fermentation product is added to a carrier, such as whey, maltodextrin, sucrose, dextrose, limestone (calcium carbonate), rice hulls, yeast culture, dried starch, and/or sodium silico aluminate. In one embodiment of the water soluble concentrate for a liquid drench or milk replacer supplement, freeze-dried fermentation product is added to a water soluble carrier, such as whey, maltodextrin, sucrose, dextrose, dried starch, sodium silico aluminate, and a liquid is added to form the drench or the supplement is added to milk or a milk replacer. In one embodiment of the gelatin capsule form, freeze-dried fermentation product is added to a carrier, such as whey, maltodextrin, sugar, limestone (calcium carbonate), rice hulls, yeast culture dried starch, and/or sodium silico aluminate. In one embodiment, the bacteria and carrier are enclosed in a degradable gelatin capsule. In one embodiment of the gels form, freeze-dried fermentation product is added to a carrier, such as vegetable oil, sucrose, silicon dioxide, polysorbate 80, propylene glycol, butylated hydroxyanisole, citric acid, ethoxyquin, and/or artificial coloring to form the gel.
The DFM(s) may optionally be admixed with a dry formulation of additives including but not limited to growth substrates, enzymes, sugars, carbohydrates, extracts and growth promoting micro-ingredients. The sugars could include the following: lactose; maltose; dextrose; maltodextrin; glucose; fructose; mannose; tagatose; sorbose; raffinose; and galactose. The sugars range from 50-95%, either individually or in combination. The extracts could include yeast or dried yeast fermentation solubles ranging from 5-50%. The growth substrates could include: trypticase, ranging from 5-25%; sodium lactate, ranging from 5-30%; and, Tween 80, ranging from 1-5%. The carbohydrates could include mannitol, sorbitol, adonitol and arabitol. The carbohydrates range from 5-50% individually or in combination. The micro-ingredients could include the following: calcium carbonate, ranging from 0.5-5.0%; calcium chloride, ranging from 0.5-5.0%; dipotassium phosphate, ranging from 0.5-5.0%; calcium phosphate, ranging from 0.5-5.0%; manganese proteinate, ranging from 0.25- 1 .00%; and, manganese, ranging from 0.25-1.0%.
To prepare DFMs described herein, the culture(s) and carrier(s) (where used) can be added to a ribbon or paddle mixer and mixed for about 15 minutes, although the timing can be increased or decreased. The components are blended such that a uniform mixture of the cultures and carriers result. The final product is preferably a dry, flowable powder. The DFM(s) or composition comprising same can then be added to animal feed or a feed premix, added to an animal's water, or administered in other ways known in the art (preferably simultaneously with the enzymes of the present invention). A feed for an animal can be supplemented with one or more DFM(s) described herein or with a composition described herein.
By "a mixture of at least two strains," is meant a mixture of two, three, four, five, six or even more strains. In some embodiments of a mixture of strains, the proportions can vary from 1% to 99%. Other embodiments of a mixture of strains are from 25% to 75%. Additional embodiments of a mixture of strains are approximately 50% for each strain. When a mixture comprises more than two strains, the strains can be present in substantially equal proportions or in different proportions in the mixture.
The DFM may be dosed appropriately.
Suitably dosages of DFM in the feed may be between about lxlO3 CFU/g feed to about lxl 09 CFU/g feed, suitably between about lxlO4 CFU/g feed to about lxlO8 CFU/g feed, suitably between about 7.5x104 CFU/g feed to about lxlO7 CFU/g feed. In one embodiment the DFM is dosed in the feedstuff at more than about 1x10 CFU/g feed, suitably more than about lxl 04 CFU/g feed, suitably more than about 7.5x104 CFU/g feed.
Suitably dosages of DFM in the feed additive composition may be between about lxl 05 CFU/g composition to about l xl O13 CFU/g composition, suitably between about lxlO6 CFU/g composition to about lxlO12 CFU/g composition, suitably between about 3.75x 107 CFU/g composition to about lxl O1 1 CFU/g composition.
In one embodiment the DFM is dosed in the feed additive composition at more than about lxlO5 CFU/g composition, suitably more than about lxlO6 CFU/g composition, suitably more than about 3.75x107 CFU/g composition. In one embodiment the DFM is dosed in the feed additive composition at more than about 2x 103 CFU/g composition, suitably more than about 2xl06 CFU/g composition, suitably more than about 3.75 107 CFU/g composition.
As used herein the term "CFU" means colony forming units and is a measure of viable cells in which a colony represents an aggregate of cells derived from a single progenitor cell.
Protease
The term protease as used herein is synonymous with peptidase or proteinase.
The protease for use in the present invention may be a subtilisin (E.C. 3.4.21.62) or a bacillolysin (E.C. 3.4.24.28) or an alkaline serine protease (E.C. 3.4.21.x) or a keratinase (E.C. 3.4.X.X). Preferably the protease in accordance with the present invention is a subtilisin.
Suitable proteases include those of animal, vegetable or microbial origin. Chemically modified or protein engineered mutants are also suitable. The protease may be a serine protease or a metalloprotease, e.g., an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from Bacillus sp., e.g., subtilisin Novo, subtilisin Caiisberg, subtilisin 309 {see, e.g., U.S. Patent No. 6,287,841), subtilisin 147, and subtilisin 168 {see, e.g. , WO 89/06279). Examples of trypsin-like proteases are trypsin (e.g., of porcine or bovine origin), and Fusarium proteases {see, e.g. , WO 89/06270 and WO 94/25583). Examples of useful proteases also include but are not limited to the variants described in WO 92/19729 and WO 98/201 15.
In one preferred embodiment the protease for use in the present invention may be one or more of the proteases in one or more of the commercial products below:
Commercial
product® Company Protease type Protease source
Avizyme 1 100 Danisco A/S Subtilisin Bacillus subtilis
Avizyme 1202 Danisco A/S Subtilisin Bacillus subtilis Avizyme 1302 Danisco A/S Subtilisin Bacillus subtilis
Avizyme 1500 Danisco A/S Subtilisin Bacillus subtilis
Avizyme 1505 Danisco A/S Subtilisin Bacillus subtilis
Kemzyme Plus Dry Kemin Bacillolysin Bacillus amyloliquefaciens
Kemzyme W dry Kemin Bacillolysin Bacillus amyloliq ue faciens
Trichoderma
longibrachiatum
Natuzyme Bioproton Protease /Trichoderma reesei
Porzyme 8300 Danisco Subtilisin Bacillus subtilis
Nocardiopsis prasina gene
Alkaline serine expressed in Bacillus
Ronozyme ProAct D S M/No vozymcs protease licheniformis
V ersazym e/C i benza
DP 100 Novus Keratinase Bacillus licheniformis
In one embodiment the protease may be a protease from B. subtilis.
In one embodiment the protease may be a Nocardiopsis protease available from Novozymes A/S.
Preferably, the protease is present in the feedstuff in range of about lOOOU/kg to about 20,000PU/kg feed, more preferably about 1500PU/kg feed to about lOOOOPU/kg feed, more preferably about 2000PU/kg feed to about 6000PU/kg feed.
In one embodiment the protease is present in the feedstuff at more than about lOOOPU/kg feed, suitably more than about 1500PU/kg feed, suitably more than about 2000PU/kg feed.
In one embodiment the protease is present in the feedstuff at less than about 20,000PU/kg feed, suitably less than about lOOOOPU/kg feed, suitably less than about 7000PU/kg feed, suitably less than about 6000PU/kg feed.
Preferably, the protease is present in the feed additive composition in range of about 200PU/g to about 400,000PU/g composition, more preferably about 300PU/g composition to about 200,000PU/g composition, and even more preferably about 5000PU/g composition to about 100,000 PU/g composition, and even more preferably about 700PU/g composition to about 70,000 PU/g composition, and even more preferably about l OOOPU/g composition to about 60,000 PU/g composition. In one embodiment the protease is present in the feed additive composition at more than about 200PU/g composition, suitably more than about 300PU/g composition, suitably more than about 400PU/g composition, suitably more than about 500PU/g composition, suitably more than about 750PU/g composition, suitably more than about 1 OOOPU/g composition.
In one embodiment the protease is present in the feed additive composition at less than about 400, OOOPU/g composition, suitably less than about 200,000PU/g composition, suitably less than about 100,000PU/g composition, suitably less than about 80, OOOPU/g composition, suitably less than about 70000PU/g composition, suitably less than about 60000PU/g composition.
It will be understood that one protease unit (PU) is the amount of enzyme that liberates from the substrate (0.6% casein solution) one microgram of phenolic compound (expressed as tyrosine equivalents) in one minute at pH 7.5 (40mM Na2P04 / lactic acid buffer) and 40°C. This may be referred to as the assay for determining 1PU.
In one embodiment suitably the enzyme is classified using the E.G. classification above, and the E.G. classification designates an enzyme having that activity when tested in the assay taught herein for determining 1 PU.
Phytase
The phytase for use in the present invention may be classified a 6-phytase (classified as E.G. 3.1.3.26) or a 3 -phytase (classified as E.G. 3.1.3.8).
In one embodiment the phytase may be a 6-phytase (E.G. 3.1.3.26).
In one preferred embodiment the phytase for use in the present invention may be one or more of the phytases in one or more of the commercial products below:
Commercial
product® Company Phytase type Phytase source
Finase ABVista 3 -phytase Trichoderma reesei
Finase EC ABVista 6-phytase E. coli gene expressed in Trichoderma reesei
Natuphos BASF 3 -phytase Aspergillus Niger
Trichoderma
phytase (type longibrach latum
Natuzyme Bioproton not specified) /Trichoderma reesei
E. coll gene expressed in
OPTIPHOS® Huvepharma AD 6-phytase Pichia pastoris
A consensus gene expressed
Phytase spl 002 DSM 3 -phytase in Hansenula polymorpha
E. coli gene expressed in
Phyzyme XP Danisco 6-phytase Schizosaccahomyces pombe
E. coli gene expressed in
Quantum 2500D, Pichia pastoris or 5000L ABVista 6-phytase Trichoderma
Citrobacter braakii gene
Ronozyme Hi-Phos expressed in Aspergillus (MIL) DSM Novozymes 6-phytase oryzae
Peniphora lycii gene expressed in Aspergillus
Ronozyme NP DSM/Novozymes 6-phytase oryzae
Peniphora lycii gene expressed in Aspergillus
Ronozyme P DSM/Novozymes 6-phytase oryzae
Rovabio PHY Adisseo 3 -phytase Penicillium funiculosum
The term consensus gene as used herein means that the DNA vector used to transform the organism contains a synthetic phytase gene based on a consensus sequence, a URA gene from the non-pathogenic yeast Saccharomyces cerevisiae and the origin of replication of the Escherichia coli plasmid pBR322.
In one embodiment the phytase is a Citrobacter phytase derived from e.g. Citrobacter freundii, preferably C. freundii NCIMB 41247 and variants thereof e.g. as disclosed in WO2006/038062 (incorporated herein by reference) and WO2006/038128 (incorporated herein by reference), Citrobacter braakii YH-15 as disclosed in WO 2004/085638, Citrobacter braakii ATCC 51113 as disclosed in WO2006/037328 (incorporated herein by reference), as well as variants thereof e.g. as disclosed in WO2007/1 12739 (incorporated herein by reference) and WO201 1/117396 (incorporated herein by reference), Citrobacter amalonaticus, preferably Citrobacter amalonaticus ATCC 25405 or Citrobacter amalonaticus ATCC 25407 as disclosed in WO2006037327 (incorporated herein by reference), Citrobacter gillenii, preferably Citrobacter gillenii DSM 13694 as disclosed in WO2006037327 (incorporated herein by reference), or Citrobacter intermedius, Citrobacter koseri, Citrobacter murliniae, Citrobacter rodentium, Cilrobacter sedl kii, Citrobacter werhnanii, Citrobacter youngae, Citrobacter species polypeptides or variants thereof.
In one embodiment the phytase may be a phytase from Citrobacter, e.g. from Citrobacter freundii, such as the phytase enzyme(s) taught in WO2006/038128, which reference is incorporated herein by reference.
In preferred embodiments, the phytase is preferably E. coli phytase marketed under the name Phy/.yme XP™ by Danisco A/S.
Alternatively the phytase may be a Buttiauxella phytase, e.g. a Buttiauxella agrestis phytase, for example, the phytase enzymes taught in WO 2006/043178, WO 2008/097619, WO2009/129489, WO2008/092901, PCT/US2009/4101 1 or PCT/IB2010/051804, all of which are incorporated herein by reference.
In one embodiment the phytase may be a phytase from Hafnia, e.g. from Hafnia alvei, such as the phytase enzyme(s) taught in US2008263688, which reference is incorporated herein by reference. In one embodiment the phytase may be a phytase from Aspergillus, e.g. from Apergillus orzyae.
In one embodiment the phytase may be a phytase from Penicillium, e.g. from Penicillium funiculosum.
Preferably, the phytase is present in the feedstuff in range of about 200FTU/kg to about l OOOFTU/kg feed, more preferably about 300FTU/kg feed to about 750FTU/kg feed, more preferably about 400FTU/kg feed to about 500FTU/kg feed. In one embodiment the phytase is present in the feedstuff at more than about 200FTU/kg feed, suitably more than about 300FTU/kg feed, suitably more than about 400FTU/kg feed. In one embodiment the phytase is present in the feedstuff at less than about l OOOFTU/kg feed, suitably less than about 750 FTU/kg feed.
Preferably, the phytase is present in the feed additive composition in range of about 40FTU/g to about 40,000FTU/g composition, more preferably about 80FTU/g composition to about 20,000FTU/g composition, and even more preferably about l OOFTU/g composition to about 10,000FTU/g composition, and even more preferably about 200FTU/g composition to about 10,000FTU/g composition. In one embodiment the phytase is present in the feed additive composition at more than about 40FTU/g composition, suitably more than about 60FTU/g composition, suitably more than about l OOFTU/g composition, suitably more than about 150FTU/g composition, suitably more than about 200FTU/g composition. In one embodiment the phytase is present in the feed additive composition at less than about 40,000FTU/g composition, suitably less than about 20,000FTU/g composition, suitably less than about 15,000FTU/g composition, suitably less than about 10,000FTU/g composition.
It will be understood that as used herein 1 FTU (phytase unit) is defined as the amount of enzyme required to release 1 μηιοΐ of inorganic orthophosphate from a substrate in one minute under the reaction conditions defined in the ISO 2009 phytase assay - A standard assay for determining phytase activity and 1 FTU can be found at International Standard ISO/DIS 30024: 1-17, 2009. In one embodiment suitably the enzyme is classified using the E.G. classification above, and the E.G. classification designates an enzyme having that activity when tested in the assay taught herein for determining 1 FTU.
Advantages
The interaction of DFMs with enzymes is complicated and without wishing to be bound by theoiy, it is very surprising that we can see an improvement in the subject's resistance to necrotic enteritis, e.g. that we see a reduction in lesion scores for instance. Prior to the present invention the combination of DFMs and enzymes (e.g. as taught herein) had not been taught for this specific purpose.
One advantage of the present invention is that the feed additive composition according to the present invention can avoid the negative effects of necrotic enteritis or can be used for improving the subject's resistance to necrotic enteritis.
Without wishing to be bound by theory, phytase catalyzes the sequential hydrolysis of phytate, a principal storage form of phosphorus in cereals and legumes, to less phosphorylated myo-inositol derivatives with concomitant release of inorganic phosphate. Hydrolysis of phytate causes a reduction of endogenous losses of amino acids to the intestinal lumen. A reduction of endogenous amino acid losses in the intestine reduces the availability of nitrogen for bacterial growth, which helps the activity of DFMs on inhibition of C. perfringens and other pathogenic bacteria.
Without wishing to be bound in theory proteases cause non-specific hydrolysis of dietary protein yielding a variety of polypeptides in the intestinal lumen. Animals finalise protein hydrolysis and absorb such amino acids. However, in the case of enteric pathogenic challenges, pathogenic bacteria may take advantage of higher peptide availability in the lumen of jejunum and ileum. DFMs inhibit the growth of entero-pathogens by for example competing for N sources, as well as by direct inhibition.
In combination these enzymes and DFMs surprisingly provide a significant improvement on the pathogen reduction and/or resistance to necrotic enteritis compared with other DFM and enzyme combinations and/or DFMs alone and/or enzyme(s) alone.
Formulation of the DFM with the enzymes
The DFM and the enzymes may be formulated in any suitable way to ensure that the formulation comprises viable DFMs and active enzymes.
In one embodiment the DFM and enzymes may be formulated as a liquid, a dry powder or a granule. The dry powder or granules may be prepared by means known to those skilled in the art, such as, in top-spray fluid bed coater, in a buttom spray Wurster or by drum granulation (e.g. High sheer granulation), extrusion, pan coating or in a microingredients mixer.
For some embodiments the DFM and/or the enzyme(s) may be coated, for example encapsulated. Suitably the DFM and enzymes may be formulated within the same coating or encapsulated within the same capsule. Alternatively one or both of the enzymes may be formulated within the same coating or encapsulated within the same capsule and the DFM could be formulated in a coating separate to the one or both of the enzymes. In some embodiments, such as where the DFM is capable of producing endospores, the DFM may be provided without any coating. In such circumstances, the DFM endospores may be simply admixed with one or both enzymes. In the latter case, the enzymes may be coated, e.g. encapsulated, for instance one or both of the enzymes may be coated, e.g. encapsulated. The enzymes may be encapsulated as mixtures (i.e. comprising one or both) of the enzymes or they may be encapsulated separately, e.g. as single enzymes. In one preferred embodiment both enzymes may be coated, e.g. encapsulated, together.
In one embodiment the coating protects the enzymes from heat and may be considered a fhennoprotectant.
In one embodiment the feed additive composition is formulated to a dry powder or granules as described in WO2007/044968 (referred to as TPT granules) or WO 1997/016076 or WO 1992/012645 (each of which is incorporated herein by reference).
In one embodiment the feed additive composition may be formulated to a granule for feed compositions comprising: a core; an active agent; and at least one coating, the active agent of the granule retaining at least 50% activity, at least 60% activity, at least 70% activity, at least 80% activity after conditions selected from one or more of a) a feed pelleting process, b) a steam-heated feed pretreatment process, c) storage, d) storage as an ingredient in an unpelleted mixture, and e) storage as an ingredient in a feed base mix or a feed premix comprising at least one compound selected from trace minerals, organic acids, reducing sugars, vitamins, choline chloride, and compounds which result in an acidic or a basic feed base mix or feed premix.
With regard to the granule at least one coating may comprise a moisture hydrating material that constitutes at least 55% w/w of the granule; and/or at least one coating may comprise two coatings. The two coatings may be a moisture hydrating coating and a moisture barrier coating. In some embodiments, the moisture hydrating coating may be between 25% and 60% w/w of the granule and the moisture barrier coating may be between 2% and 15% w/w of the granule. The moisture hydrating coating may be selected from inorganic salts, sucrose, starch, and maltodextrin and the moisture bamer coating may be selected from polymers, gums, whey and starch.
The granule may be produced using a feed pelleting process and the feed pretreatment process may be conducted between 70°C and 95°C for up to several minutes, such as between 85°C and 95°C.
In one embodiment the feed additive composition may be formulated to a granule for animal feed comprising: a core; an active agent, the active agent of the granule retaining at least 80% activity after storage and after a steam-heated pelleting process where the granule is an ingredient; a moisture barrier coating; and a moisture hydrating coating that is at least 25% w/w of the granule, the granule having a water activity of less than 0.5 prior to the steam- heated pelleting process.
The granule may have a moisture barrier coating selected from polymers and gums and the moisture hydrating material may be an inorganic salt. The moisture hydrating coating may be between 25% and 45% w/w of the granule and the moisture barrier coating may be between 2% and 10% w/w of the granule.
The granule may be produced using a steam-heated pelleting process which may be conducted between 85°C and 95°C for up to several minutes.
In some embodiments the DFM (e.g. DFM endospores for example) may be diluted using a diluent, such as starch powder, lime stone or the like. in one embodiment, the composition is in a liquid formulation suitable for consumption preferably such liquid consumption contains one or more of the following: a buffer, salt, sorbitol and/or glycerol.
In another embodiment the feed additive composition may be formulated by applying, e.g. spraying, the enzyme(s) onto a carrier substrate, such as ground wheat for example.
In one embodiment the feed additive composition according to the present invention may be fomiulated as a premix. By way of example only the premix may comprise one or more feed components, such as one or more minerals and/or one or more vitamins.
In one embodiment the DFM and/or enzymes for use in the present invention are fomiulated with at least one physiologically acceptable carrier selected from at least one of maltodextrin, limestone (calcium carbonate), cyclodextrin, wheat or a wheat component, sucrose, starch, Na2S04, Talc, PVA, sorbitol, benzoate, sorbiate, glycerol, sucrose, propylene glycol, 1 ,3- propane diol, glucose, parabens, sodium chloride, citrate, acetate, phosphate, calcium, metabisulfite, formate and mixtures thereof. Packaging
In one embodiment the feed additive composition and/or premix and/or feed or feedstuff according to the present invention is packaged.
In one preferred embodiment the feed additive composition and/or premix and/or feed or feedstuff is packaged in a bag, such as a paper bag.
In an alternative embodiment the feed additive composition and/or premix and/or feed or feedstuff may be sealed in a container. Any suitable container may be used.
Feed
The feed additive composition of the present invention may be used as or in the preparation of - a feed. The term '"feed" is used synonymously herein with "feedstuff.
The feed may be in the form of a solution or as a solid - depending on the use and/or the mode of application and/or the mode of administration.
When used as - or in the preparation of - a feed - such as functional feed - the composition of the present invention may be used in conjunction with one or more of: a nutritionally acceptable carrier, a nutritionally acceptable diluent, a nutritionally acceptable excipient, a nutritionally acceptable adjuvant, a nutritionally active ingredient.
In a preferred embodiment the feed additive composition of the present invention is admixed with a feed component to form a feedstuff. The term "feed component" as used herein means all or part of the feedstuff. Part of the feedstuff may mean one constituent of the feedstuff or more than one constituent of the feedstuff, e.g. 2 or 3 or 4. In one embodiment the term "feed component" encompasses a premix or premix constituents. Preferably the feed may be a fodder, or a premix thereof, a compound feed, or a premix thereof. In one embodiment the feed additive composition according to the present invention may be admixed with a compound feed, a compound feed component or to a premix of a compound feed or to a fodder, a fodder component, or a premix of a fodder. The term fodder as used herein means any food which is provided to an animal (rather than the animal having to forage for it themselves). Fodder encompasses plants that have been cut.
The term fodder includes hay, straw, silage, compressed and pelleted feeds, oils and mixed rations, and also sprouted grains and legumes.
Fodder may be obtained from one or more of the plants selected from: alfalfa (lucerne), barley, birdsfoot trefoil, brassicas, Chau moellier, kale, rapeseed (canola), rutabaga (swede), turnip, clover, alsike clover, red clover, subterranean clover, white clover, grass, false oat grass, fescue, Bermuda grass, brome, heath grass, meadow grasses (from naturally mixed grassland swards, orchard grass, rye grass, Timothy-grass, corn (maize), millet, oats, sorghum, soybeans, trees (pollard tree shoots for tree-hay), wheat, and legumes.
The term "compound feed" means a commercial feed in the form of a meal, a pellet, nuts, cake or a crumble. Compound feeds may be blended from various raw materials and additives. These blends are formulated according to the specific requirements of the target animal.
Compound feeds can be complete feeds that provide all the daily required nutrients, concentrates that provide a part of the ration (protein, energy) or supplements that only provide additional micronutrients, such as minerals and vitamins. The main ingredients used in compound feed are the feed grains, which include corn, soybeans, sorghum, oats, and barley.
Suitably a premix as referred to herein may be a composition composed of microingredients such as vitamins, minerals, chemical preservatives, antibiotics, fermentation products, and other essential ingredients. Premixes are usually compositions suitable for blending into commercial rations.
Any feedstuff of the present invention may comprise one or more feed materials selected from the group comprising a) cereals, such as small grains (e.g., wheat, barley, rye, oats and combinations thereof) and/or large grains such as maize or sorghum; b) by products from cereals, such as corn gluten meal, Distillers Dried Grain Solubles (DDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm kernel, and citrus pulp; c) protein obtained from sources such as soya, sunflower, peanut, lupin, peas, fava beans, cotton, canola, fish meal, dried plasma protein, meat and bone meal, potato protein, whey, copra, sesame; d) oils and fats obtained from vegetable and animal sources; e) minerals and vitamins. A feedstuff of the present invention may contain at least 30%, at least 40%, at least 50% or at least 60% by weight corn and soybean meal or com and full fat soy, or wheat meal or sunflower meal. In addition or in the alternative, a feedstuff of the present invention may comprise at least one high fibre feed material and/or at least one by-product of the at least one high fibre feed material to provide a high fibre feedstuff. Examples of high fibre feed materials include: wheat, barley, rye, oats, by products from cereals, such as com gluten meal, Distillers Dried Grain Solubles (DDGS), wheat bran, wheat middlings, wheat shorts, rice bran, rice hulls, oat hulls, palm kernel, and citrus pulp. Some protein sources may also be regarded as high fibre: protein obtained from sources such as sunflower, lupin, fava beans and cotton.
In the present invention the feed may be one or more of the following: a compound feed and premix, including pellets, nuts or (cattle) cake; a crop or crop residue: com, soybeans, sorghum, oats, barley, com stover, copra, straw, chaff, sugar beet waste; fish meal; freshly cut grass and other forage plants; meat and bone meal; molasses; oil cake and press cake; oligosaccharides; conserved forage plants: hay and silage; seaweed; seeds and grains, either whole or prepared by crushing, milling etc.; sprouted grains and legumes; yeast extract. The term feed in the present invention also encompasses in some embodiments pet food. A pet food is plant or animal material intended for consumption by pets, such as dog food or cat food. Pet food, such as dog and cat food, may be either in a diy form, such as kibble for dogs, or wet canned form. Cat food may contain the amino acid taurine. The term feed in the present invention also encompasses in some embodiments fish food. A fish food normally contains macro nutrients, trace elements and vitamins necessary to keep captive fish in good health. Fish food may be in the form of a flake, pellet or tablet. Pelleted forms, some of which sink rapidly, are often used for larger fish or bottom feeding species. Some fish foods also contain additives, such as beta carotene or sex hormones, to artificially enhance the color of ornamental fish. The term feed in the present invention also encompasses in some embodiment bird food. Bird food includes food that is used both in birdfecders and to feed pet birds. Typically bird food comprises of a variety of seeds, but may also encompass suet (beef or mutton fat). As used herein the term "contacted" refers to the indirect or direct application of the composition of the present invention to the product (e.g. the feed). Examples of the application methods which may be used, include, but are not limited to, treating the product in a material comprising the feed additive composition, direct application by mixing the feed additive composition with the product, spraying the feed additive composition onto the product surface or dipping the product into a preparation of the feed additive composition.
In one embodiment the feed additive composition of the present invention is preferably admixed with the product (e.g. feedstuff). Alternatively, the feed additive composition may be included in the emulsion or raw ingredients of a feedstuff.
For some applications, it is important that the composition is made available on or to the surface of a product to be affected/treated. This allows the composition to impart one or more of the following favourable characteristics: performance benefits. The feed additive compositions of the present invention may be applied to intersperse, coat and/or impregnate a product (e.g. feedstuff or raw ingredients of a feedstuff) with a controlled amount of DFM and enzymes.
The DFM and enzymes may be used simultaneously (e.g. when they are in admixture together or even when they are delivered by different routes) or sequentially (e.g. they may be delivered by different routes). In one embodiment preferably the DFM and enzymes are applied simultaneously. Preferably the DFM and enzymes are admixed prior to being delivered to a feedstuff or to a raw ingredient of a feedstuff. The DFM in feed additive compositions according to the present invention - can be added in suitable concentrations - such as for example in concentrations in the final feed product which offer a daily dose of between about 2x1 ο3 CFU to about 2x1011 CFU, suitably between about 2xl 06 to about lxl O10, suitably between about 3.75xl07 CFU to about IxlO10 CFU. Preferably, the feed additive composition of the present invention will be thermally stable to heat treatment up to about 70 °C; up to about 85°C; or up to about 95°C. The heat treatment may be performed for up to about 1 minute: up to about 5 minutes; up to about 10 minutes; up to about 30 minutes; up to about 60 minutes. The term thermally stable means that at least about 75% of the enzyme components and/or DFM that were present/active in the additive before heating to the specified temperature are still present/active after it cools to room temperature. Preferably, at least about 80% of the enzyme components and/or DFM that were present and active in the additive before heating to the specified temperature are still present and active after it cools to room temperature.
In a particularly preferred embodiment the feed additive composition is homogenized to produce a powder. In an alternative preferred embodiment, the feed additive composition is formulated to granules as described in WO2007/044968 (referred to as TPT granules) incorporated herein by reference.
In another preferred embodiment when the feed additive composition is formulated into granules the granules comprise a hydrated barrier salt coated over the protein core. The advantage of such salt coating is improved thermo-tolerance, improved storage stability and protection against other feed additives otherwise having adverse effect on the enzyme and/or DFM. Preferably, the salt used for the salt coating has a water activity greater than 0.25 or constant humidity greater than 60 % at 20 °C.
Preferably, the salt coating comprises a Na2S04. The method of preparing a feed additive composition may also comprise the further step of pelleting the powder. The powder may be mixed with other components known in the art. The powder, or mixture comprising the powder, may be forced through a die and the resulting strands are cut into suitable pellets of variable length. Optionally, the pelleting step may include a steam treatment, or conditioning stage, prior to formation of the pellets. The mixture comprising the powder may be placed in a conditioner, e.g. a mixer with steam injection. The mixture is heated in the conditioner up to a specified temperature, such as from 60-100°C, typical temperatures would be 70°C, 80°C, 85°C, 90°C or 95°C. The residence time can be variable from seconds to minutes and even hours. Such as 5 seconds, 10 seconds, 15 seconds, 30 seconds, 1 minutes, 2 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes and 1 hour. It will be understood that the feed additive composition of the present invention is suitable for addition to any appropriate feed material.
As used herein, the term feed material refers to the basic feed material to be consumed by an animal. It will be further understood that this may comprise, for example, at least one or more unprocessed grains, and/or processed plant and/or animal material such as soybean meal or bone meal.
As used herein, the term "feedstuff refers to a feed material to which one or more feed additive compositions have been added.
It will be understood by the skilled person that different animals require different feedstuffs, and even the same animal may require different feedstuffs, depending upon the purpose for which the animal is reared. Preferably, the feedstuff may comprise feed materials comprising maize or com, wheat, barley, triticale, rye, rice, tapioca, sorghum, and/ or any of the by-products, as well as protein rich components like soybean mean, rape seed meal, canola meal, cotton seed meal, sunflower seed mean, animal -by-product meals and mixtures thereof. More preferably, the feedstuff may comprise animal fats and / or vegetable oils.
Optionally, the feedstuff may also contain additional minerals such as, for example, calcium and/or additional vitamins. Preferably, the feedstuff is a corn soybean meal mix.
In one embodiment, preferably the feed is not pet food. In another aspect there is provided a method for producing a feedstuff. Feedstuff is typically produced in feed mills in which raw materials are first ground to a suitable particle si/.e and then mixed with appropriate additives. The feedstuff may then be produced as a mash or pellets; the later typically involves a method by which the temperature is raised to a target level and then the feed is passed through a die to produce pellets of a particular size. The pellets are allowed to cool. Subsequently liquid additives such as fat and enzyme may be added. Production of feedstuff may also involve an additional step that includes extrusion or expansion prior to pelleting - in particular by suitable techniques that may include at least the use of steam. The feedstuff may be a feedstuff for a nionogastric animal, such as poultry (for example, broiler, layer, broiler breeders, turkey, duck, geese, water fowl), swine (all age categories), a pet (for example dogs, cats) or fish, preferably the feedstuff is for poultry.
In one embodiment the feedstuff is not for a layer.
By way of example only a feedstuff for chickens, e.g. broiler chickens may be comprises of one or more of the ingredients listed in the table below, for example in the %ages given in the table below:
Ingredients Starter (%) Finisher (%)
Maize 46.2 46.7
Wheat Middlings 6.7 10.0
Maize DDGS 7.0 7.0
Soyabean Meal 48%CP 32.8 26.2
AiVVeg Fat blend 3.0 5.8
L-Lysine HC1 0.3 0.3
DL-methionine 0.3 0.3
L-threonine 0.1 0.1
Salt 0.3 0.4
Limestone 1.1 1.1
Dicalcium Phosphate 1.2 1.2
Poultry Vitamins and Micro-
0.3 0.3
minerals By way of example only the diet specification for chickens, such as broiler chickens, may be as set out. in the Table below:
Figure imgf000036_0002
By way of example only a feedstuff laying hens may be comprises of one or more ingredients listed in the table below, for example in the %ages given in the table below:
Figure imgf000036_0003
By way of example only the diet specification for laying hens may be as set out in the Table below:
Figure imgf000036_0001
Available Phosphorus (%) 0.42
Sodium (%) 0.16
By way of example only a feedstuff for turkeys may be comprises of one or more of the ingredients listed in the table below, for example in the %ages given in the table below:
Figure imgf000037_0002
By way of example only the diet specification for turkeys may be as set out in the Table below:
Figure imgf000037_0003
By way of example only a feedstuff for piglets may be comprises of one or more ingredients listed in the table below, for example in the %ages given in the table below:
Figure imgf000037_0001
Soyabean Meal 48% CP 25.7 19.9
Dried Whey 10.0 0.0
Soyabean Oil 1 .0 0.7
L-Lysine HCl 0.4 0.5
DL-methionine 0.2 0.2
L-threonine 0.1 0.2
L-tryptophan 0.03 0.04
Limestone 0.6 0.7
Dicalcium Phosphate 1.6 1.6
Swine Vitamins and Micro-
0.2 0.2
minerals
Salt 0.2 0.4
By way of example only the diet specification for piglets may be as set out in the Table below:
Figure imgf000038_0001
By way of example only a feedstuff for grower/fmisher pigs may be comprises of one or more of the ingredients listed in the table below, for example in the %ages given in the table below:
Ingredient Grower/ Finisher (%)
Maize 27.5
Soyabean Meal 48% CP 15.4
Maize DDGS 20.0
Wheat bran 1 1.1
Rice bran 12.0
Canola seed meal 10.0
Limestone 1.6
Dicalcium phosphate 0.01
Salt 0.4
Swine Vitamins and Micro-minerals 0.3
Lysine-HCl 0.2
Vegetable oil 0.5 By way of example only the diet specification for grower/finisher pigs may be as set out in the Table below:
Figure imgf000039_0001
Forms
The feed additive composition of the present invention and other components and/or the feedstuff comprising same may be used in any suitable form.
The feed additive composition of the present invention may be used in the form of solid or liquid preparations or alternatives thereof. Examples of solid preparations include powders, pastes, boluses, capsules, pellets, tablets, dusts, and granules which may be wettable, spray- dried or freeze-dried. Examples of liquid preparations include, but are not limited to, aqueous, organic or aqueous-organic solutions, suspensions and emulsions.
In some applications, DFM or feed additive compositions of the present invention may be mixed with feed or administered in the drinking water. In one embodiment the dosage range for inclusion into water is about lxl 03 CFU/animal/day to about l x lO10 CFU/animal/day, and more preferably about lx l O7 CFU/animal/day.
Suitable examples of forms include one or more of: powders, pastes, boluses, pellets, tablets, pills, capsules, ovules, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.
By way of example, if the composition of the present invention is used in a solid, e.g. pelleted form, it may also contain one or more of: excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine; disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycoUate, croscamiellose sodium and certain complex silicates; granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia; lubricating agents such as magnesium stcaratc, stearic acid, glyceryl behenate and talc may be included.
Examples of nutritionally acceptable carriers for use in preparing the forms include, for example, water, salt solutions, alcohol, silicone, waxes, petroleum jelly, vegetable oils, polyethylene glycols, propylene glycol, liposomes, sugars, gelatin, lactose, amylose, magnesium stearate, talc, surfactants, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, and the like.
Preferred excipients for the forms include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols.
For aqueous suspensions and/or elixirs, the composition of the present invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, propylene glycol and glycerin, and combinations thereof.
Non-hydroscopic whey is often used as a carrier for DFMs (particularly bacterial DFMs) and is a good medium to initiate growth.
Bacterial DFM containing pastes may be formulated with vegetable oil and inert gelling ingredients.
Fungal products may be formulated with grain by-products as carriers.
In one embodiment preferably the feed additive composition according to the present invention is not in the form of a microparticle system, such as the microparticle system taught in WO2005/123034.
Dosing The DFM and/or feed additive composition according to the present invention may be designed for one-time dosing or may be designed for feeding on a daily basis.
The optimum amount of the composition (and each component therein) to be used in the combination of the present invention will depend on the product to be treated and/or the method of contacting the product with the composition and/or the intended use for the same.
The amount of DFM and enzymes used in the compositions should be a sufficient amount to be effective and to remain sufficiently effective in improving the performance of the animal fed feed products containing said composition. This length of time for effectiveness should extend up to at least the time of utilisation of the product (e.g. feed additive composition or feed containing same).
The ratio of DFM to each enzyme in the feed can be in the ranges given below:
DFM: phyta.se (CFU/FTU): In range from 5.0xl02CFU DFM: 1 FTU enzyme to 5.0xl09 CFU
4 7
: 1FTU enzyme; preferably in the range from 7.5xl0 FU DFM: 1FTU enzyme to 2.5x10' CFU : 1 FTU enzyme.
DFM: protease (CFU/PU): In range from S.Ox l O'CFU DFM: 1PU enzyme to l .Ox lO9 CFU : 1 PU enzyme; preferably in the range from 1.25xl04CFU DFM: 1PU enzyme to 5.0xl06 CFU : 1PU enzyme. In one embodiment preferably the feedstuff comprises the following:
a protease at at least 4000PU/kg of feed;
a phytase at at least 500FTU/kg of feed; and
Envivo Pro (DFM) at at least 75,000 CFU/g to 150,000 CFU/g of feed. In one embodiment preferably the feedstuff comprises the following:
a protease at 4000PU/kg of feed;
a phytase at 500FTU/kg of feed; and
Envivo Pro (DFM) at 75,000 CFU/g to 150,000 CFU/g of feed. In one embodiment preferably the feedstuff comprises the following:
a protease at 5000PU/kg of feed;
a phytase at 625FTU/kg of feed; and
Envivo Pro (DFM) at 75,000 CFU/g to 1 50,000 CFU/g of feed.
In another embodiment the feedstuff comprises the following:
a protease at 2000PU/kg of feed;
a phytase at 500FTU/kg of feed; and
Envivo Pro (DFM) at 37,500 CFU/g to 75,000 CFU/g of feed.
In a preferred embodiment the feed additive composition comprises sufficient enzyme and DFMs to dose the feedstuff as follows:
a protease at 4000PU/kg of feed;
a phytase at 500FTU/kg of feed; and
Envivo Pro (DFM) at 75,000 CFU/g to 150,000 CFU/g of feed.
In a preferred embodiment the feed additive composition comprises sufficient enzyme and DFMs to dose the feedstuff as follows:
a protease at 2000PU/kg of feed;
a phytase at 500FTU/kg of feed; and
Envivo Pro (DFM) at 37,500 CFU/g to 75,000 CFU/g of feed.
Combination with Other Components
The DFM and enzyme(s) for use in the present invention may be used in combination with other components. Thus, the present invention also relates to combinations. The DFM in combination with a protease and phytase may be referred to herein as "the feed additive composition of the present invention". The combination of the present invention comprises the feed additive composition of the present invention (or one or more of the constituents thereof) and another component which is suitable for animal consumption and is capable of providing a medical or physiological benefit to the consumer. In one embodiment preferably the "another component" is not a further enzyme or a further DFM. The components may be prebiotics. Prebiotics are typically non-digestible carbohydrate (oligo- or polysaccharides) or a sugar alcohol which is not degraded or absorbed in the upper digestive tract. Known prebiotics used in commercial products and useful in accordance with the present invention include inulin (fructo-oligosaccharide, or FOS) and transgalacto- oligosaccharides (GOS or TOS). Suitable prebiotics include pal ati noseo 1 i gosacchari dc, soybean oligosaccharide, alginate, xanthan, pectin, locust bean gum (LBG), inulin, guar gum, galacto-oligosaccharide (GOS), fructo-oligosaccharide (FOS), non-degradable starch, lactosaccharose, lactulose, lactitol, maltitol, maltodextrin, polydextrose (i.e. Litesse®), lactitol, lactosucrose, soybean oligosaccharides, palatinose, isomalto-oligosaccharides, gluco- oligosaccharides and xylo-oligosaccharides, pectin fragments, dietary fibres, mannan- oligosaccharides.
Dietary fibres may include non-starch polysaccharides, such as arabinoxylans, cellulose and many other plant components, such as resistant dextrins, inulin, lignin, waxes, chitins, pectins, beta-glucans and oligosaccharides.
In one embodiment the present invention relates to the combination of the feed additive composition according to the present invention (or one or more of the constituents thereof) with a prebiotic. In another embodiment the present invention relates to a feed additive composition comprising (or consisting essentially of or consisting of) a DFM in combination with a phytase, a protease and a prebiotic.
The prebiotic may be administered simultaneously with (e.g. in admixture together with or delivered simultaneously by the same or different routes) or sequentially to (e.g. by the same or different routes) the feed additive composition (or constituents thereof) according to the present invention.
Other components of the combinations of the present invention include polydextrose, such as Litesse®, and/or a maltodextrin and/or lactitol. These other components may be optionally added to the feed additive composition to assist the drying process and help the survival of
DFM.
Further examples of other suitable components include one or more of: thickeners, gelling agents, emulsifiers, binders, crystal modifiers, sweeteners (including artificial sweeteners), rheology modifiers, stabilisers, anti-ox id ants, dyes, enzymes, earners, vehicles, excipients, diluents, lubricating agents, flavouring agents, colouring matter, suspending agents, disintegrants, granulation binders etc. These other components may be natural. These other components may be prepared by use of chemical and/or enzymatic techniques.
In one embodiment the DFM and/or enzymes may be encapsulated. In one embodiment the feed additive composition and/or DFM and/or enzymes is/are formulated as a dry powder or granule as described in WO2007/044968 (referred to as TPT granules) - reference incorporated herein by reference.
In one preferred embodiment the DFM and/or enzymes for use in the present invention may be used in combination with one or more lipids.
For example, the DFM and/or enzymes for use in the present invention may be used in combination with one or more lipid micelles. The lipid micelle may be a simple lipid micelle or a complex lipid micelle.
The lipid micelle may be an aggregate of orientated molecules of amphipathic substances, such as a lipid and/or an oil.
As used herein the term "thickener or gelling agent" refers to a product that prevents separation by slowing or preventing the movement of particles, either droplets of immiscible liquids, air or insoluble solids. Thickening occurs when individual hydrated molecules cause an increase in viscosity, slowing the separation. Gelation occurs when the hydrated molecules link to form a three-dimensional network that traps the particles, thereby immobilising them.
The term "stabiliser" as used here is defined as an ingredient or combination of ingredients that keeps a product (e.g. a feed product) from changing over time. The term "emulsifier" as used herein refers to an ingredient (e.g. a feed ingredient) that prevents the separation of emulsions. Emulsions are two immiscible substances, one present in droplet form, contained within the other. Emulsions can consist of oil-in-water. where the droplet or dispersed phase is oil and the continuous phase is water; or water-in-oil, where the water becomes the dispersed phase and the continuous phase is oil. Foams, which are gas-in- liquid, and suspensions, which are solid-in-liquid, can also be stabilised through the use of emulsifiers. As used herein the term "binder" refers to an ingredient (e.g. a feed ingredient) that binds the product together through a physical or chemical reaction. During "gelation" for instance, water is absorbed, providing a binding effect. However, binders can absorb other liquids, such as oils, holding them within the product. In the context of the present invention binders would typically be used in solid or low-moisture products for instance baking products: pastries, doughnuts, bread and others.
"Carriers" or "vehicles" mean materials suitable for administration of the DFM and/or enzymes and include any such material known in the art such as, for example, any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is non-toxic and which does not interact with any components of the composition in a deleterious manner.
The present invention provides a method for preparing a feed additive composition comprising admixing a DFM, a phytase and a protease with at least one physiologically acceptable carrier selected from at least one of maltodextrin, limestone (calcium carbonate), cyclodextrin, wheat or a wheat component, sucrose, starch. Na2SC>4, Talc, PVA, sorbitol, benzoate, sorbiate, glycerol, sucrose, propylene glycol, 1 ,3-propane diol, glucose, parabens, sodium chloride, citrate, acetate, phosphate, calcium, metabisulfite, formate and mixtures thereof. Examples of excipients include one or more of: microcrystalline cellulose and other celluloses, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine, starch, milk sugar and high molecular weight polyethylene glycols. Examples of disintcgrants include one or more of: starch (preferably com, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates.
Examples of granulation binders include one or more of: polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, maltose, gelatin and acacia.
Examples of lubricating agents include one or more of: magnesium stearate, stearic acid, glyceryl behenate and talc.
Examples of diluents include one or more of: water, ethanol, propylene glycol and glycerin, and combinations thereof.
The other components may be used simultaneously (e.g. when they are in admixture together or even when they are delivered by different routes) or sequentially (e.g. they may be delivered by different routes).
Preferably, when the feed additive composition of the present invention is admixed with another component(s), the DFM remains viable.
In one embodiment preferably the feed additive composition according to the present invention does not comprise chromium or organic chromium
In one embodiment preferably the feed additive according to the present invention does not contain glucanase.
In one embodiment preferably the feed additive according to the present invention does not contain sorbic acid.
Concentrates
The DFMs for use in the present invention may be in the form of concentrates. Typically these concentrates comprise a substantially high concentration of a DFM. Feed additive compositions according to the present invention may have a content of viable cells (colony forming units, CFUs) which is in the range of at least 104 CFU/g (suitably including at least 105 CFU/g, such as at least 106 CFU/g, e.g. at least 107 CFU/g, at least 10s CFU/g) to about l O10 CFU/g (or even about 10u CFU/g or about 1012 CFU/g).
When the DFM is in the form of a concentrate the feed additive compositions according to the present invention may have a content of viable cells in the range of at least 109 CFU/g to about 1012 CFU/g, preferably at least 1010 CFU/g to about 1012 CFU/g. Powders, granules and liquid compositions in the form of concentrates may be diluted with water or resuspended in water or other suitable diluents, for example, an appropriate growth medium such as milk or mineral or vegetable oils, to give compositions ready for use.
The DFM or feed additive composition of the present invention or the combinations of the present invention in the form of concentrates may be prepared according to methods known in the art.
Tn one aspect of the present invention the enzymes or feed is contacted by a composition in a concentrated form.
The compositions of the present invention may be spray-dried or freeze-dried by methods known in the art.
Typical processes for making particles using a spray drying process involve a solid material which is dissolved in an appropriate solvent (e.g. a culture of a DFM in a fermentation medium). Alternatively, the material can be suspended or emulsified in a non-solvent to form a suspension or emulsion. Other ingredients (as discussed above) or components such as antimicrobial agents, stabilising agents, dyes and agents assisting with the drying process may optionally be added at this stage.
The solution then is atomised to form a fine mist of droplets. The droplets immediately enter a drying chamber where they contact a drying gas. The solvent is evaporated from the droplets into the drying gas to solidify the droplets, thereby forming particles. The particles are then separated from the drying gas and collected.
Subject
The term "subject", as used herein, means an animal that is to be or has been administered with a feed additive composition according to the present invention or a feedstuff comprising said feed additive composition according to the present invention.
The term "subject", as used herein, means an animal. Preferably, the subject is a mammal, bird, fish or crustacean including for example livestock or a domesticated animal (e.g. a pet).
In one embodiment the "subject" is livestock.
The term "livestock", as used herein refers to any farmed animal. Preferably, livestock is one or more of cows or bulls (including calves), poultry, pigs (including piglets), poultry (including broilers, chickens and turkeys), birds, fish (including freshwater fish, such as salmon, cod, trout and carp, e.g. koi caip, and marine fish, such as sea bass), crustaceans (such as shrimps, mussels and scallops), horses (including race horses), sheep (including lambs).
In one embodiment the term livestock and/or poultry and/or chickens does not include egg layers.
In another embodiment the "subject" is a domesticated animal or pet or an animal maintained in a zoological environment.
The term "domesticated animal or pet or animal maintained in a zoological environment" as used herein refers to any relevant animal including canines (e.g. dogs), felines (e.g. cats), rodents (e.g. guinea pigs, rats, mice), birds, fish (including freshwater fish and marine fish), and horses.
In one embodiment the subject may be challenged by an enteric pathogen. By way of example a subject may have one or more enteric pathogens present in its gut or digestive tract. For example a subject may have one or more enteric pathogens in its gut or digestive tract at a level which:
i) results in loss of performance of the animal and/or
ii) is at clinically relevant levels; or
iii) is at sub-clinical levels.
The enteric pathogen may be Clostridium perfringens for example. Performance
As used herein, "animal performance" may be determined by the feed efficiency and/or weight gain of the animal and/or by the feed conversion ratio and/or by the digestibility of a nutrient in a feed (e.g. amino acid digestibility) and/or digestible energy or metabolizable energy in a feed and/or by nitrogen retention and/or by animals ability to avoid the negative effects of necrotic enteritis and/or by the immune response of the subject.
Preferably "animal performance" is determined by feed efficiency and/or weight gain of the animal and/or by the feed conversion ratio. By "improved animal performance" it is meant that there is increased feed efficiency, and/or increased weight gain and/or reduced feed conversion ratio and/or improved digestibility of nutrients or energy in a feed and/or by improved nitrogen retention and/or by improved ability to avoid the negative effects of necrotic enteritis and/or by an improved immune response in the subject resulting from the use of feed additive composition of the present invention in feed in comparison to feed which does not comprise said feed additive composition.
Preferably, by "improved animal performance" it is meant that there is increased feed efficiency and/or increased weight gain and/or reduced feed conversion ratio. As used herein, the term "feed efficiency" refers to the amount of weight gain in an animal that occurs when the animal is fed ad-libitum or a specified amount of food during a period of time. By "increased feed efficiency" it is meant that the use of a feed additive composition according the present invention in feed results in an increased weight gain per unit of feed intake compared with an animal fed without said feed additive composition being present. Feed Conversion Ratio (FCR )
As used herein, the term "feed conversion ratio" refers to the amount of feed fed to an animal to increase the weight of the animal by a specified amount.
An improved feed conversion ratio means a lower feed conversion ratio.
By "lower feed conversion ratio" or "improved feed conversion ratio" it is meant that the use of a feed additive composition in feed results in a lower amount of feed being required to be fed to an animal to increase the weight of the animal by a specified amount compared to the amount of feed required to increase the weight of the animal by the same amount when the feed does not comprise said feed additive composition.
Nutrient digestibility
Nutrient digestibility as used herein means the fraction of a nutrient that disappears from the gastro-intestinal tract or a specified segment of the gastro-intestinal tract, e.g. the small intestine. Nutrient digestibility may be measured as the difference between what is administered to the subject and what comes out in the faeces of the subject, or between what is administered to the subject and what remains in the digesta on a specified segment of the gastro intestinal tract, e.g. the ileum. Nutrient digestibility as used herein may be measured by the difference between the intake of a nutrient and the excreted nutrient by means of the total collection of excreta during a period of time; or with the use of an inert marker that is not absorbed by the animal, and allows the researcher calculating the amount of nutrient that disappeared in the entire gastro-intestinal tract or a segment of the gastro-intestinal tract. Such an inert marker may be titanium dioxide, chromic oxide or acid insoluble ash. Digestibility may be expressed as a percentage of the nutrient in the feed, or as mass units of digestible nutrient per mass units of nutrient in the feed. Nutrient digestibility as used herein encompasses starch digestibility, fat digestibility, protein digestibility, and amino acid digestibility. Energy digestibility as used herein means the gross energy of the feed consumed minus the gross energy of the faeces or the gross energy of the feed consumed minus the gross energy of the remaining digesta on a specified segment of the gastro-intestinal tract of the animal, e.g. the ileum. Metabolizable energy as used herein refers to apparent metabolizable energy and means the gross energy of the feed consumed minus the gross energy contained in the faeces, urine, and gaseous products of digestion. Energy digestibility and metabolizable energy may be measured as the difference between the intake of gross energy and the gross energy excreted in the faeces or the digesta present in specified segment of the gastro-intestinal tract using the same methods to measure the digestibility of nutrients, with appropriate corrections for nitrogen excretion to calculate metabolizable energy of feed.
Nitrogen retention
Nitrogen retention as used herein means as subject's ability to retain nitrogen from the diet as body mass. A negative nitrogen balance occurs when the excretion of nitrogen exceeds the daily intake and is often seen when the muscle is being lost. A positive nitrogen balance is often associated with muscle growth, particularly in growing animals.
Nitrogen retention may be measured as the difference between the intake of nitrogen and the excreted nitrogen by means of the total collection of excreta and urine during a period of time. It is understood that excreted nitrogen includes undigested protein from the feed, endogenous proteinaceous secretions, microbial protein, and urinary nitrogen.
Survival
The term survival as used herein means the number of subject remaining alive. The term "improved survival" may be another way of saying "reduced mortality".
Carcass yield and meat yield
The term carcass yield as used herein means the amount of carcass as a proportion of the live body weight, after a commercial or experimental process of slaughter. The term carcass means the body of an animal that has been slaughtered for food, with the head, entrails, part of the limbs, and feathers or skin removed. The term meat yield as used herein means the amount of edible meat as a proportion of the live body weight, or the amount of a specified meat cut as a proportion of the live body weight.
Weight gain
The present invention further provides a method of increasing weight gain in a subject, e.g. poultry or swine, comprising feeding said subject a feedstuff comprising a feed additive composition according to the present invention.
An ''increased weight gain" refers to an animal having increased body weight on being fed feed comprising a feed additive composition compared with an animal being fed a feed without said feed additive composition being present. Necrotic enteritis
Necrotic enteritis is an acute or chronic enterotoxemia seen in chickens, turkeys and ducks worldwide, caused by Clostridium perfringens. Necrotic enteritis is often characterised by a fibrino-necrotic enteritis, usually of the mid- small intestine. Mortality may be 5-50%, usually around 10%. Infection occurs by faecal-oral transmission. Spores of the causative organism are highly resistant. Predisposing factors include coccidiosis/coccidiasis, diet (high protein), in ducks possibly heavy strains, high viscosity diets (often associated with high rye and wheat inclusions in the diet), contaminated feed and/or water, other debilitating diseases.
The present invention relates to increasing the subject's resistance to necrotic enteritis. In other words, the present invention relates to avoiding or reducing the negative effect of necrotic enteritis.
The term "resistance to" as used herein may encompasses the term "tolerance of. Therefore in one embodiment the subject may not be resistant to necrotic enteritis but the subject may be able to tolerate the necrotic enteritis, i.e. without negative effects on performance of the subject. In one embodiment the present invention relates to a feed additive composition according to the present invention for treating or preventing necrotic enteritis in a subject. Typically the subject will be one which has been or will be challenged with Clostridium perfringens and/or Eimeria species. Such challenge may come from the environment or the application of live microorganisms in the feed or drinking water, e.g. when live coccidia vaccines are used. in another embodiment the present invention relates to a feed additive composition for preventing and/or treating coccidiosis in a subject. The present invention yet further provides a method of preventing and/or treating necrotic enteritis and/or coccidiosis wherein an effective amount of a feed additive composition according to the present invention is administered to a subject.
Immune response
Immune response as used herein means one of the multiple ways in which DFMs modulate the immune system of animals, including increased antibody production, up-regulation of cell mediated immunity, up-regulation of pro-inflammatory cytokines, and augmented toll-like receptor signalling. It is understood that immuno-stimulation of the gastro intestinal tract by DFMs may be advantageous to protect the host against disease, and that immuno- suppress! on of the gastro intestinal tract may be advantageous to the host because less nutrients and energy are used to support the immune function.
Preferably the immune response is a cellular immune response. Preferably immune response is measure by looking at immune markers.
Pathogenic bacteria
The term pathogenic bacteria as used herein means for example toxigenic Clostridia species, e.g. Clostridium perfi'ingens and/or E. coli and/or Salmonella spp and/or Campylobacter spp. In one embodiment the pathogenic bacteria may be Avian pathogenic E. coli species.
The present invention may reduce populations of pathogenic bacteria in the gastrointestinal tract of a subject. Nutrient Exretion
In one embodment the present invention relates to reducing nutrient excretion in manure. This has positive effects on reducing environmental hazards. For example, in a preferred embodiment the present invention relates to reducing nitrogen and/or phosphorus content in the subject's manure. This, therefore, reduces the amount of nitrogen and/or phosphorus in the environment, which can be beneficial.
Probiotic
For some applications, it is believed that the DFM in the composition of the present invention can exert a probiotic culture effect. It is also within the scope of the present invention to add to the composition of the present invention further probiotic and/or prebiotics.
Here, a prebiotic is: "a non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth and/or the activity of one or a limited number of beneficial bacterid".
The term "probiotic culture" as used herein defines live microorganisms (including bacteria or yeasts for example) which, when for example ingested or locally applied in sufficient numbers, beneficially affects the host organism, i.e. by conferring one or more demonstrable health benefits on the host organism. Probiotics may improve the microbial balance in one or more mucosal surfaces. For example, the mucosal surface may be the intestine, the urinary tract, the respiratory tract or the skin. The term "probiotic" as used herein also encompasses live microorganisms that can stimulate the beneficial branches of the immune system and at the same time decrease the inflammatory reactions in a mucosal surface, for example the gut.
Whilst there are no lower or upper limits for probiotic intake, it has been suggested that at least 106-1012, preferably at least 106-1010, preferably 108- 109, cfu as a daily dose will be effective to achieve the beneficial health effects in a subject.
Isolated
In one aspect, suitably the enzyme or DFM used in the present invention may be in an isolated form. The term "isolated" means that the enzyme or DFM is at least substantially free from at least one other component with which the enzyme or DFM is naturally associated in nature and as found in nature. The enzyme or DFM of the present invention may be provided in a form that is substantially free of one or more contaminants with which the substance might otherwise be associated. Thus, for example it may be substantially free of one or more potentially contaminating polypeptides and/or nucleic acid molecules.
Purified
In one aspect, preferably the enzyme and/or DFM according to the present invention is in a purified form. The term "purified" means that the enzyme and/or DFM is present at a high level. The enzyme and/or DFM is desirably the predominant component present in a composition. Preferably, it is present at a level of at least about 90%, or at least about 95% or at least about 98%, said level being determined on a dry weight/dry weight basis with respect to the total composition under consideration. It is envisaged within the scope of the present invention that the embodiments of the invention can be combined such that combinations of any of the features described herein are included within the scope of the present invention. In particular, it is envisaged within the scope of the present invention that any of the therapeutic effects of the bacteria may be exhibited concomitantly.
EXAMPLES
Example 1 Materials and Methods
Three thousand six hundred one-day-old Cobb male chicks are purchased from a commercial hatchery. At study initiation, fifty males are allocated to each treatment pen by blocks. The study consisted of the following treatments (Table 1):
Table 1. Experimental design of Example 1.
Treatment Clostridium Phytase1 Additional enzyme" DFM3 per frin gens
Challenge
1 No 500 FTU/kg None None
2 Yes 500 FTU/kg None None
3 Yes 500 FTU/kg Protease (5000 u/kg) None
4 Yes 500 FTU/kg None En viva Pro
(7.5 x 104 CFU/g)
5 Yes 500 FTU/kg Protease (5000 u/kg) Enviva Pro
(7.5 x 104 CFU/g)
Phytase from E. coli.
2 protease from Bacillus subtilis.
3 Enviva Pro ® is combination of Bacillus subtilis strains Bs2084, LSSAO l and 15AP4, provided by Danisco AJS.
Bird weights by pen were recorded at study initiation, 23 d, 35 d, and termination (42d). The pen was the unit of measure. Broiler diets were fed as crumbles (starter) or pellets (grower and finisher). Diets met or exceeded NRC standards (Table 2). The mixer was flushed to prevent cross contamination of diets. All treatment feeds were mixed using a Davis S-20 mixer and pelleted using a California Pellet Mill (cold pellet temperature 65-70 C). Samples were collected from each treatment diet from the beginning, middle, and end of each batch and blended together to confirm enzyme activities and Enviva Pro presence in feed.
Table 2. Experimental diet composition of Example 1 .
Ingredient (%) Starter Grower Finisher
Maize 53.62 57.87 59.82
Maize DDGS 10.00 1 0.00 10.00
Soybean Meal 49%CP 26.93 23.97 21.36
Ampro 55 5.00 5.00 5.00
Soy oil 2.07 0.91 1.74
Lysine 0.24 0.24 0.24
DL-methionine 0.21 0.19 0.18
L-threonine 0.01 0.01 0.01 Salt 0.30 0.34 0.35
Limestone 1.04 1.07 0.94
Dicalci urn phosphate 0.26 0.1 1 0.02
Vitamin and trace mineral premix 0.33 0.33 0.33
Calculated Nutrient Composition
CP ~~
Energy, kcal/kg
Digestible lysine
Digestible methionine
Digestible threonine
Birds receive feed ad-libitum appropriate to the treatment from Day 0 to 42. Enzymes and Enviva Pro are provided by Danisco in the appropriate mixtures and levels for all experimental treatments. All diets contained 500 FTU of E. coli phytase in the background. The pens are arranged within the facility to prevent direct contact in order to avoid contamination. A change from starter to grower occurred on Day 21. Grower diet is replaced with the finisher diet on Day 35. At each feed change, feeders are removed from pens by block, weighed back, emptied, and refilled with the appropriate treatment diet. On the final day of the study feed is weighed. Pens are checked daily for mortality. When a bird is culled or found dead, the date and removal weight (kg) are recorded. A gross necropsy is performed on all dead or culled birds to determine the sex and probable cause of death. Signs of Necrotic Enteritis are noted.
All pens had approximately 4 inches of built up litter with a coating of fresh pine shavings.
All birds are spray vaccinated prior to placement into pens with a commercial coccidiosis vaccine (Coccivac-B). On Days 18, 19, and 20 all birds, except Treatment 1 , are dosed with a broth culture of C. perfringens. A field isolate of C. perfringens known to cause NE and originating from a commercial broiler operation is utilized as the challenge organism. Fresh inoculum is used each day. The titration levels are approximately 1.0 X 10 " . Each pen receive the same amount of inoculum. The inoculum is administered by mixing into the feed found in the base of the tube feeder. On Day 21 , five birds from each pen are selected, euthanized, group weighed, and examined for the degree of presence of Necrotic Enteritis lesions. The scoring was based on a 0 to 3 score, with 0 being normal and 3 being the most severe (0 = none, 1 = mild, 2 = moderate, 3 = marked/severe; Hofacre et al., 2003 J. Appl. Poult. Res. 12:60-64). No concomitant drug therapy is used during the study.
Means were separated using pair wise t-tests. Significant differences are considered at P<().()5. Pens are used as the experimental unit.
Results
Figure 1 shows the necrotic enteritis lesion scores of broiler chickens in a necrotic enteritis challenge model, based on a 0 to 3 score system. Pooled SEM=0.15
As expected, the challenged control treatment increased lesion scores compared to the unchallenged control treatment. Addition of DFMs in a combination of a protease and phytase surprisingly reduce lesion scores compared to all other treatments.
Figure 2 shows percentage of morality related to necrotic enteritis (NE) lesions from 20 to 42 d of age.
The challenged control treatment increased NE related mortality compared to the unchallenged control treatment. Addition of DFMs reduced NE mortality compared to the challenged control, with and without protease + phytase. Figure 3 shows the body weight gain of broiler chickens from 0 to 23 d in a necrotic enteritis challenge model. Pooled SEM=28.6
Figure 3 shows that a combination of the DFM (Enviva Pro®) with a combination of a protease and a phytase significantly improves body weight gain (BW gain) in broiler chickens challenged with Clostridium perfringens compared with the challenged control. The data shows that the DFM in combination with the protease and phytase surprisingly improved total BW gain to the level of the unchallenged control + phytase. Figure 4 shows the body weight gain of broiler chickens from 0 to 12 days in a necrotic enteritis challenge model. Pooled SEM=4.86.
Figure 5 shows the feed conversion ratio 0-12 d of broiler chickens in a necrotic enteritis challenge model. Pooled SEM=0.026
The combination of Enviva Pro (DFM) with a protease and phytase significantly improved (reduced) FCR (g BW gain / g feed intake) of broilers from 0 to 12 d compared to the challenged control, and enzymes by themselves and the other treatments.
Figure 6 shows the feed conversion ratio (0-23 d) of broiler chickens in a necrotic enteritis challenge model. Pooled SEM=0.022
The combination of Enviva Pro (DFM) with a protease and phytase significantly improved (reduced) FCR (g BW gain / g feed intake) of broilers 0 to 23 days compared to the challenged control, and enzymes by themselves and the other treatments.
Example 2 Materials and Methods
One digestibility trial with broiler chickens is conducted to determine the effects of protease and DFMs treatments on top of phytase on nutrient utilisation. The cages are housed in environmentally controlled rooms. The birds receive 20-hour fluorescent illumination and, are allowed free access to the diets and water. On day 1 , a broiler live coccidiosis vaccine is given to all chicks orally. The study consists of the following treatments (Table 3).
Table 3. Experimental design of Example 2.
Treatment Phytase Protease DFM
1 500 None None
FTU/kg
2 500 Protease lj (5000 u/kg) None FTU/kg
3 500 Protease 1J (5000 u/kg) None
FTU/kg
4 500 Protease 24 (15000 u/kg) None
FTU/kg
5 500 None Enviva Pro
FTU/kg (1.5 x 105 CFU/g)
6 500 Protease 1 i (5000 u/kg) Enviva Pro
FTU/kg (1.5 x 105 CFU/g)
7 500 Protease 1J (5000 u kg) Enviva Pro
FTU/kg (1.5 x 105 CFU/g)
8 500 Protease 24 (15000 u/kg) Enviva Pro
FTU/kg (1 .5 x 105 CFU/g)
Phytase from E. coli provided by Danisco A/S.
2 Enviva Pro ® is combination of Bacillus subtilis strains Bs2084, LSSAOl and 15AP4, provided by Danisco A/S.
3 Protease from Bacillus subtilis provided by Danisco A/S.
4 Protease from Bacillus licheniformis.
A total of 512 birds are individually weighed and assigned on the basis of body weight to 64 cages (8 birds/ cage). The 8 dietary treatments are then randomly assigned to 8 cages each. Birds receive starter feed ad-libitum appropriate to the treatment from 0 to 21 days. Enzymes and Enviva Pro are provided by Danisco in the appropriate mixtures and levels for all experimental treatments. All diets contain 500 FTU of E. coli phytase in the background. The pens are arranged within the facility to prevent direct contact in order to avoid contamination. Birds are fed starter diets (Table 4) in mash form throughout the experiment. Table 4. Experimental diet composition of Example 2.
Ingredient (%) Starter
Maize 50.1 1
Maize DDGS 10.00
Soyabean Meal 48%CP 28.83 Canola Meal 5.00
An/Veg Fat blend 2.16
1. -Lysine HC1 0.33
DL-methionine 0.28
L-threonine 0.12
Inert marker (Ti02) 0.30
Salt 0.33
Limestone 1.09
Dicalcium Phosphate 1 .15
Poultry vitamins and micro-minerals 0.30
Calculated Nutrient Composition (%)
CP 23.00
ME, kcal/kg 2950
Calcium 0.85
Available phosphorus 0.38
Sodium 0.18
Digestible lysine 1.21
Digestible methionine 0.62
Digestible TSAA 0.86
Digestible threonine 0.76
On d 21 , 8 birds per cage are euthanized by cervical dislocation and contents of the lower ileum are expressed by gentle flushing with distilled water. Digesta from birds within a cage are pooled, resulting in 8 samples per dietary treatment. The digesta samples are frozen immediately after collection, lyophilised and processed. Digesta samples and diets are analysed for Ti, DM, GE, starch, fat, N, amino acids, excluding tryptophan, and soluble and insoluble non-starch polysaccharides (NSPs) as per standard procedures. Calculation of ileal digestibility coefficients is performed as reported by Ravindran et al. (2005), based on the concentration of indigestible Ti. Representative samples of excreta per cage are collected over four consecutive days (from day 1 7 to 20) for the determination of nitrogen-corrected apparent metabolizable energy (AMEn) and Nitrogen retention, based on the concentration of Ti in feed and excreta samples. Daily excreta collections are pooled within a cage, mixed in a blender and sub-sampled. Each sub sample was lyophilized, ground to pass through a 0.5 mm sieve and stored in airtight plastic containers at - 4 C pending analysis. Processed samples are analysed for Ti, DM, GE, N, and soluble and insoluble NSPs as per standard procedures.
Means are separated using pair wise t-tests. Significant differences are considered at P<0.05. Cages are used as the experimental unit.
Results
Preliminary results show that the combination of protease, phytase and DFMs exhibits a greater ileal digestibility of energy, N, amino acids, starch, fat, and/or soluble and insoluble NSPs compared to the negative control treatment + phytase and protease + phytase and/or DFMs + phytase. The combination of protease and DFMs on top of phytase exhibits a greater AME, nitrogen retention, and total tract disappearance of soluble and insoluble NSPs compared to the negative control treatment + phytase and protease + phytase and/or DFMs + phytase. The dose response of protease to these parameters exhibits a greater slope in treatments containing DFMs compared to treatments without DFMs.
Example 3 Materials and Methods
One digestibility trial with broiler chickens is conducted to determine the effects of phytase + protease and DFMs treatments on nutrient utilisation. The cages are housed in environmentally controlled rooms. The birds receive 20-hour fluorescent illumination and, allowed free access to the diets and water. On day 1 , a broiler live coccidiosis vaccine is given to all chicks in a spray cabinet. The study consists of the following treatments (Table 5).
Table 5. Experimental design of Example 3.
Figure imgf000063_0001
Phytase from E. coli.
" Protease from Bacillus subtilis provided by Danisco A/S.
Enviva Pro ® is combination of Bacillus subtilis strains Bs2084, LSSAOl and 15AP4, provided by Danisco A/S.
4 Calsporin is a DFM product containing Bacillus subtilis Strain C3102.
5 Gallipro Tect is a DFM product containing Bacillus licheniformis DSM17236.
A total of 384 birds are individually weighed and assigned on the basis of body weight to 64 cages (6 birds/ cage). The 8 dietary treatments are then randomly assigned to 8 cages each. Birds receive starter feed ad-libitum appropriate to the treatment from 0 to 21 days. Enzymes and Enviva Pro are provided by Danisco in the appropriate mixtures and levels for all experimental treatments. The pens are arranged within the facility to prevent direct contact in order to avoid contamination. Birds were fed starter diets (Table 6) in mash form throughout the experiment.
Table 6. Experimental diet composition of Example 3.
Ingredient (%) Starter
Maize ~~ 50.11
Maize DDGS 10.00
Soyabean Meal 48%CP 28.83
Canola Meal 5.00
An/Veg Fat blend 2.16 I , -Lysine HC1 0.33
DL-methionine 0.28
L-thrconine 0.12
Inert marker (TiO?) 0.30
Salt 0.33
Limestone 1.09
Dicalcium Phosphate 1.15
Poultry vitamins and micro-minerals 0.30
Calculated Nutrient Composition (%)
CP 23.00
ME, kcal/kg 2950
Calcium 0.85
Available phosphorus 0.38
Sodium 0.1 8
Digestible lysine 1 .21
Digestible methionine 0.62
Digestible TSAA 0.86
Digestible threonine 0.76
On d 21 , 6 birds per cage are euthanized by C02 asphyxiation and contents of the lower ileum are expressed by gentle flushing with distilled water. Digesta from birds within a cage are pooled, resulting in 8 samples per dietary treatment. The digesta samples are frozen immediately after collection, lyophilised and processed. Digesta samples and diets are analysed for Ti, DM, GE, starch, fat, N, and soluble and insoluble NSPs as per standard procedures. Calculation of ileal digestibility coefficients is performed as reported by Ravindran et al. (2005), based on the concentration of indigestible Ti.
Feed intake and total excreta output are measured quantitatively per cage over four consecutive days (from day 17 to 20) for the determination of nitrogen-corrected apparent metabolizable energy (AMEn) and Nitrogen retention. Daily excreta collections are pooled within a cage, mixed in a blender and sub-sampled. Each sub sample is lyophilized, ground to pass through a 0.5 mm sieve and stored in airtight plastic containers at - 4 C pending analysis. Processed samples are analysed for DM, GE, N, and soluble and insoluble NSPs as per standard procedures.
Means are separated using pair wise t-tests. Significant differences are considered at P<0.05. Cages are used as the experimental unit.
Results
Preliminary results indicate that the combination of protease + phytase and every one of the tested DFMs exhibit a greater ileal digestibility of energy, N, starch, fat, and/or soluble and insoluble NSPs compared to the negative control treatment and protease + phytase and/or each of the DFMs by themselves. The combination of protease + phytase and every one of the tested DFMs exhibit a greater AME, nitrogen retention, and total tract disappearance of soluble and insoluble NSPs compared to the negative control treatment and protease + phytase and/or each of the DFMs by themselves.
Example 4
Materials and Methods
Tissue samples were taken from broiler chicks from the trial presented in Example 1 at 23 days of age. Treatment specifications are presented in Table 1. The jejunum, pancreas and liver were removed from 2 birds from every pen and the mucosa pooled resulting in eight samples per treatment. The samples were rinsed in buffer solution (PBS) immersed in a tissue storage reagent (RNAlater) according to manufacturer's protocol and stored at -80°C. Total RNA was isolated from each tissue sample using a single step phenol-chloroform extraction method as described by Chomczynski and Saachi (1987; Anal. Biochem. 162: 156-9). Concentration of the RNA was determined by measuring the absorbance at 260nm (Nanodrop) and monitored for integrity by gel electrophoresis on 1.2% agarose gels. Only RNA of sufficient purity and having a ratio of absorption at 260nm vs. 280nm greater than 1.87 were considered for use. Microarrays were manufactured using 70 base pair oligo-nucleotides (Opereon Biotechnologies Inc) according to the protocol described by Druyan et al. (2008; Poult. Sci. 87:2418-29). The experimental design of the array was a complete interwoven loop design as described by Garosi et al. (2005; Br. J. Nutr. 93:425-32) which each sample is compared directly with the others in a multiple pair wise fashion allowing all treatments to be compared. The samples were labelled according to the method described by Druyan et al. (2008; Poult. Sci. 87:2418-29) in that that half the samples would be labelled with Cy3 and half with Cy5 which are fluorescent dyes of cyanine. Hybridisation was carried out using the Pronto Plus! Microarray Hybridisation Kit prior to the addition of Cy3 and Cy5 labelled cDNA probes and covered with a clean glass coverslip (Lifterslip) and left to hybridise for 16 hours. The microarrays were then scanned on a Scan Array Gx PLUS Microarray Scanner set to 65% laser power to acquire images. Total RNA from individual samples was reversed transcribed to produce cDNA which was then used as a template for the qPCR amplifications as described by Druyan et al. (2008; Poult. Sci. 87:2418-29). Thermocycling parameters were optimised for each gene and each gene was amplified independently in duplicate within a single instrument run. Data files were generated from the scanned images of the microarrays but extracting the intensity raw data for each slide and dye combination using ScanAlyze Softare. Intensity data files were then analysed using JMP Genomics including and initial log2 transfomiation. Data normalisation was performed using locally- weighted regression and smoothing first within array and across all arrays. The resulting normalised log2 intensities were analysed using a mixed model ANOVA.
Mean intensities were compared using a threshold of significance based on Bongerroni correction of P=0.05 (Hochberg 1998). For the complete array, including all replicates, a mean by grid intensity was calculated for each gene using the 3 side by side probes, resulting in a total of four replicated means, one from each grid, per gene. Data for the Ct ratio from the samples in duplicate (sample gene Ct: Sample GAPDH Ct) depending on treatment were subjected to one way A OVA. Results
Expression data was collected using the microarray platform and a "heat map" produced to visualise the data for jejunum (Figure 7) and pancreas (Figure 8) at 23 days of age. Relative expression levels of six genes of interest were converted to visual cues based on the scale seen in Figure 7. Lowly expressed genes are marked with a minus sign ("-"), and highly expressed genes are marked with a plus sign ("+"); whereas a greater gray intensity depicts a greater difference from the mean expression level of the treatments. The genes that were measured and their purported functions are seen in Table 7. Real-time PGR was used to validate the gene expression shown in the heat map for sucrase isomaltase (SI) and fatty acid synthase (FASN) and were highly correlated to the array data.
Table 7. Purported function of genes measured.
Figure imgf000067_0001
Figure 7 shows a heat map of expression profiles of genes of interest for all treatments for jejunum at 23 days of age.
Figure 8 shows a heat map of expression profile of genes of interest for all treatments in liver at 23 days of age.
In Figures 7 and 8 the key is as follows:
Unchallenged control = Unchallenged Control + phytase
CC = Challenged Control + phytase
CC+ Protease = Challenged Control + phytase + protease CC+ EP = Challenged Control + phytase + Enviva Pro
CC+ EP + Protease = Challenged Control + phytase + protease + Enviva Pro
The expression of acetyl CoA carboxylase A (ACACA) was down-regulated in the challenged control but the combination of protease + phytase and Enviva Pro increased this to a level comparable with the unchallenged control treatment. Enviva Pro with only phytase or a protease + phytase without Enviva Pro did not have as noticeable an effect as the combination. ACACA is involved in the production of fatty acids from acetyl CoA and is used as a marker of lipogenesis.
The expression of Glucokinase (GC ) was down-regulated in the challenged control but the combination of protease + phytase with Enviva Pro produced an up-regulation similar to the unchallenged control. The extent of the up-regulation was greater than when protease + phytase were used without a DFM. A similar pattern was also seen with sucrase iso-maltase (SI) where the combination of Enviva Pro with protease + phytase increased expression compared to both the challenged and unchallenged control. GCK is a key enzyme in glucose metabolism and SI is responsible for hydrolysis of sucrose and iso-maltose, and so has an important role in the digestion and absorption of carbohydrates in animals. The expression of oligo-peptide transport 1 (PEPT1) was increased by protease + phytase alone and when in combination with Enviva Pro. PEPT1 is part of a peptide transport system and is responsible for the uptake of a wide range of di- and tri-peptides
Tight Junction protein 1 (ZO l) was most highly expressed in the challenged control. A reduction was seen with protease + phytase but a greater down-regulation in expression was seen with protease + phytase in combination with Enviva Pro which caused a greater reduction than that seen in the unchallenged control. ZOl is a protein that is on the cytoplasmic face of tight junctions, there are various roles for this protein ranging from signal transduction for tight junction assembly to stability of the tight junctions themselves.
The T-cell antigen CD3 (CD3D) was highly expressed in the challenged control. The protease + phytase treatment had some effect in reducing the expression of this gene, but a greater effect was seen when protease + phytase were used in combination with Enviva Pro. The same results were seen in the jejunum and the liver for CD3D which strengthen the results. CD3D is a surface molecule found on T cells and plays an important role in signal transduction during T-cell receptor engagement and is part of the T-cell receptor/CD3 complex.
Fatty acid synthase (FASN) was down-regulated in the challenged control, whereas protease + phytase, and Enviva Pro up-regulated this gene. The combination of Enviva Pro and protease + phytase increased it even more. FASN is a key enzyme for fatty acid synthesis and is involved in catalysing the production of long chain saturated fatty acids.
Discussion
The increase of acetyl CoA carboxylase expression due to the addition of Enviva Pro and protease + phytase in comparison to the challenged control suggests that there was increased lipogenesis. This would occur if carbohydrate availability and digestion is higher which means there is increased energy surplus which is diverted to fat transport and storage. The increase in expression of glucokinase and sucrase isomerase with the combination of protease + phytase and Enviva Pro suggests that there was increased absorption of glucose, and increased availability of sucrose and isomaltose in the brush border, which indicates a positive interaction between the enzyme and DFMs to increase carbohydrate absorption in the small intestine and thus increase energy availability from the diet. Additionally, the decreased glucokinase expression for the challenged control suggests that the Clostridium perfringens challenge caused damage to the mucosa and that addition of Enviva Pro and protease + phytase may have acted to remedy this. The increase in expression of the peptide transporter oligopeptide transporter 1 (PEPT1 ) when protease + phytase alone and in combination with Enviva Pro suggests increased availability of peptides and thus an increased requirement for transport, which indicates an effect of enzymes and DFMs to increase the availability of peptides for the animal which allows for greater growth. The increased fatty acid synthase (FASN) expression in the liver and the increased acetyl CoA carboxylase A in the jejunum suggest increased fatty acid synthesis due to increased carbohydrate availability. Enzymes and Enviva Pro acted together to produce more available energy for the animal which resulted in more growth. The effect of Enviva Pro on reducing the expression of Tight junction protein 1 indicates lower requirement for protein turn over, which may be related to a high intestinal integrity. The increased expression in the challenged control, however, suggests that turnover/requirement of the protein was high due to failing intestinal integrity possibly due to the coccidia and Clostridium perfringens infection. The effect of a combination of protease + phytase (without Enviva Pro) or the effect of Enviva Pro with phytase alone on down- regulating ZOl is not as evident as the combination of protease + phytase + Enviva Pro. This indicates that Enviva Pro and protease + phytase in combination acts to increase intestinal integrity and thus benefit the intestinal health of the animal, increased intestinal integrity, and thus absorptive capacity, appears to be one of the mechanisms by which the effectiveness of exogenous enzymes is increased when a DFM is present.
The increased expression of T cell antigen CD3 d in the challenged control indicates increased cell-mediated immune response due to the challenge. In these conditions, birds will be undergoing sub-optimal performance because the immune response will demand energy that could be used for growth, and because some birds will experience a systemic disease response. The increased expression of this immunological marker is markedly reversed when Enviva Pro is used with phytase alone or in combination with protease + phytase. Down regulation of immune response in the intestine may be one of the mechanisms by which the effectiveness of exogenous enzymes in nutrient absorption and performance is increased when a DFM is present, particularly in situations of enteric disease challenge.
The net effect of a down-regulated immune response and higher intestinal integrity, and a better nutrient digestion and absorption with the combination of enzymes and DFMs, clearly determines enhanced production performance of broiler chickens.
All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.

Claims

1. A feed additive composition comprising a direct fed microbial in combination with a protease and a phytase.
2. A feed additive composition according to claim 1 wherein the direct fed microbial is an antipathogen direct fed microbial.
3. A feed additive composition according to claim 1 or claim 2 wherein the direct fed microbial is a viable bacterium.
4. A feed additive composition according to any one of claims 1 to 3 wherein the direct fed microbial comprises a bacterium from one or more of the following genera: Lactobacillus,
Lactococcus, Streptococcus, Bacillus, Pediococcus. Enterococcus, Leuconostoc, Carnobacterium, Propionibacierium, Bifidobacterium, Clostridium and Megasphaera and combinations thereof.
5. A feed additive composition according to any one of the preceding claims wherein the direct fed microbial comprises a bacterium from one or more of the following species:
Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Enterococcus faecium, Enterococcus spp, and Pediococcus spp, Lactobacillus spp, Bifidobacterium spp, Lactobacillus acidophilus, Pediococsus acidilactici, Lactococcus lactis, Bifidobacterium bifidum, Propionibacierium thoenii, Lactobacillus farciminus, lactobacillus rhamnosus, Clostridium butyricum, Bifidobacterium animalis ssp. animalis, Lactobacillus reuteri, Bacillus cereus, Lactobacillus salivarius ssp. salivarius, Megasphaera elsdenii, Propionibacteria sp and combinations thereof.
6. A feed additive composition according to any one of the preceding claims wherein the direct fed microbial is one or more of the following strains: Bacillus subtilis strains 3A-P4 (PTA-6506); 15A-P4 (PTA-6507); 22C-P1 (PTA-6508); 2084 (NRRL B-500130); LSSAOl (NRRL-B-50104); BS27 (NRRL B-50105); BS 18 (NRRL B-50633); and BS 278 (NRRL B- 50634).
7. A feed additive composition according to any one of the preceding claims wherein the direct fed microbial is in the form of an endospore.
8. A feed additive composition according to any one of the preceding claims wherein the protease is a subtilisin, a bacillolysin, an alkaline serine protease or a keratinase or a Nocardiopsis protease.
9. A feed additive composition according to any one of the preceding claims wherein the phytase is a 6-phytase or a 3-phytase.
10. A feed additive composition according to claim 9 wherein the phytase is a 6-phytase.
11. A feed additive composition according to any one of the preceding claims wherein the phytase is an E. coli phytase or a Buttiauxella phytase or Hafnia phytase or Citrobacter phytase or an Aspergillus phytase or a Penicillium phytase or a Trichoderma phytase or an E. coli phytase or a Hansenula phytase.
12. A feed additive composition according to any one of the preceding claims wherein the phytase is present at a dosage of between 200FTU/g feed additive composition and 10000 FTU/g feed additive composition.
13. A feed additive composition according to any one of the preceding claims wherein the protease is present at a dosage of lOOOPU/g feed additive composition and 60000PU/g feed additive composition.
14. A feed additive composition according to any one of the preceding claims wherein the DFM is present at a dosage of 3.75xl07CFU/g feed additive composition and lx l0nCFU/g feed additive composition.
15. A method for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility), or for improving nitrogen retention, or for improving the subject's resistance to necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject, or for reducing nutrient excretion in manure, which method comprising administering to a subject a direct fed microbial in combination with a protease and a phytase.
16. A method according to claim 15 comprising administering the feed additive composition according to any one of claims 1-14.
17. A method according to claim 15 or 16 wherein the direct fed microbial is an antipathogen direct fed microbi al .
18. A method according to any one of claims 15- 17 wherein the direct fed microbial is a viable bacterium.
19. A method according to any one of claims 15 to 1 8 wherein the direct fed microbial comprises a bacterium from one or more of the following genera: Lactobacillus, Lactococcus, Streptococcus, Bacillus, Pediococcus, Enterococcus, Leuconostoc, Carnobacterium , Propionibacterium, Bifidobacterium, Clostridium and Megasphaera and combinations thereof.
20. A method according to any one of claims 1 5- 19 wherein the direct fed microbial comprises a bacterium from one or more of the following species: Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Enterococcus faecium, Enterococcus spp, and Pediococcus spp, Lactobacillus spp, Bifidobacterium spp, Lactobacillus acidophilus, Pediococsus acidilactici, Lactococcus lactis, Bifidobacterium bifidum, Propionibacterium thoenii, Lactobacillus farciminus, lactobacillus rhamnosus, Clostridium butyricum, Bifidobacterium animalis ssp. animalis, Lactobacillus reuteri. Bacillus cereus, Lactobacillus salivarius ssp. salivarius, Megasphaera elsdenii, Propionibacteria sp and combinations thereof.
21. A method according to any one of claims 15-20 wherein the direct fed microbial comprises a bacterium is one or more of the following strains: Bacillus subtilis strains 3A-P4 (PTA-6506); 15A-P4 (PTA-6507); 22C-P1 (PTA-6508); 2084 (NR L B-500130); LSSA01 (NRRL-B-50104); BS27 (NRRL B-50105); BS 1 8 (NRRL B-50633); and BS 278 (NRRL B- 50634).
22. A method according to any one of claims 15-21 wherein the direct fed microbial is in the form of an endospore.
23. A method according any one of claims 15-22 wherein the protease is a subtilisin, a bacillolysin, an alkaline serine protease or a keratinase or a Nocardiopsis protease.
24. A method according any one of claims 15-23 wherein the phytase is a 6-phytase or a 3- phytase.
25. A method according to claim 24 wherein the phytase is a 6-phytase.
26. A method according any one of claims 1 5-25 wherein the phytase is an E. coli phytase or a Buttiauxella phytase or Hafnia phytase or Citrobacter phytase or an Aspergillus phytase or a Penicillium phytase or a Trichoderma phytase or an E. coli phytase or a Hansenula phytase.
27. Use of a direct fed microbial in combination with a protease and a phytase for improving the performance of a subject or for improving digestibility of a raw material in a feed (e.g. nutrient digestibility, such as amino acid digestibility) or for improving nitrogen retention) or for improving the subject's resistance to necrotic enteritis or for improving feed conversion ratio (FCR) or for improving weight gain in a subject or for improving feed efficiency in a subject or for modulating (e.g. improving) the immune response of the subject or for promoting the growth of beneficial bacteria in the gastrointestinal tract of a subject or for reducing populations of pathogenic bacteria in the gastrointestinal tract of a subject or for reducing nutrient excretion in manure.
28. Use according to claim 27 wherein the feed additive composition according to any one of claims 1-14 is used.
29. Use according to any one of claims 27-28 wherein the direct fed microbial is an antipathogen direct fed microbial.
30. Use according to any one of claims 27-29 wherein the direct fed microbial is a viable bacterium.
31. Use according to any one of claims 27-30 wherein the direct fed microbial comprises a bacterium from one or more of the following genera: Lactobacillus, Lactococcus, Streptococcus, Bacillus, Pediococcus, Enterococcus, Leuconostoc, Carnobacterium, Propionibacterium, Bifidobacterium, Clostridium and Megasphaera and combinations thereof.
32. Use according to any one of claims 27-31 wherein the direct fed microbial comprises a bacterium from one or more of the following species: Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Enterococcus faecium, Enterococcus spp, and Pediococcus spp, Lactobacillus spp, Bifidobacterium spp, Lactobacillus acidophilus, Pediococsus acidilaclici, Lactococcus lactis, Bifidobacterium bifidum, Propionibacterium thoenii, Lactobacillus farciminus, lactobacillus rhamnosus, Clostridium butyricum, Bifidobacterium animalis ssp. animalis, Lactobacillus reuteri, Bacillus cereus, Lactobacillus salivarius ssp. salivarius, Megasphaera elsdenii, Propionibacteria sp and combinations thereof.
33. Use according to any one of claims 27-32 wherein the direct fed microbial is one or more of the following strains: Bacillus subtilis strains 3A-P4 (PTA-6506); 15A-P4 (PTA-6507); 22C-P1 (PTA-6508); 2084 (NRRL B-500130); LSSAOl (NRKL-B-50104); BS27 (NRRL B- 50105); BS 18 (NRRL B-50633); and BS 278 (NRRL B-50634).
34. Use according to any one of claims 27-33 wherein the direct fed microbial is in the form of an endospore.
35. Use according to any one of claims 27-34 wherein the protease is a subtilisin, a bacillolysin, an alkaline serine protease or a keratinase or a Nocardiopsis protease.
36. Use according to any one of claims 27-35 wherein the phytase is a 6-phytase or a 3- phytase.
37. Use according to claim 36 wherein the phytase is a 6-phytase.
38. Use according to any one of claims 27-37 wherein the phytase is an E. coli phytase or a Buttiauxella phytase or Hafnia phytase or Citrobacter phytase or an Aspergillus phytase or a
Penicillium phytase or a Trichoderma phytase or an E. coli phytase or a Hansenula phytase.
39. A kit comprising a direct fed microbial, a protease, a phytase and instructions for administration.
40. A kit according to claim 39 wherein said kit comprises the feed additive composition according to any one of claims 1 -14.
41. A kit according to any one of claims 39-40 wherein the direct fed microbial is an antipathogen direct fed microbial.
42. A kit according to any one of claims 39-41 wherein the direct fed microbial is a viable bacterium.
43. A kit according to any one of claims 39-42 wherein the direct fed microbial comprises a bacterium from one or more of the following genera: Lactobacillus, Lactococcus, Streptococcus, Bacillus, Pediococcus, Enter ococcus, Leuconostoc, Camobacterium, Propionibacterium, Bifidobacterium, Clostridium and Megasphaera and combinations thereof.
44. A kit according to any one of claims 39-43 wherein the direct fed microbial comprises a bacterium from one or more of the following species: Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Enterococcus faecium, Enterococcus spp, and Pediococcus spp, Lactobacillus spp, Bifidobacterium spp, Lactobacillus acidophilus, Pediococsus acidilactici, Lactococcus lactis, Bifidobacterium bifidum, Propionibacterium thoenii, Lactobacillus farciminus, lactobacillus rhamnosus, Clostridium bulyricum, Bifidobacterium animalis ssp. animalis, Lactobacillus reuteri, Bacillus cereus, Lactobacillus salivarius ssp. salivarius, Megasphaera elsdenii, Propionibacteria sp and combinations thereof.
45. A kit according to any one of claims 39-43 wherein the direct fed microbial is one or more of the following strains: Bacillus subtilis strains 3A-P4 (PTA-6506); 15A-P4 (PTA-6507); 22C-P1 (PTA-6508); 2084 (NRRL B-500130); LSSAOl (NRRL-B-50104); BS27 (N RL B- 501 05); BS 18 (NRRL B-50633); and BS 278 (NRRL B-50634).
46. A kit according to any one of claims 39-45 wherein the direct fed microbial is in the form of an endospore.
47. A kit according to any one of claims 39-46 wherein the protease is a subtilisin. a bacillolysin, an alkaline serine protease or a keratinasc or a Nocardiopsis protease.
48. A kit according to any one f claims 39-47 wherein the phytase is a 6-phytase or a 3- phytase.
49. A kit according to claim 48 wherein the phytase is a 6-phytase.
50. A kit according to any one of claims 39-49 wherein the phytase is an E. coli phytase or a Buttiauxella phytase or Hafnia phytase or Citrobacter phytase or an Aspergillus phytase or a Penicillium phytase or a Trichoderma phytase or an E. coli phytase or a Hansenula phytase.
51. A method of preparing a feed additive composition, comprising admixing a direct fed microbial with a protease and a phytase and (optionally) packaging.
52. A feed comprising a feed additive composition according to any one of claims 1-14.
53. A feed according to claim 52 wherein the phytase is present at a dosage of between 400FTU/kg feed and 1000 FTU//kg feed.
54. A feed according to any one of claims 52-53 wherein the protease is present at a dosage of between 2000PU/kg feed to 6000PU/kg feed.
55. A feed according to any one of claims 52-54 wherein the DFM is present at a dosage of 7.5x104CFU/kg feed and lxl 07CFU/kg feed.
56. A method of preparing a feedstuff comprising admixing a feed component with a feed additive composition according to any one of claims 1 -14.
57. A premix comprising a feed additive composition comprising a direct fed microbial in combination with a protease and a phytase, and at least one mineral and/or at least one vitamin.
58. A premix comprising a feed additive composition according to any one of claims 1 -14 in combination with at least one mineral and/or at least one vitamin.
59. A feed additive composition according to any one of claims 1-14 for preventing and/or treating coccidiosis and/or necrotic enteritis in a subject.
60. A method of preventing and/or treating necrotic enteritis and/or coccidiosis wherein an effective amount of a feed additive composition according to any one of claims 1-14 is administered to a subject.
61. A feed additive composition or feed or kit or method or use or premix as defined generally herein with reference to the Figures and the Examples.
PCT/GB2012/050123 2011-02-18 2012-01-19 Feed additive composition WO2012110777A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES12701263.1T ES2657543T3 (en) 2011-02-18 2012-01-19 Food Additive Composition
EP12701263.1A EP2675285B1 (en) 2011-02-18 2012-01-19 Feed additive composition
BR112013020855-4A BR112013020855B1 (en) 2011-02-18 2012-01-19 FEED ADDITIVE COMPOSITION, KIT, METHOD TO PREPARE SUCH COMPOSITION, FEED, METHOD TO PREPARE A FEED, AND PREMIX
AU2012216897A AU2012216897A1 (en) 2011-02-18 2012-01-19 Feed additive composition
CA2825489A CA2825489A1 (en) 2011-02-18 2012-01-19 Feed additive composition
JP2013553998A JP2014508519A (en) 2011-02-18 2012-01-19 Composition for feed addition
DK12701263.1T DK2675285T3 (en) 2011-02-18 2012-01-19 FEED ADDITIVE COMPOSITION
PL12701263T PL2675285T3 (en) 2011-02-18 2012-01-19 Feed additive composition
US13/985,847 US20130330307A1 (en) 2011-02-18 2012-01-19 Feed additive composition
CN2012800093151A CN103442587A (en) 2011-02-18 2012-01-19 Feed additive composition
ZA2013/05267A ZA201305267B (en) 2011-02-18 2013-07-12 Feed additive composition
US16/257,556 US11172693B2 (en) 2011-02-18 2019-01-25 Feed additive composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1102865.1A GB201102865D0 (en) 2011-02-18 2011-02-18 Feed additive composition
GB1102865.1 2011-02-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/985,847 A-371-Of-International US20130330307A1 (en) 2011-02-18 2012-01-19 Feed additive composition
US16/257,556 Division US11172693B2 (en) 2011-02-18 2019-01-25 Feed additive composition

Publications (2)

Publication Number Publication Date
WO2012110777A2 true WO2012110777A2 (en) 2012-08-23
WO2012110777A3 WO2012110777A3 (en) 2012-10-26

Family

ID=43881331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/050123 WO2012110777A2 (en) 2011-02-18 2012-01-19 Feed additive composition

Country Status (15)

Country Link
US (2) US20130330307A1 (en)
EP (1) EP2675285B1 (en)
JP (1) JP2014508519A (en)
CN (2) CN103442587A (en)
AR (1) AR084892A1 (en)
AU (1) AU2012216897A1 (en)
BR (1) BR112013020855B1 (en)
CA (1) CA2825489A1 (en)
DK (1) DK2675285T3 (en)
ES (1) ES2657543T3 (en)
GB (1) GB201102865D0 (en)
PL (1) PL2675285T3 (en)
TW (1) TW201234976A (en)
WO (1) WO2012110777A2 (en)
ZA (1) ZA201305267B (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103250867A (en) * 2013-05-10 2013-08-21 东北农业大学 Production method of raw milk lactic acid bacteria antimicrobial peptide additive for livestock and poultry
EP2879511A1 (en) * 2012-08-03 2015-06-10 Dupont Nutrition Biosciences ApS Feed additive composition
WO2015197871A1 (en) * 2014-06-27 2015-12-30 Dsm Ip Assets B.V. A method for improving the nutritional value of animal feed
US20160213755A1 (en) * 2012-08-03 2016-07-28 Dupont Nutrition Biosciences Aps Feed Additive Composition
WO2017132230A1 (en) * 2016-01-25 2017-08-03 Novozymes A/S Method to reduce microbial bloom in poultry hatchery
CN109161501A (en) * 2018-09-07 2019-01-08 中国农业大学 A kind of feeding bacillus licheniformis and its application
US20190021341A1 (en) * 2017-07-24 2019-01-24 Church & Dwight Co., Inc. Bacillus microbial terroir for pathogen control in swine
WO2019183511A1 (en) * 2018-03-23 2019-09-26 Purina Animal Nutrition Llc Methods of feeding animals feed products containing direct-fed microbials
CN110521856A (en) * 2019-10-11 2019-12-03 江西正邦科技股份有限公司 The production method of the diligent energy property small peptide of one boar
RU2720471C1 (en) * 2019-03-21 2020-04-30 Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" Fodder additive for broiler chickens
US20210267232A1 (en) * 2020-02-28 2021-09-02 Terragen Holdings Limited Microbial feed supplement composition and method
AU2016404864B2 (en) * 2016-04-26 2021-11-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Regulation of feed efficiency and methane production in ruminating animals
KR20230074002A (en) * 2021-11-18 2023-05-26 장태호 Feed additive composition for livestock or fish comprising fermented product of bass and blue gill as effective component and uses thereof
WO2024047009A1 (en) * 2022-08-30 2024-03-07 Dsm Ip Assets B.V. Methods and uses for modifying gut flora in aquatic species
US11951138B2 (en) 2013-03-14 2024-04-09 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Microbial compositions comprising rumen microflora and uses thereof

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201102865D0 (en) 2011-02-18 2011-04-06 Danisco Feed additive composition
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
CN104232507A (en) * 2014-07-22 2014-12-24 桐乡市五丰饲料有限公司 Composite micro-ecological preparation and application thereof in feed
AU2015292271B2 (en) * 2014-07-25 2020-09-10 The University Of Queensland Bacillus amyloliquefaciens probiotic compositions, methods of production, and methods of use
AU2015296538B2 (en) 2014-07-29 2019-01-31 BiOWiSH Technologies, Inc. Animal feed compositions and feed additives
EP3215615A1 (en) * 2014-11-04 2017-09-13 Novozymes A/S Polypeptides having serine protease activity and polynucleotides encoding same and their application in animal feed
WO2016118840A1 (en) * 2015-01-23 2016-07-28 Novozymes A/S Bacillus strains improving health and performance of production animals
US11166989B2 (en) 2015-01-23 2021-11-09 Novozymes A/S Bacillus strains improving health and performance of production animals
PL3261653T3 (en) 2015-01-23 2020-03-31 Novozymes A/S Bacillus subtilis subspecies
EP3294308A4 (en) 2015-05-14 2019-03-06 University of Puerto Rico Methods for restoring microbiota of newborns
CN104957397A (en) * 2015-06-05 2015-10-07 袁玥 Special feed for artificial breeding adult mantis
CN104872381A (en) * 2015-06-05 2015-09-02 袁玥 Special feed for young mantises artificially cultured
CN104872080A (en) * 2015-06-05 2015-09-02 袁玥 Artificial feeding method of mantises
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US10632157B2 (en) 2016-04-15 2020-04-28 Ascus Biosciences, Inc. Microbial compositions and methods of use for improving fowl production
ES2978111T3 (en) 2015-06-25 2024-09-05 Native Microbials Inc Methods, apparatus and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial assemblies based on them
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
WO2018126026A1 (en) 2016-12-28 2018-07-05 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
US20200281225A1 (en) * 2015-11-09 2020-09-10 Dupont Nutrition Biosciences Aps Feed additive composition
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
CA3010505A1 (en) 2016-01-07 2017-07-13 Ascus Biosciences, Inc. Methods for improving milk production by administration of microbial consortia
US11167016B2 (en) 2016-02-18 2021-11-09 Amanoenzyme Inc. Intestinal flora improvement agent
JP7072150B2 (en) 2016-02-18 2022-05-20 天野エンザイム株式会社 Gut microbiota improver
BR112018071198A2 (en) * 2016-04-15 2019-04-24 Ascus Biosciences, Inc. methods for improving poultry agricultural production by administering microbial consortia or purified strains thereof
CN106260626A (en) * 2016-10-31 2017-01-04 韦忠 A kind of hybrid sheep culturing feed
CN106490369A (en) * 2016-12-14 2017-03-15 深圳市前海金卓生物技术有限公司 Pig starter feed core material
US12018313B2 (en) 2016-12-28 2024-06-25 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles
AU2018260547A1 (en) 2017-04-28 2019-10-10 Native Microbials, Inc. Methods for supporting grain intensive and/or energy intensive diets in ruminants with a synthetic bioensemble of microbes
CN107699515A (en) * 2017-09-25 2018-02-16 王振刚 A kind of compound probiotic and preparation method thereof, application
WO2019073460A1 (en) * 2017-10-13 2019-04-18 Stellenbosch University Probiotic composition
CN111970933A (en) 2017-10-18 2020-11-20 埃斯库斯生物科技股份公司 Increasing avian production by administering a synthetic biological pool of microorganisms or purified strains thereof
MX2020004078A (en) 2017-10-20 2020-09-25 Ms Biotech Inc Methods of producing ensiled plant materials using megasphaera elsdenii.
CN107981047A (en) * 2017-12-04 2018-05-04 北京民生牧业股份有限公司 Palm biological feed additive, preparation method and the biological feedstuff containing the additive
CN117694452A (en) 2018-06-01 2024-03-15 雷德利美国公司 Suspended feed block system for animals and method for making same
KR102196047B1 (en) * 2018-11-14 2020-12-29 건국대학교 글로컬산학협력단 Composition for preservation of a source of livestock feed comprising metabisulfite and preparation method of livestock feed using the same
EP4009809A1 (en) * 2019-08-06 2022-06-15 DSM IP Assets B.V. A method for improving the nutritional value of animal feed
KR102173806B1 (en) * 2019-11-20 2020-11-03 건국대학교 글로컬산학협력단 Lactobacillus plantarum KU18 and microorganism inoculant for silage production comprising the same
CN111011584A (en) * 2019-12-09 2020-04-17 安徽科技学院 Daily ration capable of enhancing immune function of young dogs and preparation and use thereof
KR102135554B1 (en) * 2019-12-31 2020-07-20 강기갑 Method for manufacturing probiotic materials for livestock
CN112574919B (en) * 2020-12-18 2022-11-18 广州市微生物研究所有限公司 Mycosporin secretion type probiotic agent as well as preparation method and application thereof
CN112608861B (en) * 2020-12-21 2022-08-09 青岛尚德生物技术有限公司 Composite preparation containing clostridium butyricum and pediococcus acidilactici as well as preparation method and application of composite preparation
CN113215019A (en) * 2021-02-04 2021-08-06 郑州大学 Enterococcus faecalis and application thereof
CN113632878A (en) * 2021-08-09 2021-11-12 云南师范大学 Enzyme-bacterium composite biological agent for degrading mycotoxin in fermented unconventional feed and application
CN114711328A (en) * 2022-04-29 2022-07-08 珠海市斗门区河口渔业研究所 Bifidobacterium feed additive and application thereof in sea bass breeding
CN114831248B (en) * 2022-05-30 2024-01-16 唐山市众鑫饲料有限公司 Biological mildew removing agent and preparation method and application thereof

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006270A1 (en) 1988-01-07 1989-07-13 Novo-Nordisk A/S Enzymatic detergent
WO1989006279A1 (en) 1988-01-07 1989-07-13 Novo-Nordisk A/S Mutated subtilisin genes
WO1992012645A1 (en) 1991-01-25 1992-08-06 Novo Nordisk A/S Use of an enzyme containing granulate and method for production of a pelletized fodder
WO1992019729A1 (en) 1991-05-01 1992-11-12 Novo Nordisk A/S Stabilized enzymes and detergent compositions
WO1994025583A1 (en) 1993-05-05 1994-11-10 Novo Nordisk A/S A recombinant trypsin-like protease
WO1997016076A1 (en) 1995-11-02 1997-05-09 Novo Nordisk A/S Feed enzyme preparations
WO1998020115A1 (en) 1996-11-04 1998-05-14 Novo Nordisk A/S Subtilase variants and compositions
US6287841B1 (en) 1988-02-11 2001-09-11 Genencor International, Inc. High alkaline serine protease
WO2004085638A1 (en) 2003-03-25 2004-10-07 Republic Of National Fisheries Research And Development Institute Phytase produced from citrobacter braakii
WO2005123034A2 (en) 2004-06-22 2005-12-29 Universita'degli Studi Di Milano Microparticulate systems for the oral administration of biologically active substances
WO2006038128A2 (en) 2004-10-04 2006-04-13 Danisco A/S Citrobacter freundii phytase and homologues
WO2006037328A1 (en) 2004-10-04 2006-04-13 Novozymes A/S Polypeptides having phytase activity and polynucleotides encoding same
WO2006037327A2 (en) 2004-10-04 2006-04-13 Novozymes A/S Polypeptides having phytase activity and polynucleotides encoding same
WO2006038062A1 (en) 2004-10-04 2006-04-13 Danisco A/S Microbial phytase as supplement to food or fodder
WO2006043178A2 (en) 2004-10-18 2006-04-27 Danisco A/S Enzymes
WO2007044968A2 (en) 2005-10-12 2007-04-19 Genencor International, Inc. Stable, durable granules with active agents
WO2007112739A1 (en) 2006-04-04 2007-10-11 Novozymes A/S Phytase variants
WO2008016214A1 (en) 2006-08-04 2008-02-07 Bioneer Corporation Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
WO2008092901A2 (en) 2007-01-30 2008-08-07 Novozymes A/S Polypeptides having phytase activty and polynucleotides encoding same
WO2008097619A2 (en) 2007-02-07 2008-08-14 Danisco Us, Inc., Genencor Division Variant buttiauxella sp. phytases having altered properties
US20080263688A1 (en) 2007-03-26 2008-10-23 Novozymes A/S Hafnia Phytase
US20090041011A1 (en) 2007-04-03 2009-02-12 Scott Sheppard Lawful Interception of Broadband Data Traffic
WO2009129489A2 (en) 2008-04-18 2009-10-22 Danisco Us Inc., Genencor Division Buttiauxella sp. phytase variants
US20090280090A1 (en) 2008-03-14 2009-11-12 Thomas Rehberger Methods of treating pigs with bacillus strains
US7754469B2 (en) 2005-11-30 2010-07-13 Agtech Products, Inc Microorganisms and methods for treating poultry
WO2011117396A2 (en) 2010-03-26 2011-09-29 Novozymes A/S Thermostable phytase variants

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861271A (en) * 1993-12-17 1999-01-19 Fowler; Timothy Cellulase enzymes and systems for their expressions
GB9416841D0 (en) * 1994-08-19 1994-10-12 Finnfeeds Int Ltd An enzyme feed additive and animal feed including it
TW409035B (en) * 1997-06-04 2000-10-21 Gist Brocades Bv Starch-based enzyme granulates
CO5070700A1 (en) 1998-06-05 2001-08-28 Basf Ag NOVELTY GENES OF (ADP-RIBOSA) POLYMERASE
US6436451B1 (en) * 1999-03-26 2002-08-20 Eggland's Best, Inc. Method of reducing cholesterol in chicken eggs
AU2003203142A1 (en) * 2002-01-25 2003-09-02 Dsm Ip Assets B.V. Thermostable enzyme compositions
CA2566617C (en) * 2004-05-14 2013-12-31 Agtech Products, Inc. Method and composition for reducing e.coli disease and enhancing performance using bacillus
CN101181016B (en) * 2007-12-13 2012-09-05 济南和美华饲料有限公司 Hen feedstuff for improving egg-laying performance
GB0922467D0 (en) 2009-04-24 2010-02-03 Danisco Feed supplement
CN101642186A (en) * 2009-07-31 2010-02-10 广州市希普生物饲料有限公司 Preparation method for feed without antibiotics
CN101816378A (en) * 2010-05-11 2010-09-01 蓝德安 Breeding feed additive
GB201102865D0 (en) 2011-02-18 2011-04-06 Danisco Feed additive composition
CN102771627A (en) * 2011-05-09 2012-11-14 北京奕农顺丰生物技术有限公司 Feed additive containing compound enzyme

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006270A1 (en) 1988-01-07 1989-07-13 Novo-Nordisk A/S Enzymatic detergent
WO1989006279A1 (en) 1988-01-07 1989-07-13 Novo-Nordisk A/S Mutated subtilisin genes
US6287841B1 (en) 1988-02-11 2001-09-11 Genencor International, Inc. High alkaline serine protease
WO1992012645A1 (en) 1991-01-25 1992-08-06 Novo Nordisk A/S Use of an enzyme containing granulate and method for production of a pelletized fodder
WO1992019729A1 (en) 1991-05-01 1992-11-12 Novo Nordisk A/S Stabilized enzymes and detergent compositions
WO1994025583A1 (en) 1993-05-05 1994-11-10 Novo Nordisk A/S A recombinant trypsin-like protease
WO1997016076A1 (en) 1995-11-02 1997-05-09 Novo Nordisk A/S Feed enzyme preparations
WO1998020115A1 (en) 1996-11-04 1998-05-14 Novo Nordisk A/S Subtilase variants and compositions
WO2004085638A1 (en) 2003-03-25 2004-10-07 Republic Of National Fisheries Research And Development Institute Phytase produced from citrobacter braakii
WO2005123034A2 (en) 2004-06-22 2005-12-29 Universita'degli Studi Di Milano Microparticulate systems for the oral administration of biologically active substances
WO2006037327A2 (en) 2004-10-04 2006-04-13 Novozymes A/S Polypeptides having phytase activity and polynucleotides encoding same
WO2006038128A2 (en) 2004-10-04 2006-04-13 Danisco A/S Citrobacter freundii phytase and homologues
WO2006038062A1 (en) 2004-10-04 2006-04-13 Danisco A/S Microbial phytase as supplement to food or fodder
WO2006037328A1 (en) 2004-10-04 2006-04-13 Novozymes A/S Polypeptides having phytase activity and polynucleotides encoding same
WO2006043178A2 (en) 2004-10-18 2006-04-27 Danisco A/S Enzymes
WO2007044968A2 (en) 2005-10-12 2007-04-19 Genencor International, Inc. Stable, durable granules with active agents
US7754469B2 (en) 2005-11-30 2010-07-13 Agtech Products, Inc Microorganisms and methods for treating poultry
WO2007112739A1 (en) 2006-04-04 2007-10-11 Novozymes A/S Phytase variants
WO2008016214A1 (en) 2006-08-04 2008-02-07 Bioneer Corporation Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
WO2008092901A2 (en) 2007-01-30 2008-08-07 Novozymes A/S Polypeptides having phytase activty and polynucleotides encoding same
WO2008097619A2 (en) 2007-02-07 2008-08-14 Danisco Us, Inc., Genencor Division Variant buttiauxella sp. phytases having altered properties
US20080263688A1 (en) 2007-03-26 2008-10-23 Novozymes A/S Hafnia Phytase
US20090041011A1 (en) 2007-04-03 2009-02-12 Scott Sheppard Lawful Interception of Broadband Data Traffic
US20090280090A1 (en) 2008-03-14 2009-11-12 Thomas Rehberger Methods of treating pigs with bacillus strains
WO2009129489A2 (en) 2008-04-18 2009-10-22 Danisco Us Inc., Genencor Division Buttiauxella sp. phytase variants
WO2011117396A2 (en) 2010-03-26 2011-09-29 Novozymes A/S Thermostable phytase variants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHOMCZYNSKI; SAACHI, ANAL. BIOCHEM., vol. 162, 1987, pages 156 - 159
DRUYAN ET AL., POULT. SCI., vol. 87, 2008, pages 2418 - 2429
GAROSI ET AL., BR. J. NUTR., vol. 93, 2005, pages 425 - 432
HOFACRE ET AL., J. APPL. POULT. RES., vol. 12, 2003, pages 60 - 64

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2879511A1 (en) * 2012-08-03 2015-06-10 Dupont Nutrition Biosciences ApS Feed additive composition
US20160213755A1 (en) * 2012-08-03 2016-07-28 Dupont Nutrition Biosciences Aps Feed Additive Composition
US10149891B2 (en) * 2012-08-03 2018-12-11 Dupont Nutrition Biosciences Aps Feed additive composition
EP2879511B1 (en) * 2012-08-03 2022-08-24 DuPont Nutrition Biosciences ApS Feed additive composition
US11235035B2 (en) 2012-08-03 2022-02-01 Dupont Nutrition Biosciences Aps Feed additive composition
US11951138B2 (en) 2013-03-14 2024-04-09 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Microbial compositions comprising rumen microflora and uses thereof
CN103250867A (en) * 2013-05-10 2013-08-21 东北农业大学 Production method of raw milk lactic acid bacteria antimicrobial peptide additive for livestock and poultry
US10980249B2 (en) 2014-06-27 2021-04-20 Dsm Ip Assets B.V. Method for improving the nutritional value of animal feed
WO2015197871A1 (en) * 2014-06-27 2015-12-30 Dsm Ip Assets B.V. A method for improving the nutritional value of animal feed
US11395479B2 (en) 2016-01-25 2022-07-26 Novozymes A/S Method to reduce microbial bloom in poultry hatchery
WO2017132230A1 (en) * 2016-01-25 2017-08-03 Novozymes A/S Method to reduce microbial bloom in poultry hatchery
AU2016404864B2 (en) * 2016-04-26 2021-11-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Regulation of feed efficiency and methane production in ruminating animals
AU2022200755B2 (en) * 2016-04-26 2024-01-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Regulation of feed efficiency and methane production in ruminating animals
US11939620B2 (en) 2016-04-26 2024-03-26 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Regulation of feed efficiency and methane production in ruminating animals
US20190021341A1 (en) * 2017-07-24 2019-01-24 Church & Dwight Co., Inc. Bacillus microbial terroir for pathogen control in swine
US11622569B2 (en) * 2017-07-24 2023-04-11 Church & Dwight Co., Inc. Bacillus microbial terroir for pathogen control in swine
WO2019183511A1 (en) * 2018-03-23 2019-09-26 Purina Animal Nutrition Llc Methods of feeding animals feed products containing direct-fed microbials
CN109161501A (en) * 2018-09-07 2019-01-08 中国农业大学 A kind of feeding bacillus licheniformis and its application
RU2720471C1 (en) * 2019-03-21 2020-04-30 Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" Fodder additive for broiler chickens
CN110521856A (en) * 2019-10-11 2019-12-03 江西正邦科技股份有限公司 The production method of the diligent energy property small peptide of one boar
US20210267232A1 (en) * 2020-02-28 2021-09-02 Terragen Holdings Limited Microbial feed supplement composition and method
KR102553803B1 (en) 2021-11-18 2023-07-11 장태호 Feed additive composition for livestock or fish comprising fermented product of bass and blue gill as effective component and uses thereof
KR20230074002A (en) * 2021-11-18 2023-05-26 장태호 Feed additive composition for livestock or fish comprising fermented product of bass and blue gill as effective component and uses thereof
WO2024047009A1 (en) * 2022-08-30 2024-03-07 Dsm Ip Assets B.V. Methods and uses for modifying gut flora in aquatic species

Also Published As

Publication number Publication date
JP2014508519A (en) 2014-04-10
EP2675285A2 (en) 2013-12-25
AR084892A1 (en) 2013-07-10
US20130330307A1 (en) 2013-12-12
ZA201305267B (en) 2014-09-25
US20190223470A1 (en) 2019-07-25
PL2675285T3 (en) 2018-05-30
ES2657543T3 (en) 2018-03-05
CN103442587A (en) 2013-12-11
DK2675285T3 (en) 2018-02-12
BR112013020855B1 (en) 2021-11-03
AU2012216897A1 (en) 2013-07-18
WO2012110777A3 (en) 2012-10-26
GB201102865D0 (en) 2011-04-06
BR112013020855A2 (en) 2021-04-20
US11172693B2 (en) 2021-11-16
CN107518156A (en) 2017-12-29
CA2825489A1 (en) 2012-08-23
TW201234976A (en) 2012-09-01
EP2675285B1 (en) 2017-11-15

Similar Documents

Publication Publication Date Title
US11172693B2 (en) Feed additive composition
US11235035B2 (en) Feed additive composition
US10695384B2 (en) Feed additive composition
US20200276279A1 (en) Feed additive composition
CA3004522C (en) Feed additive composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12701263

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2012216897

Country of ref document: AU

Date of ref document: 20120119

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2825489

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13985847

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2013553998

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2012701263

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012701263

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013020855

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013020855

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130815